Skip to Content

'
Gordon B. Mills, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Department Chair, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor of Medicine and Immunology, MD Anderson Cancer Center, Houston, TX
Olga Keith Wiess Distinguished University Chair for Cancer Research, MD Anderson, Houston, TX
Ann Rife Cox Chair in Gynecology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX
Administrative Director, Kleberg Center for Molecular Markers, Division of Cancer Medicine, MD Anderson
Co-Director, Zayed Institute for Personalized Cancer Therapy, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1984 University of Alberta, Edmonton, Canada, PHD, Biochemistry
1982 University of Alberta, Edmonton, Canada, FRCS, Obstetrics and Gynecology
1977 University of Alberta, Edmonton, Canada, MD, Medicine
1975 University of Alberta, Edmonton, Canada, BS, Medicine

Postgraduate Training

1/1982-1/1985 Research Fellow: Division of Immunology, The Hospital for Sick Children, Toronto, Canada, E. Gelfand
1/1982-1983 FRCS (Obstetrics and Gynecology), Canada
1/1980-1/1982 Resident (Obstetrics and Gynecology), University of Alberta, Alberta, Canada
1/1978-1/1984 Graduate Studies (Biochemistry), University of Alberta, Alberta, Canada
1/1978-1/1980 Honorary Resident (Obstetrics and Gynecology), University of Alberta, Alberta, Canada
1/1977-1/1978 Straight Intern (Obstetrics and Gynecology), University of Alberta, Alberta, Canada
1/1976-1/1978 Research Fellow, Flinders Medical Center, Adelaide, Australia, W.P. Jones

Board Certifications

1996 Texas State Board of Medical Examiners
1/1982 Royal College of Physicians and Surgeons of Canada

Experience/Service

Academic Appointments

Member Scientific Committee, EORTC/NCI/AACR, Barcelona, Spain, 8/2013
Director Institute for Personalized Cancer Therapy, MD Anderson Cancer Center, Houston, TX, 1/2010
Chair, Department of Systems Biology, MD Anderson Cancer Center, Houston, TX, 1/2006-present
Chairman, Department of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2006-present
Building Director, SCRBII, 1/2004-present
Director, Kleberg Center for Molecular Markers, MD Anderson Cancer Center, Houston, TX, 2004
Professor, Breast Medical Oncology , The University of Texas MD Anderson Cancer Center, Houston, TX, 1/2000-present
Associate Head, Division of Medicine, The University of TexasMD Anderson Cancer Center, Houston, TX, 1/1998-1/2000
Co-Director, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1996-1/1997
Professor, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1995-present
Chair, MD Anderson Cancer Center, Houston, TX, 1/1995-1/1996
Member, Tumor Biology Program, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1994-present
Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1994-present
Chief, Section of Molecular Therapeutics, The University of Texas The University of Texas MD Anderson Cancer Center, Houston, TX, 1/1994-present
Associate Professor, Department of Obstetrics and Gynecology, Immunology, Clinical Biochemistry, University of Toronto, Toronto, Canada, 1/1990-1/1994
Associate Professor, Department of Immunology, University of Toronto, Toronto, Canada, 1/1990-1/1994
Director, Department of Oncology, Oncology Research, Oncology Research Toronto Hospital, Toronto, Canada, 1/1990-1/1994
Assistant Professor, Department of Clinical Biochemistry, University of Toronto, Toronto, Canada, 1/1989-1/1990
Assistant Professor, Obstetrics and Gynecology, Immunology, Clinical Biochemistry, University of Toronto, Toronto, Canada, 1/1985-1/1990
Post Doctoral Fellow, Department of Immunology, Immunology Hospital for Sick Children University of Toronto, Toronto, Canada, 1/1982-1/1985

Administrative Appointments/Responsibilities

Administrative Director, Division of Cancer Medicine, MD Anderson, Houston, TX, 2010-present
Medical Director, MD Anderson Cancer Center, Houston, TX, 1/1996-1/2001
Department Chair, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX, 1/1995-1/2006
Administrative Director, Toronto General Hospital, Toronto, Canada, 1/1990-1/1994

Other Appointments/Responsibilities

Member, External Advisory Board for the Mayo Clinic Breast Cancer SPORE, Rochester, MN, 2/2012
Fellow, American Association for the Advancement of Science, Washington, DC, 2012-present
Visiting Professorship, Rafael Research Alumni Association, Ramban, Israel, 2008
Chair, Search Committee for Chair Bioinformatics and Computational Biology, Houston, TX, 1/2006-2/2007
Co-chair, MDACC Annual Conference: Challenges to the implementation of molecular markers and molecular imaging., Houston, TX, 1/2005
Co Chair, MDACC Annual Conference: Targeted Therapeutics, Houston, TX, 1/2004
Medical Research Council of Canada Scientist, University of Toronto, Toronto, Canada, 1/1991-1/1994
MacLaughlin Scientist, The University of Texas M. D. Anderson Cancer Center, 1/1986-1/1992
Scientist, Medical Research Council of Canada, Toronto, Canada, 1/1986-1/1991

Endowed Positions

Olga Keith and Harry Carothers Wiess Chair for Cancer Research, MD Anderson Cancer Center, Houston, TX, 2001-2004
Ransom Horne Professor in Cancer Research, MD Anderson Cancer Center, Houston, TX, 1/1998-1/2001

Consultantships

Medlyte/LPATH, La Jolla, 1/2010
Amira SAB, San Diego, CA, 11/2008
LPATH SAB Chair La Jolla California SAB, La Jolla, California, 1/2007-1/2010
Ambit SAB, San Diego, CA, 8/2006
Celgene SAB, Summit, NJ, 7/2004
Pinto Investments, Houston, 12/2003
Founder Atarigin/LPL Technoogies, Cleveland
Maxim Pharmaceuticals/Cytovia, Inc., La Jolla
Echelon Pharmaceuticals, Salt Lake City
Abbott SAB, Chicago
Semafore SAB,

Institutional Committee Activities

Member, Komen PDF Basic and Translation Review Committee, 8/2013
Member, Institutional Research Effectiveness Committee, 1/2012-present
Internal Advisory Board, Lung Spore, 2012-present
Search Committee Chair, Breast Medical Oncology, 2012-present
Member, Institututional Effectiveness, 2012-present
Member, Global Academic Program MD Anderson, 1/2010-present
member, Scientific Advisory Council Komen Foundation, 2010-present
Chair, AACR Molecular Diagnostics in Cancer Therapeutic Development Chair, 2010-present
Member, Women's Faculty Program, 1/2009-present
Member, Steering Committee TCGA, 1/2009-present
Member, AACR Scientific Committee, 1/2008-present
Member, Deans Advisory Board Natural Sciences and Mathematics University of Houston, 1/2008
member, MDACC Annual Conference: Systems Biology of Cancer, 1/2008
Chair, Search Committee Clinical Cancer Prevention, 1/2008
Chair, Search Committee Epidemiology, 1/2008
Chair, Search Committee Epidemiology, 1/2008
member, Search Committee Recruitment, 1/2008
Co Chair, MDACC Annual Conference: Individualized risk assessment, 1/2007
Member, External Collaborations committee DKFZ, 1/2007
TCGA, Data Analysis Committee, 1/2007
Member, Ovarian Cancer Steering Committee TGA, 1/2007
Member, Steering Commitee CPTAC, 1/2007
Chair, AACR Molecular Therapeutics Meeting, 1/2007
Member, Search Committee for Modeling Experimental Therapeutics, 1/2006
Member, Research Animal Priority Committee, 1/2006
Member, Research Advisory Committee, 1/2006
Member, AACR Scientific Committee, 1/2006
Organizing Committee, Challenges to implementation of targeted Therapeutics AACR meeting, 1/2006
Organizing Committee, AACR: Cancer Prevention Meeting, 1/2006
Advisory Board, WASH U Breast Spore, 1/2006
Member, Target Selection Committee TGA, 1/2006
Advisory Board, Duke Breast SPORE, 1/2006
Management Committee, CPTAC, 1/2006
Consultant, Integrative Cancer Biology Program, 1/2004
Chair, SAB Sylvester Cancer Center Miami, 1/2004
Member, SAB ICBP Program UCSF/LBNL, 1/2004
Chair, Advisory Board Life Sciences Program LBNL, 1/2004
Member, FASEB Lipids Conference, 1/2004
Member, PAACT, 1/2004
Search Committee Chair Experimental Therapeutics, 1/2004
Chair, 2004 AACR Research Awards for Broad, Junior Faculty, 1/2004
Co Chair, Lockton Search Committee, 1/2003-1/2004
Chair, Senior Scientist Search Committee Brain Tumor Center, 1/2003-1/2004
Search Committee Cellular and Molecular Oncology, 1/2003-1/2004
Internal Advisory Board Lymphoma SPORE, 1/2003
Member, Organization Commitee TAT Amersterdam, 1/2002
External Advisory Board Breast PO1 Baylor, 1/2002
External Advisory Board Ovary SPORE Seattle, 1/2002
Chair, External Advisory Board UCSF SPORE in Breast Cancer, 1/2002
Member, MRAC (Multidisciplinary Research Advisory Committee), 1/2002
Internal Advisory Board Leukemia SPORE, 1/2002
Internal Advisory Board Head and Neck SPORE, 1/2002
Chair, Technology Review Committee, 1/2002
Member, Technology Transfer Committee, 1/2002
Internal Advisory Board Brain SPORE, 1/2001-1/2004
Chair, Endowed Positions and Awards Committee, 1/2001-1/2003
Co Chair, Research Space Subcommittee of the Research Council, 1/2001-1/2003
Internal Advisory Board GI SPORE, 1/2001-1/2002
Search Committee Brain Tumor Department Chair, 1/2001-1/2002
Executive Committee Brain Tumor Program, 1/2001
Executive Committee Radiation Oncology Program, 1/2001
Member, Emphasis Committee Immunology, 1/2001
Internal Advisory Board Lung PO1, 1/2001
Internal Advisory Board Melanoma SPORE, 1/2001
Internal Advisory Board Prostate SPORE, 1/2001
Internal Advisory Board Bladder SPORE, 1/2001
Program Committee, AACR Molecular Mechanisms, 1/2001
External Advisory Board Indiana Ovarian Cancer DoD PO1, 1/2001
Gertrude B. Ellion Selection Committee AACR, 1/2001
Molecular Therapeutics Subcommittee ASCO, 1/2001
Scientific Committee Molecular Targets and Cancer Therapeutics, 1/2001
Chair, External Advisory Board Breast SPORE UCSF, 1/2001
External Advisory Board Breast SPORE Baylor, 1/2001
External Advisory Board Breast PPG Baylor, 1/2001
External Advisory Board Breast SPORE Vanderbilt, 1/2001
Member, Research Council, 1/2000-1/2006
Member, Search Committee for Molecular Therapeutics, 1/2000-1/2003
Member, Endowed Positions and Awards Committee, 1/2000-1/2003
Member, Advisory Committee of the Cancer Therapeutics Development program, 1/2000-1/2002
Member, Executive Council Science Faculty, 1/2000
Member, Advisory Committee Cardiology, 1/2000
Member, Steering Committee Breast Cancer Program, 1/2000
Chair, Ad Hoc Proteomics Committee of the ECSF, 1/2000
Member, Division of Cancer Prevention Center Steering Committee, 1/2000
Ad Hoc Member, Division of Medicine Research Space Committee, 1/1999-1/2001
Member, Genomics Planning Committee, 1/1999-1/2001
Member, Institutional Research Space Committee Advisory Group, 1/1999-1/2000
Member, Clinical Faculty Review Committee, 1/1999-1/2000
Member, Search Committee Chair Surgical Gynecology, 1/1999
Member, Executive Council of Division of Medicine, 1/1999
Program Committee, AACR Pharmacology and Experimental Therapeutics, 1/1999
External Advisory Board UCSF SPORE in Breast Cancer, 1/1999
Member, Physician Scientist Program Supervisory Committee, 1/1998-1/2002
Member, Planning Committee-Millennium Cancer Conference, 1/1998-1/2000
Search Committee, Corrine Boyer Chair in Ovarian Cancer Research, 1/1998-1/1999
Member, Multidisciplinary Program Review Committee, 1/1997-1/2002
Member, Search Committee Medical Director Clinical Cancer Genetics, 1/1997-1/1999
Member, Search Committee Human Cancer Genetics, 1/1997-1/1998
Member, Search Committee Medical Specialties, 1/1997-1/1998
Member, Steering Committee Human Cancer Genetics, 1/1996-1/2001
Chair, Cancer Genetics Implementation Committee, 1/1996-1/2001
Member, Disease Site Executive Committee (Ovary), 1/1995-1/2003
Member, Credentials Committee of the Medical Staff, 1/1995-1/2000
Advisory Committee on Research (ACOR) Alberta Cancer Board, 1/1995-1/2000
Member, Executive Committee, Division of Medicine, 1/1995-1/1999
Member, Promotions Committee, Division of Medicine, 1/1995-1/1998
Member, Surveillance Committee, 1/1995-1/1996
Member, Clinical Research Committee, 1/1995-1/1996
Member, Research Institutional Direction Working Group, 1/1995-1/1996
Member, Program Planning Committee, 1/1995-1/1996
Member, Executive Committee Ovarian Cancer Program, 1/1995
Staff Term Evaluation Committee, Department of Obstetrics and Gynecology, 1/1993-1/1995
Postgraduate Education Gynecologic Oncology Program of Toronto, 1/1993-1/1995
Finances committee Department of Obstetrics and Gynecology Toronto Hospital, 1/1993-1/1995
Planning and Priorities Task Force Toronto Hospital, 1/1993-1/1995
Oncology Steering Committee Toronto Hospital, 1/1992-1/1995
Chairman, Space and Resources Subcommittee Toronto Hospital, 1/1992-1/1995
Research Trainee Education Subcommittee Toronto Hospital, 1/1992-1/1995
Research Advisory Committee Toronto Hospital, 1/1991-1/1995
Steering Committee Gynecologic Oncology Program of Toronto, 1/1989-1/1995
Research Committee Gynecologic Oncology Program of Toronto, 1/1989-1/1995
Animal Care Committee Toronto Hospital, 1/1989-1/1993
Research Advisory Committee Department of Obstetrics and Gynecology, 1/1988-1/1995

Honors and Awards

2014 Laura Ziskin Award, SU2C/AACR
2014 President's Recognition for Faculty Excellence, MD Anderson Cancer Center
2013 Brinker Award for Excellence in Science, Susan G Komen
2012-present Fellow American Association for the Advancement of Science
2010 Olga Keith Wiess Distinguished University Chair for Cancer Research, MD Anderson Cancer Center
2009 Best Boss Award MD Anderson Cancer Center, MD Anderson Cancer Center
2009 Waun Ki Hong Award for Excellence in Team Science, MD Anderson Cancer Center
2008 Rafael Research Alumni Association Professorship at Rambam
2006 Inaugural Waun Ki Hong Award for Mentorship, MD Anderson Cancer Center
2004-2010 Anne Rife Cox Chair in Gynecology
1998 Ransom Horne Jr. Professorship in Cancer Research
1991 Medical Research Council of Canada Scientist
1988 Gordon Fisher Prize for excellence in research
1986 MacLaughlin Scientist
1986 Medical Research Council of Canada Scholar
1982 Alberta Heritage Trust Fund Fellowship
1978 Medical Research Council Fellow
1978 Visiting Consultant, Hanover Medical School
1976 Manheim-Boerhinger Scholarship-Research award tendered with W.R. Jones in Adelaide
1973 Edmonton Pipefitters Scholarship
1971 Harry W. Bass Memorial Bursary

Selected Publications

Peer-Reviewed Original Research Articles

1. Tabchy A, Hennessy BT, Hortobagyi G, Mills GB. 2010 Systems biology of breast cancer reports. In Press.
2. Liu, W., Ju., Z., Lu J., Mills GB., Akbani R.,. A Comprehensive Comparison of Normalization Methods for SuperCurve Based Reverse Phase Protein Array (RPPA) Data. In Press.
3. Mazumder T., Byers LA., Ng KS., Mills GB., Peng S., Diao L., Fan Y., Hale K., Heymach J., Myers JN., Glisson G., Johnson FM. A Comprehensive Evaluation of PI3K Pathway Inhibition and Resistance Mechanisms in Head and Neck Squamous Carcinoma. In Press.
4. Wolf J, Müller-Decker K, Flechtenmacher C, Zhang F, Shahmoradgoli M, Mills GB, Hoheisel JD, Boettcher M. An in vivo RNAi screen identifies SALL1 as a tumor suppressor in human breast cancer with a role in CDH1 regulation. Oncogene. In Press. PMID: 24292671.
5. Wolf J., Muller-Decker K., Flechtenmacher C., Zhang F., Shahmoradgoli M., Mills GB., Hoheisel JD., Boettcher M. An in vivo RNAi screen identifies SALL1 as tumor suppressor and regulator of CDH1 expression in human breast cancer. Oncogene. In Press. PMID: 24292671.
6. Yuan Y., Van Allen EM., Omberg L., Wagle N., Amin-Mansour A., Sokolow A., Byers L., Xu Y., Hess K., Diao L., Han L., Huang X., Lawrence M., Weinstein J., Stuart J., Mills GB., Garraway LA., Morgolin AA., Getz G., Liang H. Assessing the clinical utility of cancer genomic data across tumor types. Nature Biotech. In Press. PMID: 24952901.
7. Pande M., Bondy ML., Do K-A., Sahin AA., Ying J., Mills GB., Thompson PA., Brewster AM. Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease free survival Breast Cancer Research and Treatment. In Press.
8. Liu X-D., Yao J., Tripathi DN, Ding Z., Xu Y., Sun M., Zhang J., Bai S., German P., Hoang A., Zhou L., Jonasch D., Zhang X., Conti C., Efstathious Tannir NM., Eissa T., Mills GB., Walker CL., Jonasch E. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene. In Press.
9. Zhou W, Chen T, Zhao H, Eterovic AK, Meric-Bernstam F, Mills GB, Chen K. Bias from removing read duplication in ultra-deep sequencing experiments. Bioinformatics. In Press. PMID: 24389657.
10. Werner HMJ., Mills GB., RAm T. Cancer Systems Biology: A peak into the future of patient care. Nature Reviews Clin Onc. In Press.
11. Kotlyar M., Pastrello C., Pivetta, F., Sardo AL., Cumbaa C., LI H., Naranian T., Niu, Y., Ding Z., Vafaee F., Froackes-Carter F., Stagljar I., Jurisicova A., Mills GB., Maestro R., and Jurisica I. Comprehensive in silico prediction of physical protein interactions and characterization of interactome orphans. Nat Methods. In Press.
12. Liu Y., Patel L., Mills GB., Lu KH., Sood A., Ding L., Kucherlapati R., Mardis ER., Levein DA., Shmulevich I., Broaddus R., Zhang W. CTNNB1 Mutation and Wnt Pathway Activation Defines an Agressive Variant of Endometrial Carcinoma Affecting Younger Patients. TCGA Network. In Press.
13. Labid-Galy SI., Clauss A., Ng V., Duraisamy S., Elias KM., Bilal E., Davidowitz RA., Badalian-Very G., Piao H-Y., Kand U-B., Mills GB., Ganesan S., Ficarro S., Marto J., Drapkin R. Elafin function underscores the similarities between high-grade serous ovarian carcinomas and basal-like breast cancers. In Press.
14. Lehmann BD., Bauer JA., Schafer JM., Pndelton CS., Tang LJ., Johnson KC., Chen X., Mills GB., Sanders Me., Pietenpol J. Frequent PIK3CA Mutations in AR-positive Triple Negative Breast Cancer Cells Confer Sensitivity to the Combination of PI3K and AR Inhibitiors. In Press.
15. Choi MJ., Cho Kh., Lee SJ., Bae YJ., Jeong KJ., Rha SY., Choi EJ., Park JH., Kim JM., Lee JS., Mills GB., Lee HY. hTERT mediates norepinephrine-induced Slug expression and ovarian cancer cell progression. In Press.
16. Wirgand KC., Hennessey BT., Cheang M., Ju Z., McGahren M., Mills GB., Kalloger S., Finlayson S., Stemke-Hale K., Lu Y., Zhang F., Huntsman D., Mills GB., Carey MS. Loss of ARID1a/BAF250a a tumor suppressor is sufficient to activate the P13K/AKT pathway independent of P1K3CA mutation or PTEN loss in endometriosis-associated ovarian cancers. In Press.
17. Zinner, RG, Mills GB, Zinner, NR, Fosella FV, Hong WKFu, Y, Mao, L. Medicinal Algorithmic Combinatorial Screen (MACS); A Method to Identify Rare Effective Anticancer Drug Combinations. Molecular Cancer Therapeutics. In Press.
18. Javle M., Rashid A., Churi C., Kar S., Zuo M., Eterovic K., Gonzalez G., Ali S., Janku F., Shroff R., Aloiz T., Vauthey J-N., Curley S., Mills G., Roa I. Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling Human Pathology. Human Pathology. In Press.
19. Hennessy BT, Bast RC, Mills GB. Molecular diagnostics in cancer. Current Breast Cancer Reports. In Press.
20. Subbiah V., Meric-Bernstam F., Mills GB., Mills-Shaw K., Bailey AM., Rao P., Ward JF., Pagliaro LC. Next Generation Sequencing Analysis of an Unusual Responder to Sunitinib (Sutent ®) in Platinum refractory advanced Germ cell tumor Journal of Hematology & Oncology. In Press.
21. Markman M, Bast R. Ovarian Cancer: Molecular, Cellular, and Clincal Biolohy. In Press.
22. O'Leary P., Hennessey BT., Zagzozdzou A., O'Connor D., Brenan DJ., Li J., Mills GB., Gonzalez-Angulo AM., Madden SF., Sun H-D., Pu J-X., Ponten F., Uhlen M., Jirstrom K., Nowis D., Crown J., Zagozdzon R., Gallagher WM. Peroxiredoxin-1 protects against estrogen receptor a form oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in estrogen receptor-positve breast cancer. In Press.
23. Meric-Bernstam, F Akcakanat A., Chen H., Sahin A., Tarco E., Carkaci S., Adrada BE.,Singh G., Do K-A., Garces ZM., Mittendorf E., Babiera G., Wagner J., Bedrosian I, Hwang R., Krishnamurthy S., Symmans F., Gonzalez-Angulo AM., Mills GB. Proteomic biomarkers demonstrate limted intraumoral heterogeneity in breast cancer but are influenced by biospecimen variables. Clin Can Res. In Press.
24. Kim TH., Yoo J-Y., Kim HI., Gilbert J, Ku BJ., Li J., Mills GB., McCampbell, roaddus RR., Lydon JP., Lim JM., Yoon H-G and Jeong J-W. Pten-deficient endometrial cancer is suppressed by overexpression of Mig-6 through inhibition of ERK phosphorylation. Cancer Research. In Press.
25. Chavez-MacGregor M., Liu S., Gagliato D., Chen H., Do K-A., Pusztai L., Summans F., Nair L.,Hortobagyi GN., Mills GB., Meric-Bernstam F., Gonzalez Angulo AM. Relationship between differences in RNA and protein expression and the effects of race/thnicity on breast cancer outcomes. Cancer Epidemiol Biomarkers. In Press.
26. Gonzalez-Angulo A., Krop I., Akacanat A., Chen H., Liu S., Li Y., Cullotta K. Tarco E., Piha-Paul S., Moulder-Thompson S., Velez-Bravo V., Sahin A., Doyle L., Do K-A., Winer E., Mills G., Kurzrock R., and Meric-Bernstam F. SU2C Phase Ib Study of Paclitaxel and MK-2206 in Advanced Solid Tumors and Metastatic Breast Cancer. Natl. Cancer Inst. In Press.
27. Paulovich AG, Billheimer D, Ham AJ. The NCI Clinical Proteomic Technology Assessment for Cancer (CPTAC) Network (as part of the network) 2010 A reference yeast proteome for benchmarking LC-MS platform performance. Mol Cell Proteomics. In Press.
28. Watson IR., Li L., Cabeceiras PL., Mahdavi. M., Stemke-Hale K., Mills GB., Chin L. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF Cancer Research. In Press.
29. ee J., Tiwari A., Shum V., Mills GB., Mancini MA., Igoshin O and Balazsi G. Unraveling the regulatory connections between two controllers of breast cancer cell fate. Nucleic Acids Research. In Press. PMID: 24792166.
30. Li S., Shen D., Liu W., Prat A., Hoog J., Liu S., Ding L., McMichael JF., Miller C., Larson D., Fulton RS., Harrison M., Mooney T., Tao Y., Luo J., Lin L., Giuntoil T., Bumb C., Cooper C., Kitchens RT., Johnson SN., Crowder RJ., Shao J., Goncalves R., Phommaly C., Davies S., Kavuri MS., Lin A., McEachern D., Don YY., Ma C., Pluard T., Naughton M., Bose R., Suresh R., McDowell R., Michel L., Aft R., DeSchryver K., Wilson R., Want S., Mills GB., Gonzalez-Angulo A., Maher C., Perou C., Madri E., Ellis MJ. Whole genome analysis and endocrine phenotype of patient-derived xenografts from treatment-resistant breast cancers. Cell Reports. In Press.
31. Lorenzi PL., Claerhout S., Mills GB., Weinstein JN. A curated census of authography-modulating proteins and small molecules 10(7):1316-26, 7/2014. PMID: 24906121.
32. Joy A, Ramesh A, Smirnov I, Reiser M, Misra A, Shapiro WR, Mills GB, Kim S, Feuerstein BG. AKT Pathway Genes Define 5 Prognostic Subgroups in Glioblastoma. PLoS One 9(7):e100827, 7/2014. PMCID: PMC4077731.
33. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, Skinner HD, Fitzgerald AL, Osman AA, Wei Y, Xia X, Songyang Z, Mills GB, Hung MC, Caulin C, Liang J, Myers JN. Gain of function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 54(6):960-74, 6/19/2014. e-Pub 5/22/2014. PMCID: PMC4067806.
34. Ding Z, German P, Bai S, Reddy AS, Liu XD, Sun M, Zhou L, Chen X, Zhao X, Wu C, Zhang S, Mills GB, Jonasch E. Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein. Cancer Res 74(11):3127-36, 6/2014. PMCID: PMC4047720.
35. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, Ince TA, Drage MG, Dering J, Konecny GE, Matulonis U, Mills GB, Slamon DJ, Drapkin R, Brugge JS. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 124(6):2611-25, 6/2014. PMCID: PMC4038562.
36. Gonzalez-Angulo AM, Akcakanat A, Liu S, Green MC, Murray JL, Chen H, Palla SL, Koenig KB, Brewster AM, Valero V, Ibrahim NK, Moulder-Thompson S, Litton JK, Tarco E, Moore J, Flores P, Crawford D, Dryden MJ, Symmans WF, Sahin A, Giordano SH, Pusztai L, Do KA, Mills GB, Hortobagyi GN, Meric-Bernstam F. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer . Ann Oncol 25(6):1122-7, 6/2014. PMCID: PMC4037860.
37. Davies AH, Reipas KM, Pambid MR, Berns R, Stratford AL, Fotovati A, Firmino N, Astanehe A, Hu K, Maxwell C, Mills GB, Dunn SE. YB-1 Transforms Human Mammary Epithelial Cells Through Chromatin Remodeling Leading to the Development of Basal-Like Breast Cancer. Stem Cells 32(6):1437-50, 6/2014. PMID: 24648416.
38. Akbani R, Ng PK, Werner HM, Shahmoradgoli M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, Ling S, Seviour EG, Ram PT, Minna JD, Diao L, Tong P, Heymach JV, Hill SM, Dondelinger F, Städler N, Byers LA, Meric-Bernstam F, Weinstein JN, Broom BM, Verhaak RG, Liang H, Mukherjee S, Lu Y, Mills GB. A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat Commun 5:3887, 5/2014. PMID: 24871328.
39. Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM. Concordance of Genomic Alterations between Primary and Recurrent Breast Cancer. Mol Cancer Ther 13(5):1382-9, 5/2014. PMID: 24608573.
40. Sewell A, Brown B, Biktasova A, Mills GB, Lu Y, Tyson DR, Issaeva N, Yarbrough WG. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin Cancer Res 20(9):2300-11, 5/2014. PMCID: PMC4027970.
41. Panupinthu N, Yu S, Zhang D, Zhang F, Gagea M, Lu Y, Grandis JR, Dunn SE, Lee HY, Mills GB. Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer. Oncogene 33(22):2846-56, 5/2014. PMID: 23851501.
42. Werner HM, Mills GB, Ram PT. Cancer Systems Biology: a peek into the future of patient care? Nat Rev Clin Oncol 11(3):167-76, 3/2014. PMID: 24492837.
43. Jeong W, Kim SB, Sohn BH, Park YY, Park ES, Kim SC, Kim SS, Johnson RL, Birrer M, Bowtell DS, Mills GB, Sood A, Lee JS. Activation of YAP1 Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer. Anticancer Res 34(2):811-7, 2/2014. PMCID: PMC4082822.
44. Chavez-Macgregor M, Liu S, De Melo-Gagliato D, Chen H, Do KA, Pusztai L, Fraser Symmans W, Nair L, Hortobagyi GN, Mills GB, Meric-Bernstam F, Gonzalez-Angulo AM. Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. Cancer Epidemiol Biomarkers Prev 23(2):316-23, 2/2014. PMCID: PMC3946290.
45. Peng G, Chun-Jen Lin C, Mo W, Dai H, Park YY, Kim SM, Peng Y, Mo Q, Siwko S, Hu R, Lee JS, Hennessy B, Hanash S, Mills GB, Lin SY. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat Commun 5:3361, 2/2014. PMCID: PMC4017859.
46. Bailey AM, Mao Y, Zeng J, Holla V, Johnson A, Brusco L, Chen K, Mendelsohn J, Routbort MJ, Mills GB, Meric-Bernstam F. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med 17(92):101-14, 2/2014. PMID: 24534473.
47. Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Res 74(1):15-23, 1/2014. PMCID: PMC3982380.
48. Labidi-Galy SI, Clauss A, Ng V, Duraisamy S, Elias KM, Piao HY, Bilal E, Davidowitz RA, Lu Y, Badalian-Very G, Györffy B, Kang UB, Ficarro S, Ganesan S, Mills GB, Marto JA, Drapkin R. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. e-Pub 1/2014. PMID: 24469047.
49. Lui VW, Peyser ND, Ng PK, Hritz J, Zeng Y, Lu Y, Li H, Wang L, Gilbert BR, General IJ, Bahar I, Ju Z, Wang Z, Pendleton KP, Xiao X, Du Y, Vries JK, Hammerman PS, Garraway LA, Mills GB, Johnson DE, Grandis JR. Frequent Mutation of Receptor Protein Tyrosine Phosphatases Provides a Mechanism for STAT3 Hyperactivation in Head and Neck Cancer. Proc Natl Acad Sci U S A 111(3):1114-9, 1/2014. PMCID: PMC3903220.
50. Liu Y, Zhou R, Baumbusch LO, Tsavachidis S, Brewster AM, Do KA, Sahin A, Hortobagyi GN, Taube JH, Mani SA, Aarře J, Wärnberg F, Břrresen-Dale AL, Mills GB, Thompson PA, Bondy ML. Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Res Treat 143(1):189-201, 1/2014. PMID: 24305980.
51. Wiegand KC, Hennessy BT, Leung S, Wang Y, Ju Z, McGahren M, Kalloger SE, Finlayson S, Stemke-Hale K, Lu Y, Zhang F, Anglesio MS, Gilks B, Mills GB, Huntsman DG, Carey MS. A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 14(1):120, 2014. PMCID: PMC3941949.
52. Molinelli EJ, Korkut A, Wang W, Miller ML, Gauthier NP, Jing X, Kaushik P, He Q, Mills G, Solit DB, Pratilas CA, Weigt M, Braunstein A, Pagnani A, Zecchina R, Sander C. Perturbation biology: inferring signaling networks in cellular systems. PLoS Comput Biol 9(12):e1003290, 12/2013. PMCID: PMC3868523.
53. Shi R, Mills G, McLarty J, Burton G, Shi Z, Glass J. Commercial insurance triples chances of breast cancer survival in a public hospital. Breast J 19(6):664-7, Nov-Dec, 11/2013. PMID: 24015898.
54. Fabian CJ, Kimler BF, Donnelly JE, Sullivan DK, Klemp JR, Petroff BK, Phillips TA, Metheny T, Aversman S, Yeh HW, Zalles CM, Mills GB, Hursting SD. Favorable modulation of benign breast tissue and serum risk biomarkers is associated with >10 % weight loss in postmenopausal women. Breast Cancer Res Treat 142(1):119-32, 11/2013. PMCID: PMC3921968.
55. Cardnell RJ, Feng Y, Diao L, Fan YH, Masrorpour F, Wang J, Shen Y, Mills GB, Minna JD, Heymach JV, Byers LA. Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res 19(22):6322-8, 11/2013. PMCID: PMC3882158.
56. Li J, Lu Y, Akbani R, Ju Z, Roebuck PL, Liu W, Yang JY, Broom BM, Verhaak RG, Kane DW, Wakefield C, Weinstein JN, Mills GB, Liang H. TCPA: a resource for cancer functional proteomics data. Nat Methods 10(11):1046-7, 11/2013. PMCID: PMC4076789.
57. Sohn J, Do KA, Liu S, Chen H, Mills GB, Hortobagyi GN, Meric-Bernstam F, Gonzalez-Angulo AM. Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy. Ann Oncol 24(10):2522-6, 10/2013. PMCID: PMC3784335.
58. Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, Li J, Yu Y, Sasaki M, Horner JW, Burga LN, Xie J, Jurczak MJ, DePinho RA, Clish CB, Jacks T, Kibbey RG, Wulf GM, Di Vizio D, Mills GB, Cantley LC, Vander Heiden MG. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155(2):397-409, 10/2013. PMCID: PMC3850755.
59. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K, Shmulevich I, Sander C, Stuart JM. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 45(10):1113-20, 10/2013. PMCID: PMC3919969.
60. Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, Aldape K, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, TCGA Research Network. The somatic genomic landscape of glioblastoma. Cell 155(2):462-77, 10/2013. PMID: 24120142.
61. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, Harrison M, Mooney T, McMichael JF, Luo J, Tao Y, Goncalves R, Schlosberg C, Hiken JF, Saied L, Sanchez C, Giuntoli T, Bumb C, Cooper C, Kitchens RT, Lin A, Phommaly C, Davies SR, Zhang J, Kavuri MS, McEachern D, Dong YY, Ma C, Pluard T, Naughton M, Bose R, Suresh R, McDowell R, Michel L, Aft R, Gillanders W, DeSchryver K, Wilson RK, Wang S, Mills GB, Gonzalez-Angulo A, Edwards JR, Maher C, Perou CM, Mardis ER, Ellis MJ. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4(6):1116-30, 9/2013. PMCID: PMC3881975.
62. Yang JY, Yoshihara K, Tanaka K, Hatae M, Masuzaki H, Itamochi H, Cancer Genome Atlas (TCGA) Research Network, Takano M, Ushijima K, Tanyi JL, Coukos G, Lu Y, Mills GB, Verhaak RG. Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 123(9):3740-50, 9/2013. PMCID: PMC3754259.
63. Billiard J, Dennison JB, Briand J, Annan RS, Chai D, Colón M, Dodson CS, Gilbert SA, Greshock J, Jing J, Lu H, McSurdy-Freed JE, Orband-Miller LA, Mills GB, Quinn CJ, Schneck JL, Scott GF, Shaw AN, Waitt GM, Wooster RF, Duffy KJ. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer Metab 1(1):19, 9/2013. PMID: 24280423.
64. Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, Mao S, Pavlick AC, Froehlich AM, Wu MF, Tsimelzon A, Hilsenbeck SG, Chen ES, Zuloaga P, Shaw CA, Rimawi MF, Perou CM, Mills GB, Chang JC, Lewis MT. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res 73(15):4885-97, 8/2013. PMCID: PMC3732575.
65. Guo H, Gao M, Lu Y, Liang J, Lorenzi PL, Bai S, Hawke DH, Li J, Dogruluk T, Scott KL, Jonasch E, Mills GB, Ding Z. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene, 8/2013. PMCID: PMC3915040.
66. Irwin ME, Nelson LD, Santiago-O'Farrill JM, Knouse PD, Miller CP, Palla SL, Siwak DR, Mills GB, Estrov Z, Li S, Kornblau SM, Hughes DP, Chandra J. Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia. PLoS One 8(8):e70608, 8/2013. PMCID: PMC3731286.
67. Lui VW, Hedberg ML, Li H, Vangara BS, Pendleton K, Zeng Y, Lu Y, Zhang Q, Du Y, Gilbert BR, Freilino M, Sauerwein S, Peyser ND, Xiao D, Diergaarde B, Wang L, Chiosea S, Seethala R, Johnson JT, Kim S, Duvvuri U, Ferris RL, Romkes M, Nukui T, Kwok-Shing Ng P, Garraway LA, Hammerman PS, Mills GB, Grandis JR. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov 3(7):761-9, 7/2013. PMCID: PMC3710532.
68. Dennison JB, Molina JR, Mitra S, González-Angulo AM, Balko JM, Kuba MG, Sanders ME, Pinto JA, Gómez HL, Arteaga CL, Brown RE, Mills GB. Lactate dehydrogenase B: a metabolic marker of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 19(13):3703-13, 7/2013. PMCID: PMC3727144.
69. Park YY, Kim SB, Han HD, Sohn BH, Kim JH, Liang J, Lu Y, Rodriguez-Aguayo C, Lopez-Berestein G, Mills GB, Sood AK, Lee JS. Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520. Hepatology 58(1):182-91, 7/2013. PMID: 23389994.
70. Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol 7(3):647-68, 6/2013. PMCID: PMC3805042.
71. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res 73(11):3470-80, 6/2013. PMCID: PMC3853111.
72. Myhre S, Lingjćrde OC, Hennessy BT, Aure MR, Carey MS, Alsner J, Tramm T, Overgaard J, Mills GB, Břrresen-Dale AL, Sřrlie T. Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins. Mol Oncol 7(3):704-18, 6/2013. PMID: 23562353.
73. Liang J, Mills GB. AMPK: A Contextual Oncogene or Tumor Suppressor? Cancer Res 73(10):2929-35, 5/15/2013. e-Pub 5/3/2013. PMID: 23644529.
74. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 31(15):1849-57, 5/2013. PMID: 23589548.
75. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER, Levine DA. Integrated genomic characterization of endometrial carcinoma. Nature 497(7447):67-73, 5/2013. PMCID: PMC3704730.
76. Stemke-Hale K, Shipman K, Kitsou-Mylona I, de Castro DG, Hird V, Brown R, Flanagan J, Gabra H, Mills GB, Agarwal R, El-Bahrawy M. Frequency of mutations and polymorphisms in borderline ovarian tumors of known cancer genes. Mod Pathol 26(4):544-52, 4/2013. PMCID: PMC3856435.
77. Tabchy A, Eltonsy N, Housman DE, Mills GB. Systematic identification of combinatorial drivers and targets in cancer cell lines. PLoS One 8(4):e60339, 4/2013. PMCID: PMC3618473.
78. Jeong KJ, Cho KH, Panupinthu N, Kim H, Kang J, Park CG, Mills GB, Lee HY. EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol. Mol Oncol 7(1):121-9, 2/2013. PMID: 23127547.
79. Sansores-Garcia L, Atkins M, Moya IM, Shahmoradgoli M, Tao C, Mills GB, Halder G. Mask Is Required for the Activity of the Hippo Pathway Effector Yki/YAP. Curr Biol 23(3):229-35, 2/2013. PMCID: PMC4089957.
80. Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 19(3):657-67, 2/2013. PMCID: PMC3563727.
81. Gao M, Liang J, Lu Y, Guo H, German P, Bai S, Jonasch E, Yang X, Mills GB, Ding Z. Site-specific activation of AKT protects cells from death induced by glucose deprivation. Oncogene, 2/2013. PMCID: PMC3874430.
82. Westin SN, Mills GB, Myers AP. Repurposing the pap smear: one step closer to gynecologic cancer screening. Sci Transl Med 5(167):167ps1, 1/9/2013. PMCID: PMC3824959.
83. Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res 19(1):279-290, 1/2013. PMCID: PMC3567921.
84. Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT. BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation. Mol Oncol, 1/2013. PMCID: PMC4106023.
85. Yao Y, Suraokar M, Darnay BG, Hollier BG, Shaiken TE, Asano T, Chen CH, Chang BH, Lu Y, Mills GB, Sarbassov D, Mani SA, Abbruzzese JL, Reddy SA. BSTA Promotes mTORC2-Mediated Phosphorylation of Akt1 to Suppress Expression of FoxC2 and Stimulate Adipocyte Differentiation. Sci Signal 6(257):ra2, 1/2013. PMCID: PMC3748614.
86. Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res 15(1):R3, 1/2013. PMCID: PMC3672770.
87. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/2013. PMCID: PMC3461089.
88. Albeck JG, Mills GB, Brugge JS. Frequency-Modulated Pulses of ERK Activity Transmit Quantitative Proliferation Signals. Mol Cell 49(2):249-61, 1/2013. PMID: 23219535.
89. Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Res Treat 137(1):319-27, 1/2013. PMCID: PMC3556743.
90. Farhangfar CJ, Meric-Bernstam F, Mendelsohn J, Mills GB, Lucio-Eterovic AK. The Impact of Tumor Heterogeneity on Patient Treatment Decisions. Clin Chem 59(1):38-40, 1/2013. PMID: 23143327.
91. Mao Y, Chen H, Liang H, Meric-Bernstam F, Mills GB, Chen K. CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features. PLoS One 8(10):e77945, 2013. PMCID: PMC3813554.
92. Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Trevińo V, Shen H, Laird PW, Levine DA, Carter SL, Getz G, Stemke-Hale K, Mills GB, Verhaak RG. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612, 2013. PMCID: PMC3826632.
93. Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C, Dong Z, Siwak DR, Annis MG, Mills GB, Muller WJ, Siegel PM, Jones RG. LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer. Cancer Metab 1(1):18, 2013. PMID: 24280377.
94. Daemen A, Griffith OL, Heiser LM, Wang NJ, Enache OM, Sanborn Z, Pepin F, Durinck S, Korkola JE, Griffith M, Hur JS, Huh N, Chung J, Cope L, Fackler MJ, Umbricht C, Sukumar S, Seth P, Sukhatme VP, Jakkula LR, Lu Y, Mills GB, Cho RJ, Collisson EA, Van't Veer LJ, Spellman PT, Gray JW. Modeling precision treatment of breast cancer. Genome Biol 14(10):R110, 2013. PMCID: PMC3937590.
95. Lindholm EM, Krohn M, Iadevaia S, Kristian A, Mills GB, Mćlandsmo GM, Engebraaten O. Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res, 2013. PMID: 24192926.
96. Li J., Lu Y., Akbani R., Ju., Z., Liu W., Yang JY., Broom BM., Kane D., Weinstein JN., Cancer Genome Atlas Research Network., Mills GB., Han Liang. The Cancer Proteome Atlas: A Resource for Cancer Proteomics Data. Nature Methods, 2013. PMID: 24037243.
97. Mitra S, Cheng KW, Mills GB. Rab25 in cancer: a brief update. Biochem Soc Trans 40(6):1404-8, 12/1/2012. PMID: 23176489.
98. Hill SM, Lu Y, Molina J, Heiser LM, Spellman PT, Speed TP, Gray JW, Mills GB, Mukherjee S. Bayesian Inference of Signaling Network Topology in a Cancer Cell Line. Bioinformatics 28(21):2804-2810, 11/2012. PMCID: PMC3476330.
99. Gonzalez-Angulo AM, Liu S, Chen H, Chavez-Macgregor M, Sahin A, Hortobagyi GN, Mills GB, Do KA, Meric-Bernstam F. Functional proteomics characterization of residual breast cancer after neoadjuvant systemic chemotherapy. Ann Oncol, 11/2012. PMCID: PMC3603436.
100. Liang ZD, Long Y, Tsai WB, Fu S, Kurzrock R, Gagea-Iurascu M, Zhang F, Chen HH, Hennessy BT, Mills GB, Savaraj N, Kuo MT. Mechanistic Basis for Overcoming Platinum Resistance Using Copper Chelating Agents. Mol Cancer Ther 11(11):2483-94, 11/2012. PMCID: PMC3496003.
101. Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, FitzGerald LM, Krivak T, DeLoia JA, Gutin A, Mills GB, Lanchbury JS. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107(10):1776-82, 11/2012. PMCID: PMC3493866.
102. Kamel D, Brady B, Tabchy A, Mills GB, Hennessy B. Proteomic Classification of Breast Cancer. Curr Drug Targets 13(12):1495-509, 11/2012. PMID: 22974393.
103. Simpkins F, Hevia-Paez P, Sun J, Ullmer W, Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B, Azzam D, Xu XX, Ince TA, Yang JY, Verhaak RG, Lu Y, Mills GB, Slingerland JM. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin Cancer Res 18(21):5911-23, 11/2012. PMCID: PMC3698880.
104. Kim N, He N, Kim C, Zhang F, Lu Y, Yu Q, Stemke-Hale K, Greshock J, Wooster R, Yoon S, Mills GB. Systematic analysis of genotype-specific drug responses in cancer. Int J Cancer 131(10):2456-64, 11/2012. PMCID: PMC4012336.
105. Liang H, Cheung LW, Li J, Ju Z, Yu S, Stemke-Hale K, Dogruluk T, Lu Y, Liu X, Gu C, Guo W, Scherer SE, Carter H, Westin SN, Dyer MD, Verhaak RG, Zhang F, Karchin R, Liu CG, Lu KH, Broaddus RR, Scott KL, Hennessy BT, Mills GB. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 22(11):2120-9, 11/2012. PMCID: PMC3483541.
106. Sangai T, Akcakanat A, Chen H, Tarco E, Wu Y, Do KA, Miller TW, Arteaga CL, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res 18(20):5816-28, 10/2012. PMCID: PMC3772348.
107. Li X, Lu Y, Liang K, Hsu JM, Albarracin C, Mills GB, Hung MC, Fan Z. Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR. Oncogene 31(40):4372-83, 10/2012. PMCID: PMC3326223.
108. Pareja F, Ferraro DA, Rubin C, Cohen-Dvashi H, Zhang F, Aulmann S, Ben-Chetrit N, Pines G, Navon R, Crosetto N, Köstler W, Carvalho S, Lavi S, Schmitt F, Dikic I, Yakhini Z, Sinn P, Mills GB, Yarden Y. Deubiquitination of EGFR by Cezanne-1 contributes to cancer progression. Oncogene 31(43):4599-608, 10/2012. PMCID: PMC3326441.
109. Astanehe A, Finkbeiner MR, Krzywinski M, Fotovati A, Dhillon J, Berquin IM, Mills GB, Marra MA, Dunn SE. MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition. Oncogene 31(41):4434-46, 10/2012. PMID: 22249268.
110. Verhaak RG, Mills GB. Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. Breast Cancer Res 14(5):322, 10/2012. PMID: 23106814.
111. Nieto-Barajas LE, Müller P, Ji Y, Lu Y, Mills GB. A Time-Series DDP for Functional Proteomics Profiles. Biometrics 68(3):859-68, 9/2012. PMCID: PMC4091682.
112. Eltonsy N, Gabisi V, Li X, Russe KB, Mills GB, Stemke-Hale K. Detection algorithm for the validation of human cell lines. Int J Cancer 131(6):E1024-30, 9/2012. PMCID: PMC3772516.
113. Oates CJ, Hennessy BT, Lu Y, Mills GB, Mukherjee S. Network Inference Using Steady-State Data and Goldbeter-Koshland Kinetics. Bioinformatics 28(18):2342-8, 9/2012. PMCID: PMC3436851.
114. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol 9(9):542-8, 9/2012. PMID: 22850751.
115. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discov 2(9):798-811, 9/2012. PMCID: PMC3567922.
116. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the Hepatocyte Growth Factor-cMET Axis in Cancer Therapy. J Clin Oncol 30(26):3287-96, 9/2012. PMCID: PMC3434988.
117. Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY. Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors. Cancer 118(16):3993-4003, 8/2012. PMCID: PMC3674414.
118. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, Fu XD, Mills GB, Guan KL. Regulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling. Cell 150(4):780-91, 8/2012. PMCID: PMC3433174.
119. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol 126(1):47-53, 7/2012. PMCID: PMC3738300.
120. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18(7):1052-9, 7/2012. PMCID: PMC3693569.
121. Carter BZ, Qiu Y, Huang X, Diao L, Zhang N, Coombes KR, Mak DH, Konopleva M, Cortes J, Kantarjian HM, Mills GB, Andreeff M, Kornblau SM. Survivin is highly expressed in CD34+38- leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood 120(1):173-80, 7/2012. PMCID: PMC3390955.
122. Ding Z, German P, Bai S, Feng Z, Gao M, Si W, Sobieski MM, Stephan CC, Mills GB, Jonasch E. Agents That Stabilize Mutated von Hippel-Lindau (VHL) Protein: Results of a High-Throughput Screen to Identify Compounds That Modulate VHL Proteostasis. J Biomol Screen 17(5):572-80, 6/2012. PMCID: PMC3895461.
123. Ji H, Ding Z, Hawke D, Xing D, Jiang BH, Mills GB, Lu Z. AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis. EMBO Rep 13(6):554-60, 6/2012. PMCID: PMC3367238.
124. Federico L, Ren H, Mueller PA, Wu T, Liu S, Popovic J, Blalock EM, Sunkara M, Ovaa H, Albers HM, Mills GB, Morris AJ, Smyth SS. Autotaxin and its product lysophosphatidic Acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol 26(5):786-97, 5/2012. PMCID: PMC3355557.
125. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, Mersinias V, Armaka M, Xu Y, Masu M, Mills GB, Gay S, Kollias G, Aidinis V. Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 209(5):925-33, 5/2012. PMCID: PMC3348105.
126. Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 25(5):699-708, 5/2012. PMCID: PMC3341518.
127. Mu H, Calderone TL, Davies MA, Prieto VG, Wang H, Mills GB, Bar-Eli M, Gershenwald JE. Lysophosphatidic Acid induces lymphangiogenesis and IL-8 production in vitro in human lymphatic endothelial cells. Am J Pathol 180(5):2170-81, 5/2012. PMCID: PMC3349835.
128. Ram PT, Mendelsohn J, Mills GB. Bioinformatics and systems biology. Mol Oncol 6(2):147-54, 4/2012. PMCID: PMC3345061.
129. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, Mills GB, Meric-Bernstam F, Blumenschein GR, Gonzalez-Angulo AM. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res 18(8):2269-77, 4/2012. PMCID: PMC3821167.
130. Tarcic G, Avraham R, Pines G, Amit I, Shay T, Lu Y, Zwang Y, Katz M, Ben-Chetrit N, Jacob-Hirsch J, Virgilio L, Rechavi G, Mavrothalassitis G, Mills GB, Domany E, Yarden Y. EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF. FASEB J 26(4):1582-92, 4/2012. PMCID: PMC3316897.
131. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 209(4):679-96, 4/2012. PMCID: PMC3328367.
132. Wheeler S, Siwak DR, Chai R, LaValle C, Seethala RR, Wang L, Cieply K, Sherer C, Joy C, Mills GB, Argiris A, Siegfried JM, Grandis JR, Egloff AM. Tumor epidermal growth factor receptor (EGFR) and EGFR PY1068 are independent prognostic indicators for head and neck squamous cell carcinoma. Clin Cancer Res 18(8):2278-89, 4/2012. PMCID: PMC3430124.
133. Meric-Bernstam F, Akcakanat A, Chen H, Do KA, Sangai T, Adkins F, Gonzalez-Angulo AM, Rashid A, Crosby K, Dong M, Phan AT, Wolff RA, Gupta S, Mills GB, Yao J. PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors. Clin Cancer Res 18(6):1777-89, 3/15/2012. PMCID: PMC3307149.
134. Dutta B, Pusztai L, Qi Y, André F, Lazar V, Bianchini G, Ueno N, Agarwal R, Wang B, Shiang CY, Hortobagyi GN, Mills GB, Symmans WF, Balázsi G. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer 106(6):1107-16, 3/2012. PMCID: PMC3304402.
135. Worster DT, Schmelzle T, Solimini NL, Lightcap ES, Millard B, Mills GB, Brugge JS, Albeck JG. Akt and ERK Control the Proliferative Response of Mammary Epithelial Cells to the Growth Factors IGF-1 and EGF Through the Cell Cycle Inhibitor p57Kip2. Sci Signal 5(214):ra19, 3/2012. PMID: 22394561.
136. Gubanova E, Brown B, Ivanov SV, Helleday T, Mills GB, Yarbrough WG, Issaeva N. Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival. Clin Cancer Res 18(5):1257-67, 3/2012. PMCID: PMC4010255.
137. Mitra S, Stemke-Hale K, Mills GB, Claerhout S. Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. Cancer Sci 103(3):400-7, 3/2012. PMID: 22151725.
138. Wang LE, Ma H, Hale KS, Yin M, Meyer LA, Liu H, Li J, Lu KH, Hennessy BT, Li X, Spitz MR, Wei Q, Mills GB. Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes. J Cancer Res Clin Oncol 138(3):377-85, 3/2012. PMCID: PMC3526101.
139. Mills GB. An emerging toolkit for targeted cancer therapies. Genome Res 22(2):177-82, 2/2012. PMCID: PMC3266025.
140. Gonzalez-Angulo AM, Iwamoto T, Liu S, Chen H, Do KA, Hortobagyi GN, Mills GB, Meric-Bernstam F, Symmans WF, Pusztai L. Gene expression, molecular class changes and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res 18(4):1109-19, 2/2012. PMCID: PMC3288822.
141. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, Morales FC, Gao S, Mills GB, Brugge JS. Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. Cancer Cell 21(2):227-39, 2/2012. PMCID: PMC3297962.
142. Pradeep CR, Köstler WJ, Lauriola M, Granit RZ, Zhang F, Jacob-Hirsch J, Rechavi G, Nair HB, Hennessy BT, Gonzalez-Angulo AM, Tekmal RR, Ben-Porath I, Mills GB, Domany E, Yarden Y. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 31(7):907-17, 2/2012. PMCID: PMC3193899.
143. Cheng KW, Agarwal R, Mitra S, Lee JS, Carey M, Gray JW, Mills GB. Rab25 increases cellular ATP and glycogen stores protecting cancer cells from bioenergetic stress. EMBO Mol Med 4(2):125-41, 2/2012. PMCID: PMC3306554.
144. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, Gibb WJ, Wang NJ, Ziyad S, Tong F, Bayani N, Hu Z, Billig JI, Dueregger A, Lewis S, Jakkula L, Korkola JE, Durinck S, Pepin F, Guan Y, Purdom E, Neuvial P, Bengtsson H, Wood KW, Smith PG, Vassilev LT, Hennessy BT, Greshock J, Bachman KE, Hardwicke MA, Park JW, Marton LJ, Wolf DM, Collisson EA, Neve RM, Mills GB, Speed TP, Feiler HS, Wooster RF, Haussler D, Stuart JM, Gray JW, Spellman PT. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci U S A 109(8):2724-9, 2/2012. PMCID: PMC3286973.
145. Bast RC, Mills GB. Dissecting "PI3Kness": The Complexity of Personalized Therapy for Ovarian Cancer. Cancer Discov 2(1):16-8, 1/2012. PMCID: PMC3354732.
146. Cheng HY, Dong A, Panchatcharam M, Mueller P, Yang F, Li Z, Mills G, Chun J, Morris AJ, Smyth SS. Lysophosphatidic acid signaling protects pulmonary vasculature from hypoxia-induced remodeling. Arterioscler Thromb Vasc Biol 32(1):24-32, 1/2012. PMCID: PMC3241874.
147. Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, Lim JY, Li J, Lu Y, Gonzalez-Angulo AM, Jeong W, Mills GB, Safe S, Lee JS. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med 4(1):52-67, 1/2012. PMCID: PMC3376834.
148. Meric-Bernstam F, Chen H, Akcakanat A, Do KA, Lluch A, Hennessy BT, Hortobagyi GN, Mills GB, Gonzalez-Angulo AM. Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer. Breast Cancer Res 14(5):R138, 2012. PMCID: PMC4053117.
149. Claerhout S, Dutta B, Bossuyt W, Zhang F, Nguyen-Charles C, Dennison JB, Yu Q, Yu S, Balázsi G, Lu Y, Mills GB. Abortive autophagy induces endoplasmic reticulum stress and cell death in cancer cells. PLoS One 7(6):e39400, 2012. PMCID: PMC3383753.
150. Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy BT, Tsavachidou D. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 10(1):56, 2012. PMCID: PMC3561137.
151. Park YY, Park ES, Kim SB, Kim SC, Sohn BH, Chu IS, Jeong W, Mills GB, Byers LA, Lee JS. Development and validation of a prognostic gene-expression signature for lung adenocarcinoma. PLoS One 7(9):e44225, 2012. PMCID: PMC3436895.
152. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients. PLoS Genet 8(3):e1002538, 2012. PMCID: PMC3315462.
153. Hoshino D, Jourquin J, Emmons SW, Miller T, Goldgof M, Costello K, Tyson DR, Brown B, Lu Y, Prasad NK, Zhang B, Mills GB, Yarbrough WG, Quaranta V, Seiki M, Weaver AM. Network Analysis of the Focal Adhesion to Invadopodia Transition Identifies a PI3K-PKCα Invasive Signaling Axis. Sci Signal 5(241):ra66, 2012. PMCID: PMC3583194.
154. Tuna M, Ju Z, Amos CI, Mills GB. Soft tissue sarcoma subtypes exhibit distinct patterns of acquired uniparental disomy. BMC Med Genomics 5(1):60, 2012. PMCID: PMC3541987.
155. Quayle SN, Lee JY, Cheung LW, Ding L, Wiedemeyer R, Dewan RW, Huang-Hobbs E, Zhuang L, Wilson RK, Ligon KL, Mills GB, Cantley LC, Chin L. Somatic Mutations of PIK3R1 Promote Gliomagenesis. PLoS One 7(11):e49466, 2012. PMCID: PMC3498106.
156. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, Ravoori M, Kundra V, Ajani J, Lee JS, Ki Hong W, Mills GB. Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 10(12):2350-62, 12/2011. PMCID: PMC3237863.
157. Lee JS, Kim JH, Park YY, Mills GB. Systems biology approaches to decoding the genome of liver cancer. Cancer Res Treat 43(4):205-11, 12/2011. PMCID: PMC3253861.
158. Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773-84, 11/2011. PMCID: PMC3206206.
159. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, Wasan H, Gabra H. DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance. Neoplasia 13(11):1069-80, 11/2011. PMCID: PMC3223610.
160. Brewster AM, Thompson P, Sahin AA, Do K, Edgerton M, Murray JL, Tsavachidis S, Zhou R, Liu Y, Zhang L, Mills G, Bondy M. Copy number imbalances between screen- and symptom-detected breast cancers and impact on disease-free survival. Cancer Prev Res (Phila) 4(10):1609-16, 10/2011. PMCID: PMC3188338.
161. Park ES, Kim SJ, Kim SW, Yoon SL, Leem SH, Kim SB, Kim SM, Park YY, Cheong JH, Woo HG, Mills GB, Fidler IJ, Lee JS. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc Natl Acad Sci U S A 108(42):17456-61, 10/2011. PMCID: PMC3198333.
162. Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, González-Angulo AM, Mills GB, Dave B, Chang JC, Liebler DC, Arteaga CL. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 30(40):4163-74, 10/2011. PMCID: PMC3204390.
163. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10):719-25, 10/2011. PMCID: PMC3380637.
164. Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res 71(20):6524-34, 10/2011. PMCID: PMC3193577.
165. Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, Manning HC, González-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL. ERa-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338-351, 9/2011. PMCID: PMC3204388.
166. Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, Zhao JJ. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med, 8/2011. PMCID: PMC3169724.
167. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H. HDAC4-Regulated STAT1 Activation Mediates Platinum Resistance in Ovarian Cancer. Cancer Res 71(13):4412-22, 7/2011. PMCID: PMC3130134.
168. Cheung LW, Hennessy BT, Li J, Yu S, Myers AP, Djordjevic B, Lu Y, Stemke-Hale K, Zhang F, Ju Z, Cantley LC, Scherer SE, Liang H, Lu KH, Broaddus RR, Mills GB. High Frequency of PIK3R1 and PIK3R2 Mutations in Endometrial Cancer Elucidates a Novel Mechanism for Regulation of PTEN Protein Stability. Cancer Discov 1(2):170-185, 7/2011. PMCID: PMC3187555.
169. Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther 18(7):510-9, 7/2011. PMCID: PMC3875403.
170. Lu Y, Muller M, Smith D, Dutta B, Komurov K, Iadevaia S, Ruths D, Tseng JT, Yu S, Yu Q, Nakhleh L, Balazsi G, Donnelly J, Schurdak M, Morgan-Lappe S, Fesik S, Ram PT, Mills GB. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene, 6/2011. PMCID: PMC3175328.
171. Gonzalez-Angulo AM, Ferrer-Lozano J, Stemke-Hale K, Sahin A, Liu S, Barrera JA, Burgues O, Lluch AM, Chen H, Hortobagyi GN, Mills GB, Meric-Bernstam F. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer. Mol Cancer Ther 10(6):1093-101, 6/2011. PMCID: PMC3112276.
172. Gupte R, Patil R, Liu J, Wang Y, Lee SC, Fujiwara Y, Fells J, Bolen AL, Emmons-Thompson K, Yates CR, Siddam A, Panupinthu N, Pham TC, Baker DL, Parrill AL, Mills GB, Tigyi G, Miller DD. Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem 6(5):922-35, 5/2/2011. e-Pub 4/4/2011. PMCID: PMC3517046.
173. Zwang Y, Sas-Chen A, Drier Y, Shay T, Avraham R, Lauriola M, Shema E, Lidor-Nili E, Jacob-Hirsch J, Amariglio N, Lu Y, Mills GB, Rechavi G, Oren M, Domany E, Yarden Y. Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals. Mol Cell 42(4):524-35, 5/2011. PMCID: PMC3100487.
174. Miller TW, Balko JM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, González-Angulo AM, Mills GB, Miller WR, Wu H, Shyr Y, Arteaga CL. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance. Clin Cancer Res 17(7):2024-34, 4/1/2011. e-Pub 2/23/2011. PMCID: PMC3221728.
175. Halder G, Mills GB. Drosophila in cancer research: to boldly go where no one has gone before. Oncogene. e-Pub 4/18/2011. PMID: 21499298.
176. Park SY, Jeong KJ, Panupinthu N, Yu S, Lee J, Han JW, Kim JM, Lee JS, Kang J, Park CG, Mills GB, Lee HY. Lysophosphatidic acid augments human hepatocellular carcinoma cell invasion through LPA1 receptor and MMP-9 expression. Oncogene 30(11):1351-9, 3/17/2011. e-Pub 11/22/2010. PMID: 21102517.
177. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, González-Angulo AM, Mills GB, Penuel E, Winslow J, Sperinde J, Dua R, Pidaparthi S, Mukherjee A, Leitzel K, Kostler WJ, Lipton A, Bates M, Arteaga CL. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71(5):1871-82, 3/1/2011. e-Pub 2/15/2011. PMCID: PMC3221734.
178. Kim SJ, Kim JS, Park ES, Lee JS, Lin Q, Langley RR, Maya M, He J, Kim SW, Weihua Z, Balasubramanian K, Fan D, Mills GB, Hung MC, Fidler IJ. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 13(3):286-98, 3/2011. PMCID: PMC3050871.
179. Gonzalez-Angulo AM, Timms KM, Liu S, Chen H, Litton JK, Potter J, Lanchbury JS, Stemke-Hale K, Hennessy BT, Arun BK, Hortobagyi GN, Do KA, Mills GB, Meric-Bernstam F. Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer. Clin Cancer Res 17(5):1082-9, 3/2011. PMCID: PMC3048924.
180. Lui VW, Wong EY, Ho K, Ng PK, Lau CP, Tsui SK, Tsang CM, Tsao SW, Cheng SH, Ng MH, Ng YK, Lam EK, Hong B, Lo KW, Mok TS, Chan AT, Mills GB. Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death. Oncogene 30(9):1127-34, 3/2011. PMCID: PMC3428712.
181. Suo J, Snider SJ, Mills GB, Creighton CJ, Chen AC, Schiff R, Lloyd RE, Chang EC. Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium. Oncogene 30(6):724-36, 2/2011. PMCID: PMC3017639.
182. Tabchy A, Tigyi G, Mills GB. Location, location, location: a crystal-clear view of autotaxin saturating LPA receptors. Nat Struct Mol Biol 18(2):117-8, 2/2011. PMCID: PMC3584164.
183. Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills GB. Quantitative proteomic analysis in breast cancer. Drugs Today (Barc) 47(2):169-82, 2/2011. PMID: 21431104.
184. Mitra S, Cheng KW, Mills GB. Rab GTPases implicated in inherited and acquired disorders. Semin Cell Dev Biol 22(1):57-68, 2/2011. e-Pub 12/13/2010. PMID: 21147240.
185. Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC, Lev D. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene 30(4):457-70, 1/2011. PMCID: PMC3010301.
186. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17(11):1498-503, 2011. PMID: 22037646.
187. Stronach EA, Alfraidi A, Rama N, Datler C, Studd J, Agarwal R, Guney TG, Courley C, Timms K, Hennessy BT, Mills GB, Mai A, Brown R, Dina R, Gabra H. Analysis of intra-patient acquisition of platinum resistance in ovarian cancer reveal survival STAT1 activation dependent on HDAC4 mediated deacerylation. Cancer Research, 2011.
188. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 6(12):e28840, 2011. PMCID: PMC3237548.
189. Gonzalez-Angulo AM, Hennessy BT, Meric-Bernstam F, Sahin A, Liu W, Ju Z, Carey MS, Myhre S, Speers C, Deng L, Broaddus R, Lluch A, Aparicio S, Brown P, Pusztai L, Symmans WF, Alsner J, Overgaard J, Borresen-Dale AL, Hortobagyi GN, Coombes KR, Mills GB. Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics 8(1):11, 2011. PMCID: PMC3170272.
190. Claerhout S, Lim JY, Choi W, Park YY, Kim K, Kim SB, Lee JS, Mills GB, Cho JY. Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One 6(9):e24662, 2011. PMCID: PMC3170379.
191. Han CH, Huang YJ, Lu KH, Liu Z, Mills GB, Wei Q, Wang LE. Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer. J Exp Clin Cancer Res 30(1):5, 2011. PMCID: PMC3025876.
192. Thompson PA, Brewster AM, Kim-Anh D, Baladandayuthapani V, Broom BM, Edgerton ME, Hahn KM, Murray JL, Sahin A, Tsavachidis S, Wang Y, Zhang L, Hortobagyi GN, Mills GB, Bondy ML. Selective genomic copy number imbalances and probability of recurrence in early-stage breast cancer. PLoS One 6(8):e23543, 2011. PMCID: PMC3155554.
193. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, Davies MA, Liu W, Coombes K, Meric-Bernstam F, Bedrosian I, McGahren M, Agarwal R, Zhang F, Overgaard J, Alsner J, Neve RM, Kuo WL, Gray JW, Borresen-Dale AL, Mills GB. A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers. Clin Proteomics 6(4):129-151, 12/2010. PMCID: PMC3116520.
194. Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun 403(1):103-7, 12/2010. PMCID: PMC3001223.
195. Smith DM, Patel S, Raffoul F, Haller E, Mills GB, Nanjundan M. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ 17(12):1867-81, 12/2010. PMCID: PMC2932795.
196. Deus HF, Veiga DF, Freire PR, Weinstein JN, Mills GB, Almeida JS. Exposing the cancer genome atlas as a SPARQL endpoint. J Biomed Inform 43(6):998-1008, 12/2010. PMCID: PMC3071752.
197. Nanjundan M, Byers LA, Carey MS, Siwak DR, Raso MG, Diao L, Wang J, Coombes KR, Roth JA, Mills GB, Wistuba II, Minna JD, Heymach JV. Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol 5(12):1894-904, 12/2010. PMCID: PMC3374718.
198. Gupte R, Siddam A, Lu Y, Li W, Fujiwara Y, Panupinthu N, Pham TC, Baker DL, Parrill AL, Gotoh M, Murakami-Murofushi K, Kobayashi S, Mills GB, Tigyi G, Miller DD. Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg Med Chem Lett 20(24):7525-8, 12/2010. PMCID: PMC3040411.
199. Liang K, Esteva FJ, Albarracin C, Stemke-Hale K, Lu Y, Bianchini G, Yang CY, Li Y, Li X, Chen CT, Mills GB, Hortobagyi GN, Mendelsohn J, Hung MC, Fan Z. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18(5):423-35, 11/16/2010. PMCID: PMC3022383.
200. Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer? Proc Natl Acad Sci U S A 107(48):20599-600, 11/2010. PMCID: PMC2996413.
201. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis. Clin Breast Cancer 10:S59-65, 11/2010. PMID: 21115423.
202. Cheng X, Xia W, Yang JY, Hsu JL, Lang JY, Chou CK, Du Y, Sun HL, Wyszomierski SL, Mills GB, Muller WJ, Yu D, Hung MC. Activation of Murine Double Minute 2 by Akt in Mammary Epithelium Delays Mammary Involution and Accelerates Mammary Tumorigenesis. Cancer Res 70(19):7684-9, 10/2010. PMCID: PMC2948588.
203. Luyimbazi D, Akcakanat A, McAuliffe PF, Zhang L, Singh G, Gonzalez-Angulo AM, Chen H, Do KA, Zheng Y, Hung MC, Mills GB, Meric-Bernstam F. Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer. Mol Cancer Ther 9(10):2770-84, 10/2010. PMCID: PMC2965451.
204. Iadevaia S, Lu Y, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis. Cancer Res 70(17):6704-14, 9/2010. PMCID: PMC2932856.
205. Yang G, Rosen DG, Liu G, Yang F, Guo X, Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, Mills GB, Liu J. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res 16(15):3875-86, 8/2010. PMCID: PMC2930833.
206. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 21(8):1599-606, 8/2010. PMCID: PMC4092253.
207. Amos CI, Gorlov IP, Dong Q, Wu X, Zhang H, Lu EY, Scheet P, Greisinger AJ, Mills GB, Spitz MR. Nicotinic acetylcholine receptor region on chromosome 15q25 and lung cancer risk among African Americans: a case-control study. J Natl Cancer Inst 102(15):1199-205, 8/2010. PMCID: PMC2914761.
208. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, Abkevich V, Potter J, Pruss D, Glenn P, Li Y, Li J, Gonzalez-Angulo AM, McCune KS, Markman M, Broaddus RR, Lanchbury JS, Lu KH, Mills GB. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 28(22):3570-6, 8/2010. PMCID: PMC2917312.
209. Cai D, Shames DS, Raso MG, Xie Y, Kim YH, Pollack JR, Girard L, Sullivan JP, Gao B, Peyton M, Nanjundan M, Byers L, Heymach J, Mills G, Gazdar AF, Wistuba I, Kodadek T, Minna JD. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res 70(16):6477-85, 8/2010. PMCID: PMC2922434.
210. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, García-Echeverría C, Shyr Y, Arteaga CL. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 120(7):2406-13, 7/2010. PMCID: PMC2898598.
211. Pontier SM, Huck L, White DE, Rayment J, Sanguin-Gendreau V, Hennessy B, Zuo D, St-Arnaud R, Mills GB, Dedhar S, Marshall CJ, Muller WJ. Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer. Oncogene 29(23):3374-85, 6/10/2010. e-Pub 3/22/2010. PMID: 20305688.
212. Yang G, Chang B, Yang F, Guo X, Cai KQ, Xiao XS, Wang H, Sen S, Hung MC, Mills GB, Chang S, Multani AS, Mercado-Uribe I, Liu J. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Clin Cancer Res 16(12):3171-81, 6/2010. PMCID: PMC2930838.
213. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 28(16):2777-83, 6/2010. PMCID: PMC2881854.
214. Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathway-directed therapeutic strategies in cancer. Curr Opin Investig Drugs 11(6):615-28, 6/2010. PMID: 20496256.
215. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, Larsimont D, Gonzalez-Angulo AM, Pusztai L, Symmans WF, Bardelli A, Ellis P, Tutt AN, Gillett CE, Hennessy BT, Mills GB, Phillips WA, Piccart MJ, Speed TP, McArthur GA, Sotiriou C. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107(22):10208-13, 6/2010. PMCID: PMC2890442.
216. Short JD, Dere R, Houston KD, Cai SL, Kim J, Bergeron JM, Shen J, Liang J, Bedford MT, Mills GB, Walker CL. AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49(5):429-39, 5/2010. PMCID: PMC3818129.
217. Carey MS, Agarwal R, Gilks B, Swenerton K, Kalloger S, Santos J, Ju Z, Lu Y, Zhang F, Coombes KR, Miller D, Huntsman D, Mills GB, Hennessy BT. Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. Clin Cancer Res 16(10):2852-60, 5/2010. PMCID: PMC2877659.
218. Lu ZH, Shvartsman MB, Lee AY, Shao JM, Murray MM, Kladney RD, Fan D, Krajewski S, Chiang GG, Mills GB, Arbeit JM. Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res 70(8):3287-98, 4/2010. PMCID: PMC2855737.
219. Panupinthu N, Lee HY, Mills GB. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. Br J Cancer 102(6):941-6, 3/16/2010. PMCID: PMC2844037.
220. Hong B, Lui VW, Hui EP, Lu Y, Leung HS, Wong EY, Cheng SH, Ng MH, Mills GB, Chan AT. Reverse phase protein array identifies novel anti-invasion mechanisms of YC-1. Biochem Pharmacol 79(6):842-52, 3/15/2010. e-Pub 10/30/2009. PMID: 19879857.
221. Mills GB, Yarden Y. The rebirth of a phoenix: ovarian cancers are addicted to ErbB-3. Cancer Cell 17(3):217-8, 3/16/2010. PMID: 20227035.
222. Alexander A, Cai SL, Kim J, Nanez A, Sahin M, MacLean KH, Inoki K, Guan KL, Shen J, Person MD, Kusewitt D, Mills GB, Kastan MB, Walker CL. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc Natl Acad Sci U S A 107(9):4153-8, 3/2010. PMCID: PMC2840158.
223. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, Artavanis-Tsakonas S, Brugge JS. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci U S A 107(11):5012-7, 3/2010. PMCID: PMC2841923.
224. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Cheong JH, Garraway LA, Weinstein JN, Mills GB, Lee JS, Davies MA. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther 9(2):257-67, 2/2010. PMCID: PMC4085051.
225. Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA. miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17(2):246-54, 2/2010. e-Pub 9/4/2009. PMCID: PMC3648637.
226. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Noara H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle 9(1):140-6, 1/2010. PMCID: PMC2931318.
227. Tabb DL, Vega-Montoto L, Variyath AM. The NCI Clinical Proteomic Technology Assessment for Cancer (CPTAC) Network (as part of the network) 2010 Reproducibility and repeatability analysis by liquid chromatography-Tandom Mass Spectrometry. J Proteome Research, 1/2010.
228. Spizzo, R., Nicoloso, M.S, Lupin L., Lu, Y., Fogarty, J., Rosse S., Zagatte, B., Fabbri M., Veronese, A., Davuluri R., Croce., Mills G.B., Negrini M., Calin, G.A. TP53 loop regulates estrogen receptor alpha in human breast cancer. 17:246-54., 1/2010.
229. An J, Wei Q, Liu Z, Lu KH, Cheng X, Mills GB, Wang LE. Messenger RNA expression and methylation of candidate tumor-suppressor genes and risk of ovarian cancer-a case-control analysis. Int J Mol Epidemiol Genet 1(1):1-10, 2010. PMCID: PMC2916180.
230. Luyimbazi D, Akcakanat A, Zhang L, Singh G, Zheng Y, Hung M-C, Mills GB, Meric-Bernstam F. mTor and eIF4E regulate stearoyl CoA desaturates 1 expression through modulation of SREBP1. Mol Can Ther 9. e-Pub 2010.
231. Ding Z, Liang J, Li J, Lu Y, Ariyaratna V, Lu Z, Davies MA, Westwick JK, Mills GB. Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase. PLoS One 5(3):e9910, 2010. PMCID: PMC2845649.
232. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R. Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res 12(3):R40, 2010. PMCID: PMC2917035.
233. Irie HY, Shrestha Y, Selfors LM, Frye F, Iida N, Wang Z, Zou L, Yao J, Lu Y, Epstein CB, Natesan S, Richardson AL, Polyak K, Mills GB, Hahn WC, Brugge JS. PTK6 regulates IGF-1-induced anchorage-independent survival. PLoS One 5(7):e11729, 2010. PMCID: PMC2909213.
234. Altman MK, Gopal V, Jia W, Yu S, Hall H, Mills GB, McGinnis AC, Bartlett MG, Jiang G, Madan D, Prestwich GD, Xu Y, Davies MA, Murph MM. Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid. Mol Cancer 9:140, 2010. PMCID: PMC2895597.
235. Liu S, Murph M, Panupinthu N, Mills GB. ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8(22):3695-701, 11/2009. e-Pub 11/2009. PMID: 19855166.
236. Byers LA, Sen B, Saigal B, Diao L, Wang J, Nanjundan M, Cascone T, Mills GB, Heymach JV, Johnson FM. Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res 15(22):6852-61, 11/2009. PMCID: PMC2935176.
237. Agarwal R, Jurisica I, Mills GB, Cheng KW. The Emerging Role of the RAB25 Small GTPase in Cancer. Traffic 10(11):1561-8, 11/2009. e-Pub 7/2009. PMID: 19719478.
238. Wu X, Ye Y, Kiemeney LA, Sulem P, Rafnar T, Matullo G, Seminara D, Yoshida T, Saeki N, Andrew AS, Dinney CP, Czerniak B, Zhang ZF, Kiltie AE, Bishop DT, Vineis P, Porru S, Buntinx F, Kellen E, Zeegers MP, Kumar R, Rudnai P, Gurzau E, Koppova K, Mayordomo JI, Sanchez M, Saez B, Lindblom A, de Verdier P, Steineck G, Mills GB, Schned A, Guarrera S, Polidoro S, Chang SC, Lin J, Chang DW, Hale KS, Majewski T, Grossman HB, Thorlacius S, Thorsteinsdottir U, Aben KK, Witjes JA, Stefansson K, Amos CI, Karagas MR, Gu J. Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. Nat Genet 41(9):991-5, 9/2009. e-Pub 8/2009. PMCID: PMC3313685.
239. Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res 69(15):6299-306, 8/2009. PMCID: PMC2727605.
240. Woodman SE, Trent JC, Stemke-Hale K, Lazar AJ, Pricl S, Pavan GM, Fermeglia M, Gopal YN, Yang D, Podoloff DA, Ivan D, Kim KB, Papadopoulos N, Hwu P, Mills GB, Davies MA. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 8(8):2079-85, 8/2009. e-Pub 8/2009. PMCID: PMC3346953.
241. Mills GB, Jurisica I, Yarden Y, Norman JC. Genomic amplicons target vesicle recycling in breast cancer. J Clin Invest 119(8):2123-7, 8/2009. PMCID: PMC2719927.
242. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, Sandy P, Hoersch S, Sheng Q, Gupta PB, Boehm JS, Reiling JH, Silver S, Lu Y, Stemke-Hale K, Dutta B, Joy C, Sahin AA, Gonzalez-Angulo AM, Lluch A, Rameh LE, Jacks T, Root DE, Lander ES, Mills GB, Hahn WC, Sellers WR, Garraway LA. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16(1):21-32, 7/2009. PMCID: PMC2752826.
243. Li TT, Alemayehu M, Aziziyeh AI, Pape C, Pampillo M, Postovit LM, Mills GB, Babwah AV, Bhattacharya M. Beta-arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol Cancer Res 7(7):1064-77, 7/2009. PMID: 19609003.
244. Dillon RL, Marcotte R, Hennessy BT, Woodgett JR, Mills GB, Muller WJ. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. Cancer Res 69(12):5057-64, 6/2009. PMID: 19491266.
245. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, Yu S, Stephens LC, Cui X, Murrow G, Coombes K, Muller W, Hung MC, Perou CM, Lee AV, Fang X, Mills GB. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell 15(6):539-50, 6/2009. PMID: 19477432.
246. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 15(11):3654-62, 6/2009. PMCID: PMC2887710.
247. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9(6):415-28, 6/2009. PMCID: PMC2814299.
248. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, Liu W, Stivers D, Baggerly K, Carey M, Lluch A, Monteagudo C, He X, Weigman V, Fan C, Palazzo J, Hortobagyi GN, Nolden LK, Wang NJ, Valero V, Gray JW, Perou CM, Mills GB. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69(10):4116-24, 5/2009. PMCID: PMC2737191.
249. Chen Y, Guggisberg N, Jorda M, Gonzalez-Angulo A, Hennessy B, Mills GB, Tan CK, Slingerland JM. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors. Clin Cancer Res 15(10):3396-405, 5/2009. PMID: 19451593.
250. Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D. Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther 8(5):1157-68, 5/2009. e-Pub 5/2009. PMID: 19417153.
251. Miller TW, Pérez-Torres M, Narasanna A, Guix M, Stĺl O, Pérez-Tenorio G, Gonzalez-Angulo AM, Hennessy BT, Mills GB, Kennedy JP, Lindsley CW, Arteaga CL. Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 69(10):4192-201, 5/2009. PMCID: PMC2724871.
252. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth. Am J Pathol 174(5):1869-79, 5/2009. PMCID: PMC2671275.
253. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, Traina TA, Hudis C, Hortobagyi GN, Gerald WL, Mills GB, Hennessy BT. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 15(7):2472-8, 4/2009. e-Pub 3/2009. PMID: 19276248.
254. O'Reilly KE, Warycha M, Davies MA, Rodrik V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, Mills G, Osman I. Phosphorylated 4E-BP1 is associated with poor survival in melanoma. Clin Cancer Res 15(8):2872-8, 4/2009. e-Pub 3/2009. PMCID: PMC3995540.
255. Yim EK, Peng G, Dai H, Hu R, Li K, Lu Y, Mills GB, Meric-Bernstam F, Hennessy BT, Craven RJ, Lin SY. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 15(4):304-14, 4/2009. PMCID: PMC2673492.
256. Zinner RG, Barrett BL, Popova E, Damien P, Volgin AY, Gelovani JG, Lotan R, Tran HT, Pisano C, Mills GB, Mao L, Hong WK, Lippman SM, Miller JH. Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells. Mol Cancer Ther 8(3):521-32, 3/2009. PMID: 19276160.
257. Pamuklar Z, Federico L, Liu S, Umezu-Goto M, Dong A, Panchatcharam M, Fulkerson Z, Fulerson Z, Berdyshev E, Natarajan V, Fang X, van Meeteren LA, Moolenaar WH, Mills GB, Morris AJ, Smyth SS. Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis. J Biol Chem 284(11):7385-94, 3/2009. PMCID: PMC2652269.
258. Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H. Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. Cancer Res 69(6):2461-70, 3/2009. e-Pub 3/2009. PMID: 19276367.
259. Lai SY, Koppikar P, Thomas SM, Childs EE, Egloff AM, Seethala RR, Branstetter BF, Gooding WE, Muthukrishnan A, Mountz JM, Lui VW, Shin DM, Agarwala SS, Johnson R, Couture LA, Myers EN, Johnson JT, Mills G, Argiris A, Grandis JR. Intratumoral Epidermal Growth Factor Receptor Antisense DNA Therapy in Head and Neck Cancer: First Human Application and Potential Antitumor Mechanisms. J Clin Oncol 27(8):1235-42, 3/2009. PMCID: PMC2667824.
260. Hung MC, Mills GB, Yu D. Oxygen sensor boosts growth factor signaling. Nat Med 15(3):246-7, 3/2009. PMID: 19265822.
261. Zhang L, Wei Q, Mao L, Liu W, Mills GB, Coombes K. Serial dilution curve: a new method for analysis of reverse phase protein array data. Bioinformatics 25(5):650-4, 3/2009. PMCID: PMC2647837.
262. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med 15(3):120-8, 3/2009. e-Pub 2/2009. PMID: 19246245.
263. Hennessy BT, Gonzalez-Angulo AM, Carey MS, Mills GB. A systems approach to analysis of molecular complexity in breast cancer. Clin Cancer Res 15(2):417-9, 1/2009. PMID: 19147744.
264. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69(2):565-72, 1/2009. PMCID: PMC2737189.
265. Kornblau SM, Tibes R, Qiu YH, Chen W, Kantarjian HM, Andreeff M, Coombes KR, Mills GB. Functional proteomic profiling of AML predicts response and survival. Blood 113(1):154-64, 1/2009. PMCID: PMC2951831.
266. Hung MC, Mills GB, Yu D. Less oxygen but more RTK:HIF links oxygen- sensing pathway to receptor tyrosine kinase (RTK) endocytosis. Nature Med, 1/2009.
267. Addona T, Abbatiello S, Skates, SJ. Multi Site assessment of precision and reproducibilty of multiple reaction monotoring-based measurements of proteins in plasma. Nature Biotech, 1/2009. PMCID: PMC2855883.
268. Ihle NT, Lemos R, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69(1):143-50, 1/2009. PMCID: PMC2613546.
269. Wang Y, Carlton VE, Karlin-Neumann G, Sapolsky R, Zhang L, Moorhead M, Wang ZC, Richardson AL, Warren R, Walther A, Bondy M, Sahin A, Krahe R, Tuna M, Thompson PA, Spellman PT, Gray JW, Mills GB, Faham M. High quality copy number and genotype data from FFPE samples using Molecular Inversion Probe (MIP) microarrays. BMC Med Genomics 2:8, 2009. PMCID: PMC2649948.
270. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, Aldape K, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. Clin Cancer Res 15(24):7538-7546, 2009. PMCID: PMC2805170.
271. Murph MM, Liu W, Yu S, Lu Y, Hall H, Hennessy BT, Lahad J, Schaner M, Helland A, Kristensen G, Břrresen-Dale AL, Mills GB. Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis. PLoS One 4(5):e5583, 2009. PMCID: PMC2679144.
272. Maurer M, Su T, Koujak S, Hopkins BD, Saal LH, Barley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim D, Ferris JS, Gruvberger Sk, Laasko M, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon C, Isola J, Terry MB, Toler A, Landry DW, Mills GB, Zhao JJ, Murty VVS, Hibshooosh H, Parsons R. PDK1 potentiates upstream P13K pathway aberration in brest carcinoma. Cancer Research 69. e-Pub 2009.
273. Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang LE. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med 2(4):289-99, 2009. PMCID: PMC2802047.
274. Cheng KW, Agarwal R, Mills GB. Ras-superfamily GTP-ases in ovarian cancer. Cancer Treat Res 149:229-40, 2009. PMID: 19763439.
275. Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH, Kim YS, Park HJ, Seo SY, Geo SY, Mills G, Kim KW, Hong WK, Suh YG, Lee HY. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila) 1(7):577-87, 12/2008. PMCID: PMC2738643.
276. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest 118(12):3917-29, 12/2008. PMCID: PMC2582930.
277. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer 8(11):835-50, 11/2008. PMID: 18948996.
278. Yu S, Murph MM, Lu Y, Liu S, Hall HS, Liu J, Stephens C, Fang X, Mills GB. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 100(22):1630-42, 11/2008. PMCID: PMC2720766.
279. Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 99(8):1265-8, 10/2008. PMCID: PMC2570525.
280. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res 68(19):7966-74, 10/2008. PMCID: PMC2561224.
281. Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, Sawaya R, Hess KR, Mills GB, Kawamura H, Hashimoto Y, Urata Y, Fujiwara T, Kondo S. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Ther 15(17):1233-9, 9/2008. PMID: 18580968.
282. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog 47(9):701-6, 9/2008. PMCID: PMC2580832.
283. Murph MM, Nguyen GH, Radhakrishna H, Mills GB. Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta 1781(9):547-57, 9/2008. PMCID: PMC2565514.
284. Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 68(16):6496-506, 8/2008. PMCID: PMC3011867.
285. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68(15):6084-91, 8/2008. PMCID: PMC2680495.
286. Nanjundan M, Cheng KW, Zhang F, Lahad J, Kuo WL, Schmandt R, Smith-McCune K, Fishman D, Gray JW, Mills GB. Overexpression of SnoN/SkiL, amplified at the 3q26.2 locus, in ovarian cancers: a role in ovarian pathogenesis. Mol Oncol 2(2):164-81, 8/2008. PMCID: PMC2598416.
287. Grote T, Siwak DR, Fritsche HA, Joy C, Mills GB, Simeone D, Whitcomb DC, Logsdon CD. Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: accurate detection of CA19-9 levels in pancreatic cancer. Proteomics 8(15):3051-60, 8/2008. PMCID: PMC2992687.
288. Hasegawa Y, Murph M, Yu S, Tigyi G, Mills GB. Lysophosphatidic acid (LPA)-induced vasodilator-stimulated phosphoprotein mediates lamellipodia formation to initiate motility in PC-3 prostate cancer cells. Mol Oncol 2(1):54-69, 6/2008. PMCID: PMC2597858.
289. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 68(9):3243-50, 5/2008. PMCID: PMC2929908.
290. Amos CI, Wu X, Broderick P, Gorlov IP, Gu J, Eisen T, Dong Q, Zhang Q, Gu X, Vijayakrishnan J, Sullivan K, Matakidou A, Wang Y, Mills G, Doheny K, Tsai YY, Chen WV, Shete S, Spitz MR, Houlston RS. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 40(5):616-22, 5/2008. PMCID: PMC2713680.
291. Aoki H, Kondo Y, Aldape K, Yamamoto A, Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K, Shinojima N, Shingu T, Tamada Y, Zhang L, Conrad C, Bogler O, Mills G, Sawaya R, Kondo S. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy 4(4):467-75, 5/2008. PMID: 18259115.
292. Muller M, Obeyesekere M, Mills GB, Ram PT. Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R. FASEB J 22(5):1393-403, 5/2008. PMID: 18171696.
293. Ji Y, Lu Y, Mills GB. Bayesian models based on test statistics for multiple hypothesis testing problems. Bioinformatics 24(7):943-9, 4/2008. PMID: 18245123.
294. Liu S, Fang X, Hall H, Yu S, Smith D, Lu Z, Fang D, Liu J, Stephens LC, Woodgett JR, Mills GB. Homozygous deletion of glycogen synthase kinase 3beta bypasses senescence allowing Ras transformation of primary murine fibroblasts. Proc Natl Acad Sci U S A 105(13):5248-53, 4/2008. PMCID: PMC2278194.
295. Zhu QS, Ren W, Korchin B, Lahat G, Dicker A, Lu Y, Mills G, Pollock RE, Lev D. Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha. Cancer Res 68(8):2895-903, 4/2008. PMID: 18413758.
296. Astanehe A, Arenillas D, Wasserman WW, Leung PC, Dunn SE, Davies BR, Mills GB, Auersperg N. Mechanisms underlying p53 regulation of PIK3CA transcription in ovarian surface epithelium and in ovarian cancer. J Cell Sci 121(Pt 5):664-74, 3/2008. e-Pub 2/2008. PMID: 18270270.
297. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol 108(3):652-7, 3/2008. e-Pub 12/2007. PMID: 18096210.
298. Yang JY, Zong CS, Xia W, Yamaguchi H, Ding Q, Xie X, Lang JY, Lai CC, Chang CJ, Huang WC, Huang H, Kuo HP, Lee DF, Li LY, Lien HC, Cheng X, Chang KJ, Hsiao CD, Tsai FJ, Tsai CH, Sahin AA, Muller WJ, Mills GB, Yu D, Hortobagyi GN, Hung MC. ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol 10(2):138-48, 2/2008. PMCID: PMC2376808.
299. Raphael, BJ., Volik S., Yu, P., Wu C., Huang G., Linardopoulou, E., Trask B., Walman R., Costello, J. Pienta K., Mills G.B., Bajsarowicz, Kobayashi, Y., Sridharan S., Paris, P., Tao, Q., aerni S., Brown R.P., Bahir A., Gray J.W., Cheng J., de Jong P., Nefedov M. Ried T., Padilla-Nash H., Collins C. A sequence-based survey of the complex structural organization of tumor genomes. Genome Biology(9), 1/2008.
300. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68(1):206-15, 1/2008. PMID: 18172313.
301. Kim, W-Y, Chang, D.J. Hennessy B., Kang, HJ., Yoo J., Han S-H., Park HJ., Geo Sy, Mills G.B., Kim K-W., Hong WK., Suh Y-G, and Lee. Development of novel derivatives of a natural anticancer drug, Deguelin, using reverse phase protein array (RPPA). Cancer Prev. Res(1):577-87, 1/2008. PMCID: PMC2738643.
302. Metcalfe, KA, Carmelis D, Lubinski J, Moller P, Ghadirain P, Foulkes W, Friedman E, Kim Sing C, Ainsworth P, Rosem B, Domchek S, Isaasc C, Wagner T, Tung N, Manoukian Sm Ciouch F, Sun P, Narod S. International variation in rates of uptake of prevention options in BRCA1 and BRCA2 mutation carriers. Int. J. Cancer, 1/2008. PMCID: PMC2936778.
303. Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, Aldape KD, Bogler O, Yung WK, Coombes K, Mills GB, Vasconcelos AT, Almeida JS. Exploratory analysis of the copy number alterations in glioblastoma multiforme. PLoS One 3(12):e4076, 2008. PMCID: PMC2605252.
304. Murph MM, Smith DL, Hennessy B, Lu Y, Joy C, Coombes KR, Mills GB. Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol 622(622):183-195, 2008. PMID: 18546628.
305. Hennessy BT, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes KR, Liu J, Lu Y, Gray JW, Mills GB. Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead. Adv Exp Med Biol 617:23-40, 2008. PMCID: PMC2844243.
306. Stanislaus R, Carey M, Deus HF, Coombes K, Hennessy BT, Mills GB, Almeida JS. RPPAML/RIMS: a metadata format and an information management system for reverse phase protein arrays. BMC Bioinformatics 9:555, 2008. PMCID: PMC2639439.
307. Gajewiak J, Tsukahara R, Tsukahara T, Fujiwara Y, Yu S, Lu Y, Murph M, Mills GB, Tigyi G, Prestwich GD. Alkoxymethylenephosphonate analogues of (Lyso) phosphatidic acid stimulate signaling networks coupled to the LPA2 receptor. ChemMedChem 2(12):1789-98, 12/2007. PMID: 17952880.
308. Hennessy BT, Lu Y, Poradosu E, Yu Q, Yu S, Hall H, Carey MS, Ravoori M, Gonzalez-Angulo AM, Birch R, Henderson IC, Kundra V, Mills GB. Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res 13(13):7421-31, 12/2007. PMID: 18094426.
309. Xu ZX, Liang J, Haridas V, Gaikwad A, Connolly FP, Mills GB, Gutterman JU. A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase. Cell Death Differ 14(11):1948-57, 11/2007. e-Pub 8/2007. PMID: 17690712.
310. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12(4):395-402, 10/2007. PMID: 17936563.
311. Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 31(31):753-60, 10/2007. PMID: 17786305.
312. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, Mao JH, Yu M, Miller MA, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Mills GB, Huntsman DG, Gray JW. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res 13(19):5745-55, 10/2007. PMID: 17908964.
313. Lu CH, Wyszomierski SL, Tseng LM, Sun MH, Lan KH, Neal CL, Mills GB, Hortobagyi GN, Esteva FJ, Yu D. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res 13(19):5883-8, 10/2007. PMID: 17908983.
314. Caswell PT, Spence HJ, Parsons M, White DP, Clark K, Cheng KW, Mills GB, Humphries MJ, Messent AJ, Anderson KI, McCaffrey MW, Ozanne BW, Norman JC. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 13(13):496-510, 10/2007. PMID: 17925226.
315. Lu Y, Li X, Liang K, Luwor R, Siddik ZH, Mills GB, Mendelsohn J, Fan Z. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67(17):8240-7, 9/2007. PMID: 17804738.
316. Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR, Sawaya R, Mills GB, Gilchrest BA, Kondo S. Telomere 3' overhang specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J 21(21):2918-30, 9/2007. e-Pub 4/2007. PMID: 17449721.
317. Brugge J, Hung MC, Mills GB. A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2):104-7, 8/2007. PMID: 17692802.
318. Estrella VC, Eder AM, Liu S, Pustilnik TB, Tabassam FH, Claret FX, Gallick GE, Mills GB, Wiener JR. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway. Int J Oncol 31(2):441-9, 8/2007. PMID: 17611702.
319. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB. Non-parametric quantification of protein lysate arrays. Bioinformatics 23(15):1986-94, 8/2007. e-Pub 6/2007. PMID: 17599930.
320. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, Chun K, Hennessy B, Mills GB, Nawaz Z, Slingerland JM. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 117(8):2205-15, 8/2007. PMCID: PMC1906730.
321. Yamasaki F, Johansen MJ, Zhang D, Krishnamurthy S, Felix E, Bartholomeusz C, Aguilar RJ, Kurisu K, Mills GB, Hortobagyi GN, Ueno NT. Acquired Resistance to Erlotinib in A-431 Epidermoid Cancer Cells Requires Downregulation of MMAC1/PTEN and Upregulation of Phosphorylated Akt. Cancer Res 67(67):5779-5788, 6/2007. PMID: 17575145.
322. Amit I, Citri A, Shay T, Lu Y, Katz M, Zhang F, Tarcic G, Siwak D, Lahad J, Jacob-Hirsch J, Amariglio N, Vaisman N, Segal E, Rechavi G, Alon U, Mills GB, Domany E, Yarden Y. A module of negative feedback regulators defines growth factor signaling. Nat Genet 39(4):503-12, 4/2007. e-Pub 2/2007. PMID: 17322878.
323. Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K, Kuo WL, Smith-McCune K, Fishman D, Gray JW, Mills GB. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67(7):3074-84, 4/2007. PMID: 17409414.
324. Zhang Q, Bhola NE, Lui VW, Siwak DR, Thomas SM, Gubish CT, Siegfried JM, Mills GB, Shin D, Grandis JR. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol Cancer Ther 6(4):1414-24, 4/2007. PMID: 17431120.
325. Nanjundan M, Zhang F, Schmandt R, Smith-McCune K, Mills GB. Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions. Oncogene 26(18):2574-84, 4/2007. e-Pub 10/2006. PMID: 17072347.
326. Fang D, Hawke D, Zheng Y, Xia Y, Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T, Lu Z. Phosphorylation of beta -catenin by AKT promotes beta -catenin transcriptional activity. J Biol Chem 282(282):11221-9, 4/2007. e-Pub 2/2007. PMCID: PMC1850976.
327. Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, Yokoyama T, Mills GB, Kondo S. Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26(13):1840-51, 3/2007. e-Pub 9/2006. PMID: 17001313.
328. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9(2):218-24, 2/2007. PMID: 17237771.
329. Tabe Y, Jin L, Tsutsumi-Ishii Y, Xu Y, McQueen T, Priebe W, Mills GB, Ohsaka A, Nagaoka I, Andreeff M, Konopleva M. Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res 67(2):684-94, 1/2007. PMID: 17234779.
330. Younes MN, Yigitbasi OG, Yazici YD, Jasser SA, Bucana CD, El-Naggar AK, Mills GB, Myers JN. Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 133(1):15-23, 1/2007. PMID: 17224516.
331. Badour K, McGavin MK, Zhang J, Freeman S, Vieira C, Filipp D, Julius M, Mills GB, Siminovitch KA. Interaction of the Wiskott-Aldrich syndrome protein with sorting nexin 9 is required for CD28 endocytosis and cosignaling in T cells. Proc Natl Acad Sci U S A 104(104):1593-8, 1/2007. e-Pub 1/2007. PMCID: PMC1785243.
332. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28(1):174-82, 1/2007. e-Pub 7/2006. PMID: 16829690.
333. Hu, J. He, X., Baggerly, K.A, Coombes, K.R., B.T. and Mills G.B., 2007. Nonparametrtic quantification of protein lysate arrays. Bioinformatics(23):1986-94, 1/2007. PMID: 17599930.
334. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills G. Liquid chromatography mass spectrometry for quantifying plasma lysophospholipids: potential biomarkers for cancer diagnosis. Methods Enzymol 433:1-25, 2007. PMID: 17954226.
335. Hennessy BT, Mills GB. Ovarian cancer: homeobox genes, autocrine/paracrine growth, and kinase signaling. Int J Biochem Cell Biol 38(9):1450-6, 2007. PMID: 16682246.
336. Bast RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res 174:91-100, 2007. PMID: 17302189.
337. Murph M, Mills GB. Targeting the lipids LPA and S1P and their signalling pathways to inhibit tumour progression. Expert Rev Mol Med 9(28):1-18, 2007. e-Pub 10/2007. PMID: 17935635.
338. Acconcia F, Manavathi B, Mascarenhas J, Talukder AH, Mills G, Kumar R. An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration. Cancer Res 66(22):11030-8, 11/2006. PMID: 17108142.
339. Ping B, He X, Xia W, Lee DF, Wei Y, Yu D, Mills G, Shi D, Hung MC. Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers. Int J Oncol 29(5):1103-10, 11/2006. PMID: 17016640.
340. Stemke-Hale K, Hennessy B, Mills GB, Mitra R. Molecular screening for breast cancer prevention, early detection, and treatment planning: combining biomarkers from DNA, RNA, and protein. Curr Oncol Rep 8(6):484-91, 11/2006. PMID: 17040626.
341. Murph M, Tanaka T, Liu S, Mills GB. Of spiders and crabs: the emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clin Cancer Res 12(22):6598-602, 11/2006. PMID: 17121877.
342. Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. Expert Opin Pharmacother 7(16):2243-61, 11/2006. PMID: 17059381.
343. Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A 103(44):16472-7, 10/31/2006. e-Pub 10/23/2006. PMCID: PMC1637606.
344. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB. A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A 103(41):15014-9, 10/2006. e-Pub 10/2006. PMCID: PMC1636760.
345. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5(10):2512-21, 10/2006. PMID: 17041095.
346. Almeida JS, Chen C, Gorlitsky R, Stanislaus R, Aires-de-Sousa M, Eleutério P, Carriço J, Maretzek A, Bohn A, Chang A, Zhang F, Mitra R, Mills GB, Wang X, Deus HF. Data integration gets 'Sloppy'. Nat Biotechnol 24(9):1070-1, 9/2006. PMID: 16964209.
347. Liang K, Lu Y, Li X, Zeng X, Glazer RI, Mills GB, Fan Z. Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine. Mol Pharmacol 70(3):1045-52, 9/2006. e-Pub 6/2006. PMID: 16782806.
348. Rai R, Dai H, Multani AS, Li K, Chin K, Gray J, Lahad JP, Liang J, Mills GB, Meric-Bernstam F, Lin SY. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell 10(2):145-57, 8/2006. e-Pub 7/2006. PMCID: PMC1557410.
349. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, Uchiyama A, Murakami-Murofushi K, Koh E, Bandle RW, Byun HS, Bittman R, Fan D, Murph M, Mills GB, Tigyi G. Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 281(32):22786-93, 8/2006. e-Pub 6/2006. PMID: 16782709.
350. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 6/2006. PMID: 16778094.
351. Li X, Lu Y, Jin W, Liang K, Mills GB, Fan Z. Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity. J Biol Chem 281(19):13837-43, 5/2006. e-Pub 3/2006. PMID: 16549426.
352. Rosen DG, Yang G, Deavers MT, Malpica A, Kavanagh JJ, Mills GB, Liu J. Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma. Cancer 106(9):1925-32, 5/2006. PMID: 16568440.
353. Zhang Q, Thomas SM, Lui VW, Xi S, Siegfried JM, Fan H, Smithgall TE, Mills GB, Grandis JR. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 103(18):6901-6, 5/2006. e-Pub 4/2006. PMCID: PMC1458991.
354. Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer. Eur J Hum Genet 14(4):381-3, 4/2006. PMID: 16418735.
355. Zeng Z, Samudio IJ, Zhang W, Estrov Z, Pelicano H, Harris D, Frolova O, Hail N, Chen W, Kornblau SM, Huang P, Lu Y, Mills GB, Andreeff M, Konopleva M. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 66(7):3737-46, 4/2006. PMID: 16585200.
356. Mandal M, Younes M, Swan EA, Jasser SA, Doan D, Yigitbasi O, McMurphey A, Ludwick J, El-Naggar AK, Bucana C, Mills GB, Myers JN. The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck. Oral Oncol 42(4):430-9, 4/2006. e-Pub 1/2006. PMCID: PMC1414640.
357. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res 66(6):2904-6, 3/2006. PMID: 16540635.
358. Zhu QS, Xia L, Mills GB, Lowell CA, Touw IP, Corey SJ. G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood 107(5):1847-56, 3/2006. e-Pub 11/2005. PMCID: PMC1895701.
359. Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB, Yung WK. Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther 5(3):637-44, 3/2006. PMID: 16546978.
360. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res 66(5):2740-8, 3/2006. PMID: 16510595.
361. Qian L, Xu Y, Simper T, Jiang G, Aoki J, Umezu-Goto M, Arai H, Yu S, Mills GB, Tsukahara R, Makarova N, Fujiwara Y, Tigyi G, Prestwich GD. Phosphorothioate Analogues of Alkyl Lysophosphatidic Acid as LPA(3) Receptor-Selective Agonists. ChemMedChem 1(3):376-383, 3/2006. PMID: 16892372.
362. Visentin B, Vekich JA, Sibbald BJ, Cavalli AL, Moreno KM, Matteo RG, Garland WA, Lu Y, Yu S, Hall HS, Kundra V, Mills GB, Sabbadini RA. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9(3):225-38, 3/2006. PMID: 16530706.
363. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Mills GB, Younes A. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br J Haematol 132(4):503-11, 2/2006. PMID: 16412023.
364. Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24(3):354-60, 1/2006. PMID: 16421416.
365. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4(12):988-1004, 12/2005. PMID: 16341064.
366. Koul D, Shen R, Bergh S, Lu Y, de Groot JF, Liu TJ, Mills GB, Yung WK. Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma. Mol Cancer Ther 4(11):1681-8, 11/2005. PMID: 16275989.
367. Huang G, Krig S, Kowbel D, Xu H, Hyun B, Volik S, Feuerstein B, Mills GB, Stokoe D, Yaswen P, Collins C. ZNF217 suppresses cell death associated with chemotherapy and telomere dysfunction. Hum Mol Genet 14(21):3219-25, 11/2005. e-Pub 10/2005. PMID: 16203743.
368. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11(17):6116-26, 9/2005. PMID: 16144910.
369. Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC, Luo RZ. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res 65(15):6701-10, 8/2005. PMID: 16061651.
370. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A 102(35):12519-24, 8/2005. e-Pub 8/2005. PMCID: PMC1188258.
371. Younes MN, Kim S, Yigitbasi OG, Mandal M, Jasser SA, Dakak Yazici Y, Schiff BA, El-Naggar A, Bekele BN, Mills GB, Myers JN. Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther 4(8):1146-56, 8/2005. PMID: 16093430.
372. Liu Z, Wang LE, Wang L, Lu KH, Mills GB, Bondy ML, Wei Q. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer. Clin Cancer Res 11(13):4968-76, 7/2005. PMID: 16000597.
373. Lahad JP, Mills GB, Coombes KR. Stem cell-ness: a "magic marker" for cancer. J Clin Invest 115(6):1463-7, 6/2005. PMCID: PMC1137015.
374. Xu Y, Aoki J, Shimizu K, Umezu-Goto M, Hama K, Takanezawa Y, Yu S, Mills GB, Arai H, Qian L, Prestwich GD. Structure-activity relationships of fluorinated lysophosphatidic acid analogues. J Med Chem 48(9):3319-27, 5/2005. PMID: 15857137.
375. Mandal M, Kim S, Younes MN, Jasser SA, El-Naggar AK, Mills GB, Myers JN. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92(10):1899-905, 5/2005. PMID: 15870708.
376. Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Res 65(7):2516-9, 4/2005. PMID: 15805241.
377. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. Cancer Res 65(8):3336-46, 4/2005. PMID: 15833867.
378. Sheehan KM, Calvert VS, Kay EW, Lu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA, Petricoin EF, Wulfkuhle JD. Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4(4):346-55, 4/2005. e-Pub 1/25/2005. PMID: 15671044.
379. Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F. Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res 65(5):1961-72, 3/1/2005. PMID: 15753396.
380. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem 280(3):2092-104, 1/2005. e-Pub 10/2004. PMID: 15504738.
381. Spitz MR, Wu X, Mills G. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23(2):267-75, 1/2005. PMID: 15637390.
382. Nunez MI, Rosen DG, Ludes-Meyers JH, Abba MC, Kil H, Page R, Klein-Szanto AJ, Godwin AK, Liu J, Mills GB, Aldaz CM. WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. BMC Cancer 5(1):64, 2005. e-Pub 6/2005. PMCID: PMC1173095.
383. Liu S, Yu S, Hasegawa Y, Lapushin R, Xu HJ, Woodgett JR, Mills GB, Fang X. Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase. J Biol Chem 279(49):51075-81, 12/2004. PMID: 15466414.
384. Meric-Bernstam F, Mills GB. Mammalian target of rapamycin. Semin Oncol 31(6 Suppl 16):10-7; discussion 33, 12/2004. PMID: 15799239.
385. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N, Liu J, Smith-McCune K, Lu KH, Fishman D, Gray JW, Mills GB. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10(11):1251-6, 11/2004. PMID: 15502842.
386. Mondesire WH, Jian W, Zhang H, Ensor J, Hung MC, Mills GB, Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 10(20):7031-42, 10/15/2004. PMID: 15501983.
387. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 92(6):1115-40, 8/15/2004. PMID: 15258897.
388. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 64(10):3479-85, 5/15/2004. PMID: 15150101.
389. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10(10):3291-300, 5/15/2004. PMID: 15161682.
390. Cheng KW, Lahad JP, Mills GB. Analysis of molecular aberrations in ovarian cancer allows novel target identification. J Obstet Gynaecol Can 26(5):461-74, 5/2004. PMID: 15151733.
391. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC. A genetically defined model for human ovarian cancer. Cancer Res 64(5):1655-63, 3/1/2004. PMID: 14996724.
392. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 279(10):9653-61, 3/5/2004. e-Pub 12/11/2003. PMID: 14670967.
393. Noh WC, Mondesire WH, Peng J, Jian W, Zhang H, Dong J, Mills GB, Hung MC, Meric-Bernstam F. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 10(3):1013-23, 2/1/2004. PMID: 14871980.
394. Zhao S, Konopleva M, Cabreira-Hansen M, Xie Z, Hu W, Milella M, Estrov Z, Mills GB, Andreeff M. Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia 18(2):267-75, 2/2004. PMID: 14628071.
395. Andreeff M, Milella M, Carter BZ, Tabe Y, Ricciardi MR, Sneed T, Ruvolo P, Contractor R, Tsao T, Schober W, Evans R, McQueen T, Zeng Z, Kornblau SM, McCubrey J, Estey E, Mills GB, Reed JC, Konopleva M. Targeted therapy of AML new concepts. Ann Hematol 83 Suppl 1:S51-3, 2004. PMID: 15124670.
396. Qian L, Xu Y, Hasegawa Y, Aoki J, Mills GB, Prestwich GD. Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity. J Med Chem 46(26):5575-8, 12/2003. PMID: 14667211.
397. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol 30(5 Suppl 16):93-104, 10/2003. PMID: 14613030.
398. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278(41):40057-66, 10/2003. PMID: 12869565.
399. Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, Stracke ML. Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63(17):5446-53, 9/2003. PMID: 14500380.
400. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res 9(10 Pt 1):3534-45, 9/2003. PMID: 14506139.
401. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3(8):582-91, 8/2003. PMID: 12894246.
402. Hu SX, Wang S, Wang JP, Mills GB, Zhou Y, Xu HJ. Expression of endogenous granzyme B in a subset of human primary breast carcinomas. Br J Cancer 89(1):135-9, 7/2003. PMID: 12838314.
403. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Jr, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 90(1):44-50, 7/2003. PMID: 12821340.
404. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278(26):23630-8, 6/2003. PMID: 12714585.
405. Lu Y, Wang H, Mills GB. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 7(2):205-28, 6/2003. PMID: 14763163.
406. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene 22(19):2897-909, 5/2003. PMID: 12771940.
407. Knuefermann C, Lu Y, Liu B, Jin W, Liang K, Wu L, Schmidt M, Mills GB, Mendelsohn J, Fan Z. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 22(21):3205-12, 5/2003. PMID: 12761490.
408. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N, Tsurutani J, Dennis PA, Mills GB, Arteaga CL. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22(18):2812-22, 5/2003. PMID: 12743604.
409. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB, Claret FX. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 278(21):19245-56, 5/2003. PMID: 12637505.
410. Hasegawa Y, Erickson JR, Goddard GJ, Yu S, Liu S, Cheng KW, Eder A, Bandoh K, Aoki J, Jarosz R, Schrier AD, Lynch KR, Mills GB, Fang X. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor. J Biol Chem 278(14):11962-9, 4/2003. PMID: 12554733.
411. Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 17(4):575-88, 4/2003. PMID: 12554765.
412. Liang K, Jin W, Knuefermann C, Schmidt M, Mills GB, Ang KK, Milas L, Fan Z. Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy. Mol Cancer Ther 2(4):353-60, 4/2003. PMID: 12700279.
413. Tanyi JL, Morris AJ, Wolf JK, Fang X, Hasegawa Y, Lapushin R, Auersperg N, Sigal YJ, Newman RA, Felix EA, Atkinson EN, Mills GB. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer. Cancer Res 63(5):1073-82, 3/2003. PMID: 12615725.
414. Aytac U, Sato K, Yamochi T, Yamochi T, Ohnuma K, Mills GB, Morimoto C, Dang NH. Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors. Br J Cancer 88(3):455-62, 2/2003. PMID: 12569391.
415. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC, Jr. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene 22(4):484-97, 1/2003. PMID: 12555062.
416. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88(1):73-9, 2003. PMID: 12504632.
417. Bast RC, Jr, Mills GB. General keynote: molecular therapeutics and pharmocogenomics. Gynecol Oncol 88(1 Pt 2):S84-7; discussion S93-6, 2003. PMID: 12586093.
418. Liotta LA, Petricoin EF, 3rd, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC. General keynote: proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 88(1 Pt 2):S25-8; discussion S37-42, 2003. PMID: 12586081.
419. Gray JW, Suzuki S, Kuo WL, Polikoff D, Deavers M, Smith-McCune K, Berchuck A, Pinkel D, Albertson D, Mills GB. Specific keynote: genome copy number abnormalities in ovarian cancer. Gynecol Oncol 88(1 Pt 2):S16-21; discussion S22-4, 2003. PMID: 12586079.
420. Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Jr, Gray J. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol 88(1 Pt 2):S88-92; discussion S93-6, 2003. PMID: 12586094.
421. Ni Z, Anini, Y, Fang, X, Mills, G, Brubaker, PL, Jin, T. Transcriptional activation of the proglucagon gene by lithium and beta-catenin in intestinal endocrine L cells. J Biol Chem 278:1380-1387, 2003.
422. Bondar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ. Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1(12):989-97, 10/2002. PMID: 12481421.
423. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158(2):227-33, 7/2002. PMID: 12119361.
424. Tanyi JL, Lapushin R, Eder A, Auersperg N, Tabassam FH, Roth JA, Gu J, Fang B, Mills GB, Wolf J. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 85(3):451-8, 6/2002. PMID: 12051873.
425. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 94(11):844-51, 6/2002. PMID: 12048272.
426. Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 1582(1-3):257-64, 5/2002. PMID: 12069836.
427. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22(7):2099-110, 4/2002. PMID: 11884598.
428. Koul D, Jasser SA, Lu Y, Davies MA, Shen R, Shi Y, Mills GB, Yung WK. Motif analysis of the tumor suppressor gene MMAC/PTEN identifies tyrosines critical for tumor suppression and lipid phosphatase activity. Oncogene 21(15):2357-64, 4/2002. PMID: 11948419.
429. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, Unate H. Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21(13):1945-54, 3/2002. PMID: 11960367.
430. Buchholz TA, Wu X, Hussain A, Tucker SL, Mills GB, Haffty B, Bergh S, Story M, Geara FB, Brock WA. Evidence of haplotype insufficiency in human cells containing a germline mutation in BRCA1 or BRCA2. Int J Cancer 97(5):557-61, 2/2002. PMID: 11807777.
431. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res 62(4):1087-92, 2/2002. PMID: 11861387.
432. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306):572-7, 2/2002. PMID: 11867112.
433. Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res 107:259-83, 2002. PMID: 11775454.
434. Bast RC, Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res 107:61-97, 2002. PMID: 11775462.
435. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, Bast RC, Jr. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene 20(57):8258-69, 12/2001. PMID: 11781840.
436. Zhu Y, Spitz MR, Lei L, Mills GB, Wu X. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter enhances lung cancer susceptibility. Cancer Res 61(21):7825-9, 11/2001. PMID: 11691799.
437. Bast RC, Jr, Mills GB, Young RC. Translational research--traffic on the bridge. Biomed Pharmacother 55(9-10):565-71, 11/2001. PMID: 11769968.
438. Aytac U, Claret FX, Ho L, Sato K, Ohnuma K, Mills GB, Cabanillas F, Morimoto C, Dang NH. Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint. Cancer Res 61(19):7204-10, 10/2001. PMID: 11585756.
439. Mills GB, Lu Y, Fang X, Wang H, Eder A, Mao M, Swaby R, Cheng KW, Stokoe D, Siminovitch K, Jaffe R, Gray J. The role of genetic abnormalities of PTEN and the phosphatidylinositol 3-kinase pathway in breast and ovarian tumorigenesis, prognosis, and therapy. Semin Oncol 28(5 Suppl 16):125-41, 10/2001. PMID: 11706404.
440. Wolf BB, Schuler M, Li W, Eggers-Sedlet B, Lee W, Tailor P, Fitzgerald P, Mills GB, Green DR. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 276(36):34244-51, 9/2001. PMID: 11429402.
441. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, Jr, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res 61(15):5895-904, 8/2001. PMID: 11479231.
442. Mills GB, Lu Y, Kohn EC. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the PI3K pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Proc Natl Acad Sci U S A 98(18):10031-3, 8/2001. PMID: 11526226.
443. Braunstein I, Cohen-Barak O, Shachaf C, Ravel Y, Yalon-Hacohen M, Mills GB, Tzukerman M, Skorecki KL. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells. Cancer Res 61(14):5529-36, 7/2001. PMID: 11454703.
444. Ho L, Aytac U, Stephens LC, Ohnuma K, Mills GB, McKee KS, Neumann C, LaPushin R, Cabanillas F, Abbruzzese JL, Morimoto C, Dang NH. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. Clin Cancer Res 7(7):2031-40, 7/2001. PMID: 11448921.
445. Liu B, Fang M, Lu Y, Lu Y, Mills GB, Fan Z. Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br J Cancer 85(2):303-11, 7/2001. PMID: 11461094.
446. Mujoo K, Haridas V, Hoffmann JJ, Wachter GA, Hutter LK, Lu Y, Blake ME, Jayatilake GS, Bailey D, Mills GB, Gutterman JU. Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis. Cancer Res 61(14):5486-90, 7/2001. PMID: 11454696.
447. Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K, Mills GB. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J Biol Chem 276(29):27455-61, 7/2001. PMID: 11337495.
448. Hu YL, Tee MK, Goetzl EJ, Auersperg N, Mills GB, Ferrara N, Jaffe RB. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 93(10):762-8, 5/2001. PMID: 11353786.
449. Narod SA, Sun P, Ghadirian P, Lynch H, Isaacs C, Garber J, Weber B, Karlan B, Fishman D, Rosen B, Tung N, Neuhausen SL. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Lancet(9267):1467-1470, 5/2001. PMID: 11377596.
450. Asselin E, Mills GB, Tsang BK. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 61(5):1862-8, 3/2001. PMID: 11280739.
451. Kruzelock RP, Cuevas BD, Wiener JR, Xu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC, Jr. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene 19(54):6277-85, 12/2000. PMID: 11175342.
452. Mao M, Fang X, Lu Y, Lapushin R, Bast RC, Jr, Mills GB. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J 352 Pt 2:475-82, 12/2000. PMID: 11085941.
453. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Jr, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J 352 Pt 1:135-43, 11/2000. PMID: 11062066.
454. Suzuki S, Moore DH, 2nd, Ginzinger DG, Godfrey TE, Barclay J, Powell B, Pinkel D, Zaloudek C, Lu K, Mills G, Berchuck A, Gray JW. An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60(19):5382-5, 10/2000. PMID: 11034075.
455. Fang X, Yu SX, Lu Y, Bast RC, Jr, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A 97(22):11960-5, 10/2000. PMID: 11035810.
456. Imai A, Furui T, Tamaya T, Mills GB. A gonadotropin-releasing hormone-responsive phosphatase hydrolyses lysophosphatidic acid within the plasma membrane of ovarian cancer cells. J Clin Endocrinol Metab 85(9):3370-5, 9/2000. PMID: 10999836.
457. Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, Kumar R, Bast RC, Jr. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res 60(13):3522-31, 7/2000. PMID: 10910064.
458. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 6(6):2482-91, 6/2000. PMID: 10873103.
459. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T, Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills GB. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann N Y Acad Sci 905:188-208, 4/2000. PMID: 10818454.
460. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6(3):880-6, 3/2000. PMID: 10741711.
461. Ramondetta L, Mills GB, Burke TW, Wolf JK. Adenovirus-mediated expression of p53 or p21 in a papillary serous endometrial carcinoma cell line (SPEC-2) results in both growth inhibition and apoptotic cell death: potential application of gene therapy to endometrial cancer. Clin Cancer Res 6(1):278-84, 2000. PMID: 10656459.
462. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC, Jr. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res 6(1):260-70, 2000. PMID: 10656457.
463. Bast RC, Yu Y, Xu FJ, Le XF, Mills GB. Molecular approaches to management of epithelial ovarian cancer. Int J Gynecol Cancer 10(S1):2-7, 2000. PMID: 11240724.
464. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res 5(12):4308-18, 12/1999. PMID: 10632375.
465. Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC, Jr, Mills GB, Silva EG. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res 5(12):4053-8, 12/1999. PMID: 10632339.
466. Wolf JK, Mills GB, Bazzet L, Bast RC, Jr, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol 75(2):261-6, 11/1999. PMID: 10525383.
467. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC, Jr, Mills GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 5(11):3704-10, 11/1999. PMID: 10589790.
468. Fang X, Yu S, Eder A, Mao M, Bast RC, Jr, Boyd D, Mills GB. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene 18(48):6635-40, 11/1999. PMID: 10597268.
469. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC, Jr. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res 5(11):3653-60, 11/1999. PMID: 10589783.
470. Lu Y, Lin YZ, LaPushin R, Cuevas B, Fang X, Yu SX, Davies MA, Khan H, Furui T, Mao M, Zinner R, Hung MC, Steck P, Siminovitch K, Mills GB. The PTEN/MMAC1/TEP tumor suppressor gene decreases cell growth and induces apoptosis and anoikis in breast cancer cells. Oncogene 18(50):7034-45, 11/1999. PMID: 10597304.
471. Cuevas B, Lu Y, Watt S, Kumar R, Zhang J, Siminovitch KA, Mills GB. SHP-1 regulates Lck-induced phosphatidylinositol 3-kinase phosphorylation and activity. J Biol Chem 274(39):27583-9, 9/1999. PMID: 10488096.
472. Zebrowski BK, Liu W, Ramirez K, Akagi Y, Mills GB, Ellis LM. Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Ann Surg Oncol 6(4):373-8, 6/1999. PMID: 10379858.
473. Zhang J, Somani AK, Watt S, Mills GB, Siminovitch KA. The Src-homology domain 2-bearing protein tyrosine phosphatase-1 inhibits antigen receptor-induced apoptosis of activated peripheral T cells. J Immunol 162(11):6359-67, 6/1999. PMID: 10352248.
474. Wolf JK, Kim TE, Fightmaster D, Bodurka D, Gershenson DM, Mills G, Wharton JT. Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. Gynecol Oncol 73(1):27-34, 4/1999. PMID: 10094876.
475. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Jr, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5(3):655-63, 3/1999. PMID: 10100719.
476. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC, Jr. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A 96(1):214-9, 1/1999. PMID: 9874798.
477. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21(1):99-102, 1999. PMID: 9916799.
478. Davies MA, Lu Y, Sano T, Fang X, Tang P, LaPushin R, Koul D, Bookstein R, Stokoe D, Yung WK, Mills GB, Steck PA. Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis. Cancer Res 58(23):5285-90, 12/1998. PMID: 9850049.
479. Lu Y, Cuevas B, Gibson S, Khan H, LaPushin R, Imboden J, Mills GB. Phosphatidylinositol 3-kinase is required for CD28 but not CD3 regulation of the TEC family tyrosine kinase EMT/ITK/TSK: functional and physical interaction of EMT with phosphatidylinositol 3-kinase. J Immunol 161(10):5404-12, 11/1998. PMID: 9820515.
480. Bast RC, Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 13(4):179-87, 10/1998. PMID: 10228898.
481. Koul D, Obeyesekere NU, Gutterman JU, Mills GB, Choubey D. p202 self-associates through a sequence conserved among the members of the 200-family proteins. FEBS Lett 438(1-2):21-4, 10/1998. PMID: 9821952.
482. Haas-Kogan D, Shalev N, Wong M, Mills G, Yount G, Stokoe D. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 8(21):1195-8, 10/1998. PMID: 9799739.
483. Koul D, Lapushin R, Xu HJ, Mills GB, Gutterman JU, Choubey D. p202 prevents apoptosis in murine AKR-2B fibroblasts. Biochem Biophys Res Commun 247(2):379-82, 6/1998. PMID: 9642135.
484. Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC, Jr, Ostrowski MC. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res 58(10):2253-9, 5/1998. PMID: 9605774.
485. Gibson S, Truitt K, Lu Y, Lapushin R, Khan H, Imboden JB, Mills GB. Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK. Biochem J 330 ( Pt 3):1123-8, 3/1998. PMID: 9494076.
486. Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast RC, Jr, Mills GB. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene 16(1):1-8, 1/1998. PMID: 9467937.
487. Radvanyi LG, Raju K, Spaner D, Mills GB, Miller RG. Interleukin-2 reverses the defect in activation-induced apoptosis in T cells from autoimmune lpr mice. Cell Immunol 183(1):1-12, 1/1998. PMID: 9578714.
488. Pusztai L, Siddik ZH, Mills GB, Bast RC, Jr. Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol 37(7-8):629-40, 1998. PMID: 10050979.
489. Shi Y, Wang R, Sharma A, Gao C, Collins M, Penn L, Mills GB. Dissociation of cytokine signals for proliferation and apoptosis. J Immunol 159(11):5318-28, 12/1997. PMID: 9548471.
490. Shi YF, Hill M, Novak A, Chen ZQ, Wang RX, Liew CC, Mills GB. Human hematopoietic cell express two forms of the cytokine receptor common gamma-chain (gamma c). Cell Res 7(2):195-205, 12/1997. PMID: 9444398.
491. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA, et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57(23):5221-5, 12/1997. PMID: 9393738.
492. Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, Bast RC, Mills GB, Li J, Hu SX. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene 15(21):2589-96, 11/1997. PMID: 9399646.
493. Marengere LE, Okkenhaug K, Clavreul A, Couez D, Gibson S, Mills GB, Mak TW, Rottapel R. The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28. J Immunol 159(7):3220-9, 10/1997. PMID: 9317120.
494. Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC, Jr. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res 3(9):1629-34, 9/1997. PMID: 9815853.
495. Fang X, Gibson S, Flowers M, Furui T, Bast RC, Jr, Mills GB. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem 272(21):13683-9, 5/1997. PMID: 9153219.
496. Wang R, Fang Q, Zhang L, Radvany L, Sharma A, Noben-Trauth N, Mills GB, Shi Y. CD28 ligation prevents bacterial toxin-induced septic shock in mice by inducing IL-10 expression. J Immunol 158(6):2856-61, 3/1997. PMID: 9058822.
497. Okita M, Gaudette DC, Mills GB, Holub BJ. Elevated levels and altered fatty acid composition of plasma lysophosphatidylcholine(lysoPC) in ovarian cancer patients. Int J Cancer 71(1):31-4, 3/1997. PMID: 9096662.
498. Somani AK, Bignon, JS Mills, GB, Siminovitch, KA, Branch, DR. Src kinase activity is regulated by the SHP-1 protein-tyrosine phosphates. J Biol Chem 272(21113-21119), 1/1997.
499. Phipps DJ, Read SE, Piovesan JP, Mills GB, Branch DR. HIV infection in vitro enhances the activity of src-family protein tyrosine kinases. Aids 10(11):1191-8, 9/1996. PMID: 8883579.
500. Frankel A, Mills GB. Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells. Clin Cancer Res 2(8):1307-13, 8/1996. PMID: 9816301.
501. Radvanyi LG, Shi Y, Mills GB, Miller RG. Cell cycle progression out of G1 sensitizes primary-cultured nontransformed T cells to TCR-mediated apoptosis. Cell Immunol 170(2):260-73, 6/1996. PMID: 8660826.
502. Teng JM, Liu XR, Mills GB, Dupont B. CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C. J Immunol 156(9):3222-32, 5/1996. PMID: 8617944.
503. Wiener JR, Kassim SK, Yu Y, Mills GB, Bast RC, Jr. Transfection of human ovarian cancer cells with the HER-2/neu receptor tyrosine kinase induces a selective increase in PTP-H1, PTP-1B, PTP-alpha expression. Gynecol Oncol 61(2):233-40, 5/1996. PMID: 8626139.
504. Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU. Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 183(4):1407-14, 4/1996. PMID: 8666899.
505. Gibson S, August A, Kawakami Y, Kawakami T, Dupont B, Mills GB. The EMT/ITK/TSK (EMT) tyrosine kinase is activated during TCR signaling: LCK is required for optimal activation of EMT. J Immunol 156(8):2716-22, 4/1996. PMID: 8609388.
506. Radvanyi LG, Shi Y, Vaziri H, Sharma A, Dhala R, Mills GB, Miller RG. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 156(5):1788-98, 3/1996. PMID: 8596028.
507. Gibson S, August A, Branch D, Dupont B, Mills GM. Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK. J Biol Chem 271(12):7079-83, 3/1996. PMID: 8636141.
508. Jurisicova A, Casper RF, MacLusky NJ, Mills GB, Librach CL. HLA-G expression during preimplantation human embryo development. Proc Natl Acad Sci U S A 93(1):161-5, 1/1996. PMID: 8552596.
509. Truitt KE, Shi J, Gibson S, Segal LG, Mills GB, Imboden JB. CD28 delivers costimulatory signals independently of its association with phosphatidylinositol 3-kinase. J Immunol 155(10):4702-10, 11/1995. PMID: 7594470.
510. Teodorczyk-Injeyan JA, Cembrzynska-Nowak M, Lalani S, Peters WJ, Mills GB. Immune deficiency following thermal trauma is associated with apoptotic cell death. J Clin Immunol 15(6):318-28, 11/1995. PMID: 8576318.
511. Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Jr, Mills GB. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer 76(9):1615-20, 11/1995. PMID: 8635066.
512. Kawakami Y, Yao L, Tashiro M, Gibson S, Mills GB, Kawakami T. Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/Emt, on Fc epsilon RI cross-linking on mast cells. J Immunol 155(7):3556-62, 10/1995. PMID: 7561053.
513. Mogil RJ, Radvanyi L, Gonzalez-Quintial R, Miller R, Mills G, Theofilopoulos AN, Green DR. Fas (CD95) participates in peripheral T cell deletion and associated apoptosis in vivo. Int Immunol 7(9):1451-8, 9/1995. PMID: 7495753.
514. Goldsmith MA, Lai SY, Xu W, Amaral MC, Kuczek ES, Parent LJ, Mills GB, Tarr KL, Longmore GD, Greene WC. Growth signal transduction by the human interleukin-2 receptor requires cytoplasmic tyrosines of the beta chain and non-tyrosine residues of the gamma c chain. J Biol Chem 270(37):21729-37, 9/1995. PMID: 7665592.
515. Shi Y, Radvanyi LG, Sharma A, Shaw P, Green DR, Miller RG, Mills GB. CD28-mediated signaling in vivo prevents activation-induced apoptosis in the thymus and alters peripheral lymphocyte homeostasis. J Immunol 155(4):1829-37, 8/1995. PMID: 7543534.
516. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 309 ( Pt 3):933-40, 8/1995. PMID: 7639713.
517. Phipps DJ, Reed-Doob P, MacFadden DK, Piovesan JP, Mills GB, Branch DR. An octapeptide analogue of HIV gp120 modulates protein tyrosine kinase activity in activated peripheral blood T lymphocytes. Clin Exp Immunol 100(3):412-8, 6/1995. PMID: 7539724.
518. Xu Y, Casey G, Mills GB. Effect of lysophospholipids on signaling in the human Jurkat T cell line. J Cell Physiol 163(3):441-50, 6/1995. PMID: 7775587.
519. Pani G, Kozlowski M, Cambier JC, Mills GB, Siminovitch KA. Identification of the tyrosine phosphatase PTP1C as a B cell antigen receptor-associated protein involved in the regulation of B cell signaling. J Exp Med 181(6):2077-84, 6/1995. PMID: 7539038.
520. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 55(9):1982-8, 5/1995. PMID: 7728769.
521. Branch DR, Mills GB. pp60c-src expression is induced by activation of normal human T lymphocytes. J Immunol 154(8):3678-85, 4/1995. PMID: 7535811.
522. Xu Y, Gaudette, DC, Boynton, JD, Frankel, A, Fang, XJ, Sharma, A, Hurteau, J, Casey, G, Goodbody, A, Mellors, A, Holub, B, Mills, GB. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1:1223-1232, 1995.
523. Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC, Jr. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int J Cancer 59(2):242-7, 10/1994. PMID: 7927925.
524. August A, Gibson S, Kawakami Y, Kawakami T, Mills GB, Dupont B. CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line. Proc Natl Acad Sci U S A 91(20):9347-51, 9/1994. PMID: 7524075.
525. Tsao PW, Mills GB, Diaz RJ, Radde IC, Parkinson D, Waddell J, Wilson GJ, Coles JG. Evidence that increases in lymphocyte tyrosine phosphorylation precede cardiac allograft rejection. Effects of cyclosporine and potential use in clinical management. Transplantation 58(4):451-7, 8/1994. PMID: 7521079.
526. Simon HU, Tsao PW, Siminovitch KA, Mills GB, Blaser K. Functional platelet-activating factor receptors are expressed by monocytes and granulocytes but not by resting or activated T and B lymphocytes from normal individuals or patients with asthma. J Immunol 153(1):364-77, 7/1994. PMID: 8207248.
527. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A. Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74(1):93-9, 7/1994. PMID: 8004589.
528. Hurteau JA, Simon HU, Kurman C, Rubin L, Mills GB. Levels of soluble interleukin-2 receptor-alpha are elevated in serum and ascitic fluid from epithelial ovarian cancer patients. Am J Obstet Gynecol 170(3):918-28, 3/1994. PMID: 8141226.
529. Truitt KE, Mills GB, Turck CW, Imboden JB. SH2-dependent association of phosphatidylinositol 3'-kinase 85-kDa regulatory subunit with the interleukin-2 receptor beta chain. J Biol Chem 269(8):5937-43, 2/1994. PMID: 7509794.
530. Simon HU, Mills GB, Kozlowski M, Hogg D, Branch D, Ishimi Y, Siminovitch KA. Molecular characterization of hNRP, a cDNA encoding a human nucleosome-assembly-protein-I-related gene product involved in the induction of cell proliferation. Biochem J 297 ( Pt 2):389-97, 1/1994. PMID: 8297347.
531. Hogg D, Guidos C, Bailey D, Amendola A, Groves T, Davidson J, Schmandt R, Mills G. Cell cycle dependent regulation of the protein kinase TTK. Oncogene 9(1):89-96, 1994. PMID: 8302607.
532. Schmandt R, Hill M, Amendola A, Mills GB, Hogg D. IL-2-induced expression of TTK, a serine, threonine, tyrosine kinase, correlates with cell cycle progression. J Immunol 152(1):96-105, 1994. PMID: 8254211.
533. Hack N, Sue AQuan A, Mills GB, Skorecki KL. Expression of human tyrosine kinase-negative epidermal growth factor receptor amplifies signaling through endogenous murine epidermal growth factor receptor. J Biol Chem 268(35):26441-6, 12/1993. PMID: 8253771.
534. Mills GB, Schmandt R, Gibson S, Leung B, Hill M, May C, Shi YF, Branch DR, Radvanyi L, Truitt KE, et al. Transmembrane signaling by the interleukin-2 receptor: progress and conundrums. Semin Immunol 5(5):345-64, 10/1993. PMID: 8260651.
535. Gibson S, Leung B, Squire JA, Hill M, Arima N, Goss P, Hogg D, Mills GB. Identification, cloning, and characterization of a novel human T-cell-specific tyrosine kinase located at the hematopoietin complex on chromosome 5q. Blood 82(5):1561-72, 9/1993. PMID: 8364206.
536. Cyopick P, Culliton R, Brockhausen I, Sutherland DR, Mills GB, Baker M. Role of aberrant sialylation of chronic myeloid leukemia granulocytes on binding and signal transduction by chemotactic peptides and colony stimulating factors. Leuk Lymphoma 11(1-2):79-90, 9/1993. PMID: 8220157.
537. Franklin RA, Mazer B, Sawami H, Mills GB, Terada N, Lucas JJ, Gelfand EW. Platelet-activating factor triggers the phosphorylation and activation of MAP-2 kinase and S6 peptide kinase activity in human B cell lines. J Immunol 151(4):1802-10, 8/1993. PMID: 7688385.
538. Radvanyi LG, Mills GB, Miller RG. Religation of the T cell receptor after primary activation of mature T cells inhibits proliferation and induces apoptotic cell death. J Immunol 150(12):5704-15, 6/1993. PMID: 8515084.
539. Matthews KE, Mills GB, Horsfall W, Hack N, Skorecki K, Keating A. Bead transfection: rapid and efficient gene transfer into marrow stromal and other adherent mammalian cells. Exp Hematol 21(5):697-702, 5/1993. PMID: 8513872.
540. Fang XJ, Keating A, Flowers M, Liew CC, Gupta H, Mills GB, Sherman M. The v-raf oncogene enhances tumorigenicity and suppresses differentiation in vivo in a rat hepatocyte cell line. Carcinogenesis 14(4):669-74, 4/1993. PMID: 7682480.
541. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 53(6):1304-11, 3/1993. PMID: 8443809.
542. Tsao PW, Mills GB, Diaz RJ, Radde IC, Martell MF, Augustine JM, Parkinson D, Waddell J, Wilson GJ, Coles JG. Identification of a subpopulation of reactive large granular mononuclear cells in allogeneic heart transplantation. J Heart Lung Transplant 12(2):230-8, 3/1993. PMID: 8476895.
543. Mills GB, Arima N, May C, Hill M, Schmandt R, Li J, Miyamoto NG, Greene WC. Neither the LCK nor the FYN kinases are obligatory for IL-2-mediated signal transduction in HTLV-I-infected human T cells. Int Immunol 4(11):1233-43, 11/1992. PMID: 1472476.
544. Simon HU, Mills GB, Hashimoto S, Siminovitch KA. Evidence for defective transmembrane signaling in B cells from patients with Wiskott-Aldrich syndrome. J Clin Invest 90(4):1396-405, 10/1992. PMID: 1401074.
545. Teodorczyk-Injeyan JA, Sparkes BG, Lalani S, Peters WJ, Mills GB. IL-2 regulation of soluble IL-2 receptor levels following thermal injury. Clin Exp Immunol 90(1):36-42, 10/1992. PMID: 1382903.
546. Bacus SS, Stancovski I, Huberman E, Chin D, Hurwitz E, Mills GB, Ullrich A, Sela M, Yarden Y. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells. Cancer Res 52(9):2580-9, 5/1992. PMID: 1373672.
547. Mills GB, Schmandt, R, McGrill, M, Jacobs, K, May, C, Rodricks AM, Cambell, S, Hogg D. Expression of TTK, a novel human protein kinase, is associated with cell proliferation. 267:16000-16006, 1/1992.
548. Lazarus AH, Mills GB, Crow AR, Delovitch TL. Antigen-induced Fc receptor-dependent and -independent B cell desensitization. An elevation in [Ca2+]i is not sufficient and protein kinase C activation is not required for these pathways of surface IgM-mediated desensitization. J Immunol 147(6):1739-45, 9/1991. PMID: 1890301.
549. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Peters WJ. Immunosuppression follows systemic T lymphocyte activation in the burn patient. Clin Exp Immunol 85(3):515-8, 9/1991. PMID: 1893634.
550. Fung MR, Scearce RM, Hoffman JA, Peffer NJ, Hammes SR, Hosking JB, Schmandt R, Kuziel WA, Haynes BF, Mills GB, et al. A tyrosine kinase physically associates with the beta-subunit of the human IL-2 receptor. J Immunol 147(4):1253-60, 8/1991. PMID: 1869821.
551. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Peters WJ. Soluble interleukin 2-receptor alpha secretion is related to altered interleukin 2 production in thermally injured patients. Burns 17(4):290-5, 8/1991. PMID: 1930662.
552. Roifman CM, Chin K, Gazit A, Mills GB, Gilon C, Levitzki A. Tyrosine phosphorylation is an essential event in the stimulation of B lymphocytes by Staphylococcus aureus Cowan I. J Immunol 146(9):2965-71, 5/1991. PMID: 1707926.
553. Padeh S, Levitzki A, Gazit A, Mills GB, Roifman CM. Activation of phospholipase C in human B cells is dependent on tyrosine phosphorylation. J Clin Invest 87(3):1114-8, 3/1991. PMID: 1705565.
554. Jordan ML, Vidgen DF, Wright J, Odell M, Mills GB. Sustained increases in cytosolic calcium during T lymphocyte allosensitization, proliferation, and acquisition of locomotor function. Transplantation 51(2):464-8, 2/1991. PMID: 1825245.
555. Klotz LH, Kulkarni C, Mills G. End stage renal disease serum contains a specific renal cell growth factor. J Urol 145(1):156-60, 1991. PMID: 1984082.
556. Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, Baker MA. Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood 77(1):84-93, 1991. PMID: 1984805.
557. Stanley JB, Gorczynski R, Huang CK, Love J, Mills GB. Tyrosine phosphorylation is an obligatory event in IL-2 secretion. J Immunol 145(7):2189-98, 10/1990. PMID: 1697878.
558. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 86(3):851-5, 9/1990. PMID: 2394835.
559. Schuh AC, Sutherland DR, Horsfall W, Mills GB, Dube I, Baker MA, Siminovitch K, Bailey D, Keating A. Chronic myeloid leukemia arising in a progenitor common to T cells and myeloid cells. Leukemia 4(9):631-6, 9/1990. PMID: 2168506.
560. McGroarty RJ, Mills GB, de Harven E. Immunogold labeling of the low-affinity (55 kd) IL2 receptor on the surface of IL2 receptor-bearing cultured cells and mitogen-activated peripheral blood lymphocytes. J Leukoc Biol 48(3):213-9, 9/1990. PMID: 2391447.
561. Cruz TF, Mills G, Pritzker KP, Kandel RA. Inverse correlation between tyrosine phosphorylation and collagenase production in chondrocytes. Biochem J 269(3):717-21, 8/1990. PMID: 1697163.
562. Kandel RA, Pritzker KP, Mills GB, Cruz TF. Fetal bovine serum inhibits chondrocyte collagenase production: interleukin 1 reverses this effect. Biochim Biophys Acta 1053(2-3):130-4, 7/1990. PMID: 2166583.
563. Lazarus AH, Mills GB, Delovitch TL. Antigen-induced Ca2+ signaling and desensitization in B cells. J Immunol 144(11):4147-55, 6/1990. PMID: 2341715.
564. Haliotis T, Trimble W, Chow S, Bull S, Mills G, Girard P, Kuo JF, Hozumi N. Expression of ras oncogene leads to down-regulation of protein kinase C. Int J Cancer 45(6):1177-83, 6/1990. PMID: 2190939.
565. Mills GB, Zhang N, May C, Hill M, Chung A. Suramin prevents binding of interleukin 2 to its cell surface receptor: a possible mechanism for immunosuppression. Cancer Res 50(10):3036-42, 5/1990. PMID: 1692253.
566. Klip A, Mills GB, Britt BA, Elliott ME. Halothane-dependent release of intracellular Ca2+ in blood cells in malignant hyperthermia. Am J Physiol 258(3 Pt 1):C495-503, 3/1990. PMID: 2107750.
567. Mills GB, Hill M, McGill M, May C, Stanley J, Stewart DJ, Mellors A, Gelfand EW. Interrelationship between signals transduced by phytohemagglutinin and interleukin 1. J Cell Physiol 142(3):539-51, 3/1990. PMID: 1690213.
568. Mills GB, May C, McGill M, Fung M, Baker M, Sutherland R, Greene WC. Interleukin 2-induced tyrosine phosphorylation. Interleukin 2 receptor beta is tyrosine phosphorylated. J Biol Chem 265(6):3561-7, 2/1990. PMID: 2303462.
569. Grinstein S, Furuya W, Lu DJ, Mills GB. Vanadate stimulates oxygen consumption and tyrosine phosphorylation in electropermeabilized human neutrophils. J Biol Chem 265(1):318-27, 1/1990. PMID: 1688431.
570. Burdett E, Mills GB, Klip A. Effect of GTP gamma S on insulin binding and tyrosine phosphorylation in liver membranes and L6 muscle cells. Am J Physiol 258(1 Pt 1):C99-108, 1990. PMID: 2105654.
571. Mills GB, May C, Hill M, Gelfand EW. Role of protein kinase C in interleukin 1, anti-T3, and mitogenic lectin-induced interleukin 2 secretion. J Cell Physiol 141(2):310-7, 11/1989. PMID: 2808540.
572. Stanley JB, Gorczynski RM, Delovitch TL, Mills GB. IL-2 secretion is pertussis toxin sensitive in a T lymphocyte hybridoma. J Immunol 142(10):3546-52, 5/1989. PMID: 2523928.
573. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Falk RE, Peters WJ. Increase of serum interleukin 2 receptor level in thermally injured patients. Clin Immunol Immunopathol 51(2):205-15, 5/1989. PMID: 2784753.
574. Mills GB, May C, Hill M, Ebanks R, Roifman C, Mellors A, Gelfand EW. Physiologic activation of protein kinase C limits IL-2 secretion. J Immunol 142(6):1995-2003, 3/1989. PMID: 2784146.
575. Ebanks R, Roifman C, Mellors A, Mills GB. The diacylglycerol analogue, 1,2-sn-dioctanoylglycerol, induces an increase in cytosolic free Ca2+ and cytosolic acidification of T lymphocytes through a protein kinase C-independent process. Biochem J 258(3):689-98, 3/1989. PMID: 2786413.
576. Nasmith PE, Mills GB, Grinstein S. Guanine nucleotides induce tyrosine phosphorylation and activation of the respiratory burst in neutrophils. Biochem J 257(3):893-7, 2/1989. PMID: 2930492.
577. Bjorge JD, Kudlow JE, Mills GB, Paterson AJ. Inhibition of stimulus-dependent epidermal growth factor receptor and transforming growth factor-alpha mRNA accumulation by the protein kinase C inhibitor staurosporine. FEBS Lett 243(2):404-8, 1/1989. PMID: 2465187.
578. Church JG, Mills GB, Buick RN. Activation of the Na+/H+ antiport is not required for epidermal growth factor-dependent gene expression, growth inhibition or proliferation in human breast cancer cells. Biochem J 257(1):151-7, 1989. PMID: 2537620.
579. Kumagai N, Benedict SH, Mills GB, Gelfand EW. Cyclosporin A inhibits initiation but not progression of human T cell proliferation triggered by phorbol esters and calcium ionophores. J Immunol 141(11):3747-52, 12/1988. PMID: 3263432.
580. Kumagai N, Benedict SH, Mills GB, Gelfand EW. Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores. J Cell Physiol 137(2):329-36, 11/1988. PMID: 3263971.
581. Mills GB, Girard P, Grinstein S, Gelfand EW. Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C. Cell 55(1):91-100, 10/1988. PMID: 2844411.
582. Haliotis T, Trimble W, Chow S, Mills G, Girard P, Kuo JF, Govindji N, Hozumi N. The cell biology of ras-induced transformation: insights from studies utilizing an inducible hybrid oncogene system. Anticancer Res 8(5A):935-45, 9/1988. PMID: 2845854.
583. Balazsovits J, Mills G, Falk J, Falk R. Prostaglandins inhibit proliferation of the murine P815 mastocytoma by decreasing cytoplasmic free calcium levels [( Ca+2]i). Prostaglandins 36(2):191-204, 8/1988. PMID: 3141977.
584. Gelfand EW, Cheung RK, Mills GB, Grinstein S. Uptake of extracellular Ca2+ and not recruitment from internal stores is essential for T lymphocyte proliferation. Eur J Immunol 18(6):917-22, 6/1988. PMID: 3133231.
585. Mills GB, May C, McGill M, Roifman CM, Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 48(5):1066-71, 3/1988. PMID: 3422589.
586. Schaffer FM, Benedict SH, Petsche D, Lau A, Williams BR, Mills GB, Gelfand EW. Interferon and phorbol esters down-regulate sIgM expression by independent pathways. J Cell Physiol 134(2):245-52, 2/1988. PMID: 2831237.
587. Teodorczyk-Injeyan JA, Sparkes BG, Falk RE, Peters WJ, Mills GB. Interleukin-2 secretion and transmembrane signalling in burned patients. J Trauma 28(2):152-7, 2/1988. PMID: 3126303.
588. Kumagai N, Benedict SH, Mills GB, Gelfand EW. Comparison of phorbol ester/calcium ionophore and phytohemagglutinin-induced signaling in human T lymphocytes. Demonstration of interleukin 2-independent transferrin receptor gene expression. J Immunol 140(1):37-43, 1988. PMID: 3121740.
589. Mills GB, May C. Binding of interleukin 2 to its 75-kDa intermediate affinity receptor is sufficient to activate Na+/H+ exchange. J Immunol 139(12):4083-7, 12/1987. PMID: 2826580.
590. Roifman CM, Mills GB, Stewart D, Cheung RK, Grinstein S, Gelfand EW. Response of human B cells to different anti-immunoglobulin isotypes: absence of a correlation between early activation events and cell proliferation. Eur J Immunol 17(12):1737-42, 12/1987. PMID: 3500860.
591. Benedict SH, Mills GB, Gelfand EW. Interleukin 2 activates a receptor-associated protein kinase. J Immunol 139(5):1694-7, 9/1987. PMID: 3040857.
592. Estrov Z, Roifman C, Mills G, Grunberger T, Gelfand EW, Freedman MH. The regulatory role of interleukin 2-responsive T lymphocytes on human marrow granulopoiesis. Blood 69(4):1161-6, 4/1987. PMID: 3103713.
593. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Falk RE, Peters WJ. Impaired expression of interleukin-2 receptor (IL2R) in the immunosuppressed burned patient: reversal by exogenous IL2. J Trauma 27(2):180-7, 2/1987. PMID: 3102753.
594. Gelfand EW, Cheung RK, Mills GB. The cyclosporins inhibit lymphocyte activation at more than one site. J Immunol 138(4):1115-20, 2/1987. PMID: 3492542.
595. Gelfand EW, Mills GB, Cheung RK, Lee JW, Grinstein S. Transmembrane ion fluxes during activation of human T lymphocytes: role of Ca2+, Na+/H+ exchange and phospholipid turnover. Immunol Rev 95:59-87, 2/1987. PMID: 2437015.
596. Kumagai N, Benedict, SH, Mills, GB, Gelfland. Requirements for the simultaneous presence of phorbol esters and calcium ionophores in the expression of human T lymphocyte proliferation-realted genes. J Immunol 139:1115-1120, 1/1987.
597. Gelfand EW, Cheung RK, Mills GB, Grinstein S. Role of membrane potential in the response of human T lymphocytes to phytohemagglutinin. J Immunol 138(2):527-31, 1/1987. PMID: 3098848.
598. Roifman CM, Mills GB, Cheung RK, Gelfand EW. Mitogenic response of human thymocytes: identification of functional Ca2+-dependent and independent signals. Clin Exp Immunol 66(1):139-49, 10/1986. PMID: 3100117.
599. Teodorczyk-Injeyan JA, Sparkes BG, Mills GB, Peters WJ, Falk RE. Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression. Clin Exp Immunol 65(3):570-81, 9/1986. PMID: 2946498.
600. Gelfand EW, Cheung RK, Grinstein S, Mills GB. Characterization of the role for calcium influx in mitogen-induced triggering of human T cells. Identification of calcium-dependent and calcium-independent signals. Eur J Immunol 16(8):907-12, 8/1986. PMID: 3091377.
601. Mills GB, Stewart DJ, Mellors A, Gelfand EW. Interleukin 2 does not induce phosphatidylinositol hydrolysis in activated T cells. J Immunol 136(8):3019-24, 4/1986. PMID: 3082978.
602. Mills GB, Cheung RK, Cragoe EJ, Jr, Grinstein S, Gelfand EW. Activation of the Na+/H+ antiport is not required for lectin-induced proliferation of human T lymphocytes. J Immunol 136(4):1150-4, 2/1986. PMID: 3003191.
603. Grinstein S, Mack E, Mills GB. Osmotic activation of the Na+/H+ antiport in protein kinase C-depleted lymphocytes. Biochem Biophys Res Commun 134(1):8-13, 1/1986. PMID: 3004445.
604. Mills GB, Lee JW, Cheung RK, Gelfand EW. Characterization of the requirements for human T cell mitogenesis by using suboptimal concentrations of phytohemagglutinin. J Immunol 135(5):3087-93, 11/1985. PMID: 2995486.
605. Roifman CM, Mills GB, Chu M, Gelfand EW. Functional comparison of recombinant interleukin 2 (IL-2) with IL-2-containing preparations derived from cultured cells. Cell Immunol 95(1):146-56, 10/1985. PMID: 3875424.
606. Mills GB, Cragoe EJ, Jr, Gelfand EW, Grinstein S. Interleukin 2 induces a rapid increase in intracellular pH through activation of a Na+/H+ antiport. Cytoplasmic alkalinization is not required for lymphocyte proliferation. J Biol Chem 260(23):12500-7, 10/1985. PMID: 2995378.
607. Dosch HM, Ledgley CJ, White D, Lam P, Mills GB. Lymphocyte function in human bone marrow. II. Characterization of an interleukin 2-sensitive T precursor-cell population. J Clin Immunol 5(5):345-56, 9/1985. PMID: 3902872.
608. Mills GB, Ledgley CJ, Hibi T, White D, Lam P, Dosch HM. Lymphocyte function in human bone marrow. I. Characterization of two T cell populations regulating immunoglobulin secretion. J Immunol 134(5):3036-41, 5/1985. PMID: 3156927.
609. Gelfand EW, Cheung RK, Mills GB, Grinstein S. Mitogens trigger a calcium-independent signal for proliferation in phorbol-ester-treated lymphocytes. Nature 315(6018):419-20, 5/1985. PMID: 3923369.
610. Mills GB, Cheung RK, Grinstein S, Gelfand EW. Interleukin 2-induced lymphocyte proliferation is independent of increases in cytosolic-free calcium concentrations. J Immunol 134(4):2431-5, 4/1985. PMID: 3919094.
611. Mills GB, Cheung RK, Grinstein S, Gelfand EW. Increase in cytosolic free calcium concentration is an intracellular messenger for the production of interleukin 2 but not for expression of the interleukin 2 receptor. J Immunol 134(3):1640-3, 3/1985. PMID: 3918108.
612. Mills GB, Hannigan G, Stewart D, Mellors A, Williams B, Gelfand EW. Interferons do not signal cells through rapid alterations in phosphatidylinositide hydrolysis, cytoplasmic free calcium, or cytoplasmic alkalinization. Prog Clin Biol Res 202:357-67, 1985. PMID: 2421315.
613. Mills GB, Carlson G, Paetkau V. Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity. J Immunol 125(5):1904-9, 11/1980. PMID: 6968766.
614. Shaw J, Monticone V, Mills G, Paetkau V. Effects of costimulator on immune responses in vitro. J Immunol 120(6):1974-80, 6/1978. PMID: 149174.
615. Paetkau V, Mills G, Gerhart S, Monticone V. Proliferation of murine thymic lymphocytes in vitro is mediated by the concanavalin A-induced release of a lymphokine (costimulator). J Immunol 117(4):1320-4, 10/1976. PMID: 1086323.
616. Gerhart S, Mills G, Monticone V, Paetkau V. Quantitative analysis of the proliferative activity induced in murine thymocytes by concanavalin A. J Immunol 117(4):1314-9, 10/1976. PMID: 1086322.
617. Mills G, Monticone V, Paetkau. The role of macrophages in thymocyte mitogenesis. J Immunol 117(4):1325-30, 10/1976. PMID: 1086324.
618. Bagaisee H, Aparicio Sarrios-Rodiles M, Lu Y, Mills GB. 2010 Conceptual Model and Reporting Guidelines for Minimum Information About an RNAi Experiment (MIARE): Towards RNAi Data Standards. Submitted.
619. Rexer B, Ham AJ, Rinehard C, Hill S, Granja-Ingram N, Gonzalex-Angulo A, Mills G, Dave B, Chang J, Liebler DC, Artega C. 2010 Phosphoproteomic mass spectroscopy profiling links src family kinases to escape from HER2 tyrosin kinase inhibitors. Submitted.
620. Mitra R., Muller P., Ji Y., Zhu Y., Mills GB., Lu Y. A Bayesian Graphical Model for Joint Inference across related RPPA Experiments. Submitted.
621. Meric-Bernstam FM., Johnson A., Holla V., Bailey AM., Brusco L., Chen K., Routbort M., Patel K., Zeng J., Kopetz S., Davies M., Piha-Paul S., Hong D., Eterovic KA., Tsimberadou A., Broaddus R., Bernstam EV., Shaw K., Mendelsohn J., Mills GB. A Decision Support Framework for Genomically-Informed Cancer Therapy. Submitted.
622. Smith D, Obeyesekere M, Lu Y, Mills GB. A novel GSK3-dependent feedback loop in the phosphatidylinositol 3-kinase pathway. Submitted.
623. Nanjundan M, Mills GB. A Novel Role for Wild Type AML1B in Mediating Lung Cell Epithelial-Mesenchymal Transformation. Submitted.
624. Ding, A, Lin, S-Y, Mills GB. A novel screening method for protein-protein interactions performed in mammalian cells identifies novel binding partners for the AKT1 proto-oncogene. Submitted.
625. Lam EYK., Mok TSK., Wong CSC., Ng YK., Tsoi H., Chan HYE., Chan WY., Ng PKS., Chan AKC., Lau W-S., Cheung YS., Tsui SKW., Lau CPY., Won EYL., Lai PPS., Ng MHL., Chnge SH., Lee SKY.,Janne PA., Wilson GM., Mills GB., Liu VWY. A novel signaling axis of BCL-2/TIGAR in NADPH regulation reveals an ocengenic role of TIGAR in the absence of functional. Submitted.
626. Yang JY., Werner HMJ., Li J., Westin SN., Lu Y., Salvesen HB., Mills GB., and Liang H. A Protein-marker Driven Integrative Prognostic Model for Early-stage Endometrioid Endometrial Carcinoma. Submitted.
627. Cheung LWT, Yu S., Zhang D., Li J., Panupinthu N., Mitra S., Ju Z., Yu Q., Liang H., Hawke DH., Lu Y., Broaddus RR., Mills GB. A recurrent neomorphic p85α mutant activates the MAPK pathway dictating therapeutic response to MAPK pathway inhibitors. Submitted.
628. Ju Z., Liu W., Roebuck P., Siwak D., Zhang N., Lu Y., Davies M., Mills GB., Coombes K. A robust classifier for the quality control of reverse phase protein arrays. Submitted.
629. Nanjundan M, Zhang F, Shaw P, Lu K, Gray JW, Mills GB. Aberrrant splicing of EVI1 in the 3q26.2 amplicon retargets EVI1 activity in ovarian cancer. Submitted.
630. Joy A., Ramesh A., Smirnov I., Misra A., Reiser M., Shapiro WR., Mills GB., Kim S., Fuerstein BG. AKT pathway genes define 6 prognostic subgroups in glioblastome multiforme. Submitted.
631. Liang J, Shao, S, Xu, Z, Hennessy, B, Kondo S, Dumont D, Gutterman, JU, Walker CL, Slingerland, JM, Mills GB. AMP activated protein kinase-dependent phosphorylation of p27KIP1 mediates the decision to enter autophagy or apoptosis. Submitted.
632. Liang J., Xu Z-X., Lu Y., Yu W., Werle KD., Zhou G., Gambello MJ., Mills GB. AMPK regulates autography selectivity and mitochondrial sureillance in proliferating cells. Submitted.
633. Mak M., Diao L., Gibbons DL., Tong P., William WN., Wang J., Ng P., Cardnell R., Giri U., Warmr S., Bearss D., Mollsard A., Myers J., Heymach JV., El-Naggar A., Mills GB., Hayes N., Cope L., Robertson G., Byers LA. An Integrated analysis of epithelial-mesenchymal transition (EMT) in squamous cancers of the head and neck (HNSCC) and lung (LUSC) identifies altered molecular patterns at the DNA, RNA, and protein level in mesenchymal tumors and novel EMT targets including Axl and immune checkpoint inhibitors. Submitted.
634. Shen J., Peng Y, Lan L., Zhang W., Yang L., Stark J., Zou L. Uray IP., Wu X., Brown PH Mills GB and Peng G. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors. Submitted.
635. Smith D, Haller D, Mills GB, and Ram PT. Arsenic trioxide alters expression of TGfb signaling mediatorsand induces autophagy/apoptois in ovarian cells in ovarian cells. Submitted.
636. Mao M, Cuevas B, Lu Y, Wang H, Mills GB. Association and Regulation of PKC on P13K by Phorbol Esters and Oxidants through Src kinases. Submitted.
637. Liu X-D., Yao J., Tripathi DN, Ding Z., Xu Y., Sun M., Zhang J., Bai S., German P., Hoang A., Zhou L., Jonasch D., Zhang X., Conti C., Efstathious Tannir NM., Eissa T., Mills GB., Walker CL., Jonasch E. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Submitted.
638. Agoston ES., Sousa A.D., Jones M., Krohn M., Selfors LM., Liu W., Chen K., Yong M., Buchwald P., Hale K., Cohick E., Sergent P., Witt A., Koshekbaeva Z., Gao G., Aoston AT., Merritt MA., Foster R., Rueda B., Crum CP., Brugge JS., Mills GB., Ince TA. Chacterization of novel ovarian tumor cell lines that retain the phenotype of primary tumors. Submitted.
639. McAuliffe P., Akcakanat, Gonzalez-Angulo AM., Sangai T., Stemke-Hale K., chen H., Do K-A., Sharma C., Symmans WF., Gagea-lurascu MG., Naff KA., Sahin A., Multani A., Mills GB., Meric-Bernstam F. Chacterization of patient-derived breast cancer xenografts demostrates molecular evolution in the P13K pathway. Submitted.
640. Han L., Li J., Zhang R., Werner HMJ.,Yuan Y., Eterovic KA., Nair N., Yu S., Yang Y., Cheung LWT., Lu Y., The Cancer Genome Atlas Research Network, Scott KL., Li JB., Mills GB. Liang H. Clinical relevance and therapeutic liability of RNA editing in cancer. Submitted.
641. Sohn J., Parainyantikul N., Liu S., Lee J., Hortobagyi G., Mills GB., Ueno NT., Gonzalez-Angulo A. cMet activation and EGFR therapy resistance in triple negative breast cancer. Submitted.
642. Palu CC, Freire PR, Deus HF, Zhang L, Mills GB, Vasconcelos ATR, and Almeida JS. CNViewer: a browser based application for exploratory population analysis of copy number variation. Submitted.
643. Van Allen E., Lui V., Johnson JT., Duvvuri U., Bauman J., Stransky N., Goetz EM., Chiosea S., Close D., Johnston PA., Zeng Y., CArter SA., McKenns A., Getz G., Gilbert B., Pendleton K., Li H., Mills GB., Garraway LA., Grandis JR. Complete Response to brief erlotinib monotherapy in an advance head and neck tumor with somatic MAPK1 mutation. Submitted.
644. Meric-Bernstram F., Frampton GM., Ferrer-Lozano J., Yelensky R., Stevens P., Wang Y., Palmer GA., Su X., Barrera JJ., Burgues O., Cronin MT., Lluch AM., Shahin A., Mills GB., Gonzalez-Angulo AM. Comprehensive genomic aberrations of primary and recurrent breast cancer. Submitted.
645. Abkevich V., Timms KM., Tran T., Williams DJ., Hennessy BT., Carey MS., Mills GB., Lanchbury JS., Gutin A. Computational method for detecting Loss of heterozygosity (LOH) regions in cancer cell lines and solid tumors using SNP arrays. Submitted.
646. Park ES, Kim SJ, Kim SB, Woo HG, Kim SM, Park YY, Mills GB, Fidler IJ, and Lee JS. Cross-species hybridization of microarrays (CHM) reveals global reprogramming of the transcriptome during brain metastasis. Submitted.
647. Zhao D., Besser A., Wander S., Sun J., Wang B., Ince T., Zhou W., Guo W., Mills G., Theodorescu D., Slingerland J. Cytoplasmic p27 promotes epithelial-mesenchymal transition an tumor metastasis via STAT3-mediated Twist1 upregulation. Submitted.
648. Zhao J., Zhang Y., Hill J., Hartman Z., Mazumdar A., Savage M.,Mills GB.,Beown P. DAPK-1, a Death Signaling Transducer, is Critical for the Tumorigenicity of p53 Mutant Breast Cancer. Submitted.
649. Korkola, J., Collisson, E., Heiser L., Oates C., Bayani N. Itani S., Esch A., Thompson W., Griffith O., Wang N., Kuo W-L., Cooper B., Billig J., Ziyad S., Hung J., Jakkula L., Feiler H., Lu Y., Mills G., Spellman P., Tomlin C., Mukherjee S., Gray JW. Decoupling of the PI3K pathway via mutation necessitates combinatorial treatment in HER2+ breast cancer. Submitted.
650. Fox M., Balko JM., Kuba MG., Gonzalez-Angulo AM., Mills GB. Mayer IA., Abramson V., Means JA., Kelley MC., Farley JS., Mesxoely IM., Artega CL. Deep kinome sequencing identifies a novel D189Y mutation in the Src family kinase LYN as a mediator of endocrine resistance in ER+breast cancer. Submitted.
651. Yuan Y., Van Allen EM., Omberg L., Wagle N., Sokolow A., Xu Y., Hess K., Diao L., Han L., Huang X., Lawrence M., The Cancer Genome Atlas Research Network., Stuart J., Mills GB., Garraway LA., Morgolin AA., Getz G., Liang H.,. Dissecting the clinical prognostic and predictive utility of cancer genomic data across tumor types. Submitted.
652. Gungor H., Saleem A., Curry E., Babar S., Dina R., ElpBahrawy MA., Rama N., Chen M.m Pickford E., Agarwal R., Blagden S., Carme S., Salinas C., Stemke-Hale K., Mills GB., Madison S., Krachery E., Santiago-Walker A., Smith D., Morris S., Stronach E., Gabra H. Dose-Finding PET and predictive biomarker study in platinum resistant ovarian cancer demostrates tolerability and activity for the pan-AKT inhibotor GSK2141795. Submitted.
653. McCampbell AS., Dere R., Kim S., Zhou L., Djordjevic B., Soliman P., Xie Q., Wei C., Wu W., Mills GB., Hurstings S., Lu Kh., Broaddus RR., Walker CC. Early involvement of p27 in Progression of Endometrial Carcinoma Arising in the Setting of Obesity. Submitted.
654. Nanjundan M, Nakayama Y, Cheng, KW, Lahad JP, Kuo W-LLapuk, A, Yamada, K, Auersperg N, Liu J, Smith-McCune, K, Lu, KH, Fishman, D, Gray JW, Mills GB. Ecotropic viral integration site 1, located in the 3q26 amplicon in ovarian cancer, controls cell proliferation and migration . Submitted.
655. Liu S., Meng X.,Chen H., Liu W., Miller T., Lu Y., Zhang F., Iurascu MG., Arteaga CL., Mills GB., Meric-Bernstam F., Gonzalez-Angulo AM. Effects of src and insulin-like growth factor-I receptor inhibition on acquired endocrine therapy resistant breast cancer. Submitted.
656. Gonzalez-Angulo A., Liu S., Meric-Bernstam, F., Parinyanitikul N., Wang B., Eterovic AK., Zheng X., Gagea M., Chavez-MacGregor M., Ueno NT., Lei X., Zhou W., Litton JK., Nair L., Tripathy D., Brown PH., Hortobagyi GN., Chen K., Mendelsohn and Mills G. Functional Consequence of the METT1010I SNP in Breast Cancer. Submitted.
657. Hu X., Feng SD., Greshock J., Zhang D., Hu Z., Zhang YY., Wamt LP., Li C., Katsaros D., Montone K., Lu Y., Tanyi YL., Li H., Mills GB., Zhang L. Functional genomic approach identifies oncogenic long-non-coding RNA FAL-1 that associates with BMI1 and represses p21 expression in human cancer. Submitted.
658. Sarkar TR., Battula VL., Werden SJ., Vijay GV., Ramirez- Pena EQ., Rodriguez-Canales JR., Taube JH., Sphyris N., Chang JT., Mills GB., Wistuba II., Miura N., Lewis MT., Porter W., Andreef M., Mani SA. GD3 Synthase regulates EMT, cancer stem cells and mestasis via the HGF/c-Met signaling pathway. Submitted.
659. Cho JY, Claerhout S, Lim JY, Park YY, Kim K, Kim SB, Mills GB, Lee JS. Gene expression signature-based connectivity map analysis identifies vorinostat as a therapeutic agent against human gastric cancer. Submitted.
660. Liu Y., Zhou R., Tsavachidis S., Brewster A., Murray JL., Do KA., Sahin A., Hotobagyi GN., Taube JH., Mani SA., Batts LM., Mills GB., Kamrudin S., Bondy ML., Thompson PA., Borreson-Dale AL. Genome-wide Molecular Inversion Probe Array Profiling Reveals DNA Copy Number Imbalances Associated with Breast Cancer Bone and Non-Bone Metastasis. Submitted.
661. Raghavan CR., Zhang F., Zhao Z., Pradeep S., Pecot CV., Rodriguez-Aguayo C., Han H-D., Lu Y., Borresen-Dale AL., Lopez-Bernstein G., Flores ER., Sood AK., Mills GB. Genomic amplification of microRNA-569 at 3q26.2 leads to the loss of TP53INP1 and promotes aggresiveness of epithelial cancers. Submitted.
662. Kuo W, Fridyand J, Novak B, Takano H, Konczal D, Lapuk A, Yamada K, Spellman P, Guan Y, Smith-McCune K, Shaw P, Glenn P, Zaloudek C, Lu K, Deavers M, Collins C, Chin K, Godgson G, Kim U, Pinkel D, Tanaka T, Berchuck A, Mills GB, Jain A, Gray JW. Genomic deregulation of transcription in serous ovarian cancers; prognostic markers and therapeutic targets. Submitted.
663. Tsavachidou D., Li Y., Zhang D., Liu W., Lu Y., Mills GB. Glycogen is an YBX1-inducible energy reserve supporting renal cancer growth and contributing to poor patient outcomes. Submitted.
664. Bruno D., Smith D., Lu Y., Mills GB. GSK is required for optimal AKT activation. Submitted.
665. Stadler N., Dondelinger F., Hill SM., Ng PKS., Akbani K., Werner HMJ., Lu Y., Mills GB., Mukherjee S. High-dimensional statistical approaches reveal heterogeneity in signaling networks across human cancers. Submitted.
666. Xu H, Wang S, Zhou J, Jiang, L, Mills GB, Vyniou, N and Hu S. Induction of an endogenous granzyme B upon retinoblastoma protein-mediated senescent arrest of human osteosarcoma cells. Submitted.
667. Zheng, Z, Samudio, IJ, Estrov, Z, Pelicano, H, Harris, D, Hail, N, Lu, Y, Huang, P, Mills GB, Andreeff, M, Konopleva M. Inhibition of AKT signaling by a small-molecular KP372-1 induces mitochondrial dysfunction and apoptosis in AML . Submitted.
668. Gopal YNV., Rizos H., Chen G., Deng W., Frederick DT., Cooper ZA., Scolyer RA., Pupo G., Komurov K., Sehgal V., Zhang J., Pate L., Pereirar CG., Broom BM. Mills GB., Ram P., Smith PD., Wargo JA. Long GV., and Dvaies MA. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitorsmediated by PGC1α and elevated Oxidative Phosphorylation in melanoma. Submitted.
669. He N., Kim N., Song M., Park C., Wang X., Park E., Kim KA., Park J., Kim K., Zhang F., Mills GB., Yoon S. Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11-driven regulation of PDE4D. Submitted.
670. Gopal YNV., Park ES., Fox PS., Smith DL., Deng W., Bassett RL., Loose DS., Mills GB., Lee JS., Davis MA. Integrated transcriptomic and protemics identifies a unique melanoma transcriptional signature associated with phosphorylated GSK3. Submitted.
671. Shackleford TJ, Esteva FJ, Zhang Q, Drakos I, Koropati A, Tian L, Kute T, Le XF, Liu W, Sahin AA, Hortobagyi G, Mills GB, Rassidakis GZ, and Claret FX. JAB1 confers trastuzumab resistance by nuclear transport of p27. Submitted.
672. Lee J., MacEachern SN., Lu Y., Mills GB. Local-mass preserving prior distributions for nonparametric Bayesian models. Submitted.
673. Berns K., Gennissen A., Hijmans EM., Guo W., Knijnenburg TA., van der Heijden MS., Hindriksen S., Nijkanp W., Wessels LFA., Mills GB., Biejersbergen RL., and Bernards R. Loss of ARID1A confers resistance to multiple targeted cancer drugs through activation of AKT signaling. Submitted.
674. Hasegawa, Y, Umezu-Goto, Mand Mills GB. Lysophosphatidic acid (LPA) analogs, D-3-deoxy-phosphophatidyl-myo-inositol ether lipid (DPIEL) and lysophosphatidylglycerol (LPG), antagonize LPA receptor activation . Submitted.
675. Cheng H-Y, Dong A, Mills GB, Chun J, Morris AJ, Smyth SS. Lysophosphatidic acid signaling protects pulmonary vasculature. Submitted.
676. Speers C., Wheatley K., Sexton K., Greiner D., Tsimelzon A., Hilsenbeck S., Mills GB., Chang J., Brown P. Maternal embryonic leucine zipper kinase (MELK) is a key regulator of proliferation in estrogen receptor-negative breast cancer and is a associated with poor overall survival. Submitted.
677. Cheong J-H., Park ES., Park KC., Shin YS., Liang J., Ki HJ., Huh Y., Mills GB. Metabolic regulator PGC-1a Promotes Angiogens is a Metastasis in nutrient deprivation selected tumor cell. Submitted.
678. Lee E., Yang J., Park Y., Kim N., Yook J., Huh Y-M., Cheong J-H., Mills GB. Metabolic stress induced stem-liked transition of cancer cells through Wnt activity. Submitted.
679. Boggs A., Vitolo MI., Whipple RA., Charpentier MS., Slovic J., Ioffe OB., Tutle KC., Goloubeva OG., Lu Y., Mills GB., Martin SS. Metastatic and basal-like breast tumors exhibit elevated a-tubulin acetylation that promotes microtentacles and tumor cell reattachment. Submitted.
680. Wiemann S, Mehrle A, Hahne F, Hermjakob H, Mills GB, Vidal M, Wrobel DJ. MIACA-Minimum information about cellular assay and the cellular assay object model. Submitted.
681. Javle M., Rashid A., Churi C., Kar S., Zuo M., Eterovic K., Gonzalez G., Ali S., Janku F., Shroff R., Aloiz T., Vauthey J-N., Curley S., Mills GB, Roa I. Molecular Characterization of Gallbladder Cancer using Somatic Mutation Profiling. Submitted.
682. O’Reilly, K, Rojo F, She, Q-B, Solit, D, Mills, GB, Lane, H, Hofmann, F, Hicklin, DJ, Ludwig, DL, Baselga, J, Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Submitted.
683. Chowdhuri SR., Toutbort MJ., Patel KP., Singh RR., Broaddus R., Lazar AJ., Sahin A., Mills GB., Mendelsohn J., Meric-Bernstam F., Yao H., Aldape K., Luthra R. Multigene Clinical Mutational Profiling of Breast Carcinoma using Next Generation Sequencing (NGS). Submitted.
684. Weinstein JN., Kane DW., Wakefield C., Casasent TD., Ryan M., Mills GB., Broom BM. Next Generation clustered heat maps. Submitted.
685. Broom G., Kane DW., Dodda D., Nguyen L., Akbani R., Wakenfield C., Casasent TD., Ryan M., Mills GB., Kopetz SC., Weinstein JN. Next-generation clustered heat maps for interactive exploration of molecular profiling data. Submitted.
686. Tuna M, Thompson PA, Jacobs S, Lee W, Mitra R, Sahin AA, Mills, Bondy ML, Krahe R. Optimized copy number analysis from formalin-fixed paraffin-embedded breast cancer tissues using high-density SNP arrays. Submitted.
687. Fu X., Creighton C., Biswal NC., Kumar V., Shea M., Herrera S., Gutierrez C., Wang T., Nanda S., Giulian M., Morrison G., Nardon A., Karlin KL., Westbrook TF., Mills GB., Lee AV., Hilsenbeck SG., Gray JW., Joshi A., Osborerne CK., Shiff R. Overcoming endocrine resistance in ER-positive breast cancer due to reduced PTEN levels by co-targeting mTOR, AKT, or MEK. Submitted.
688. Kim TH., Yoo J-Y., Kim HI., Gilbert J, KU BJ., Li J., Mills GB., McCampbell, Roaddus RR., Lyndon JP., Lim JM., Yoon H-G., Jeong J-W. Overexpression of Mig-6 suppresses endometrial cancer development and progression in ablation of Pten mice. Submitted.
689. Madden SF., Clarke C., Stordal B., Carey M., Broaddus R., McGallagher WM., Crown J., Clynes M., Mills GB., Hennessey B. OvMark: a user-friendly tool for examining putative prognostic biomarkers in publicity available ovarian cancer datasets. Submitted.
690. Dillon LM., Bean JR., Yang W., Symonds LK., Shee K., Balko JM., Friedman DB., Liu S., Gonzalez-Angulo AM., Mills GB. P-REX1 creates a positive feedback loop to activate growth factor receptor, P13K/AKT, and MEK/ERK signaling in ER+breast cancer. Submitted.
691. Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Ghazoui Z, Dowsett M, Chen H, Highman C, Shyr Y, Arteaga CL. P13K hyperactivation promotes the hormone-independent growth of estrogen receptor-postive breast cancer. Submitted.
692. Hsu Y-H., Wu T-J., Chan L-C., Hsu JL., Yao J., Fan Y-F., Wei Y., Wu Y., Huan W-C., Liu C-L., Chang Y-C., Mang M-Y., Li C-W., Shen J., Chen M-K., Sahim AA., Sood A., Mills GB., Yu D., Hortobagyi GN., Hung M-C. PCK-a, CDK6, and MET as Therapeutic Targets for Triple-Negative breast cancer. Submitted.
693. Tsang Y-H., Dogruluk T., Espita M., Lu H., Ramanathan S., Chong Z., Chen F., Nair N., Minelli R., Tedeschi P., Chang Q., Dennison J., Li M., Ying H., Bertino J., Gingras M-C., Ittman M., Chen K., Creighton CJ., Eterovic AK., Potts T., Mills GB., Scott KJ. Personalized Functionalization Identifies Rare Oncogenic Drivers of Pancreatic Cancer. Submitted.
694. Lu G., Zhang Q., Huang Y., Song J. Tomaino R., Ehrenberger T., Lim E. Liu W., Bronson RT., Bowman M., Dillon DA., Gygi SP. Mills GB., Richardson AL, Signoretti S., Yaffe YB., and Kaelin WG. Phosphorylation of ETS1 by Src Family Kinases Prevents its Recognition by the COP1 Tumor Suppressor. Submitted.
695. Korkola J., Collisson E., Heiser L., Oates C., Bayani N., Itani S., Esch A., Griffith O., Want N., Kuo W-L., Cooper B., Billig J., Ziyad S., Hung J., Jakkula L., Feiler H., Lu Y., Mills G., Spellman P., Tomlin C., Mukherjee S., Gray JW. PIK3CA mutations predict synergy between lapatinib and AKT inhibitors in HER2+breast cancer. Submitted.
696. Tangen IL., Werner HM., Berg A., Halle MK., Kusonmanol K., Trovik J., Horvik E., Mills GB., Krakstad, C., Salvesen HB. Progesterone receptor loss increases from primary to metastatic endometrial cancer lesions and suggests a potential therapeutic opportunity for CDK2 inhibitors. Submitted.
697. Meric-Bernstram F., Akcakanat A., Chen H., Sahin A., Tarco E., Carkaci S., Adrada BE., Singh G., Do KA., Garces ZM, Mittendorf E., Babiera G., Wagner J., Bedrosian I., Hwang R., Krishnamurthy S., Symmans F., Gonzalez-Angulo AM., Mills GB. Proteomic biomarkers demostrate limited intraumoral heterogenity in breast cancer but are influenced by biospecimen variables. Submitted.
698. Hennessey B., Ju Z., Agarwal R., Lluch A., Carey MS., MyhreS.,Lee JS., Gonzalez-Angulo AM., Kunkler IH., Kerr G., Thomas JS., Coombes KR., Overgard J., Alsner J., Broaddus R., Deng L., Sahi A., Velero V., Harrison DJ., Borresen-Dale A-l., Mills GB. Proteomic Predictors of Outcome After Adjuvant Anti-Hormonal Therapy for Hormone Receptor-Positive Breast Cancer. Submitted.
699. Ding Z., German P., Bai S., Reedy SA., Liu X., Sun M., Zhou L., Zhao X., Wu C., Chen X., Zhang S., Mills GB., Jonasch E. Proteomsome inhibition augments proteins levels and function of von Hippel Lindau R167Q mutant. Submitted.
700. Westin SN., Ju Z., Broaddus RR., Krakstad C., Li J., Pal N., Lu KH., Hennessy B., Klempner SJ., Werner HM., Salvesen J., Cantely LC., Mills GB., Myers AP. PTEN loss is a context dependent determinant of patient outcomes in obese and non-obese endometroid endometrial cancer patients. Submitted.
701. Cheng KW, Lee J-S, Gray JW, Mills GB. Rab25 improves bioenergetics providing a survival advantage during nutrient restriction. Submitted.
702. Cheng KW., Agarwal R., Mitra S., Mills GB. Rab25 small GTPase mediates secretion of tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) by cancer cells protecting cells from effects of TRAIL. Submitted.
703. Nanjudan M, Byers LA, Carey M, Siwak D, Wistuba I, Dao L, Want J, Coombes K, Mills Gb, Minna J, Heymach JV. Reverse phase protein array identifies a proteonomic signature of non-small lung cancer. Submitted.
704. Zhang G., Frederick DT., Wei Z., Basu D., Chae YC., Krepler C., Xu X., Wu L., Choi H., DimWamwa E., Shanna B., Zhang D., Guha M., Srinivasan S., Xiao M., Liu S., Sproesser K., Gu ., Xu C., Liu Q., Keeney F., Xu W., Braffort P., Karakousis GC., Schuchter LM., Gangadhar T., AMaravadi RK., Li L., Wang T., Torigian DA., Weeraratna A., Davies MA., Mills GB., Wargo JA., Adadhani NG., Altieris DC., Flaherty KT., and Herlyn M. Reversibly Senescent State Induced by MAPK Pathway Inhibitors in Melanoma is Prevented by Targeting Mitochondrial Hsp90-directed Protein Folding. Submitted.
705. Nanjudan M, Lu Y, Mills GB. Role of the trans-acting splicing factor, ASF/SF2 in ovarian cancer. Submitted.
706. Sewell A., Brown B., Biktasova A., Mills GB., Tyson DR., Issaeva N., Yarbrough WG. RPPA profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Submitted.
707. Stanislaus R, Lu Y, Hennessy BT, Baggerly K, Coombes K, Mills GB, Almeida J. RPPAML:2010 A proposal for Reverse Phase Protein Array data exchange language. Submitted.
708. Park YY., Kim SB., Kim SC., Park ES., Sohn BH., Lim JJ., Rohn JW., Chu IS., Kim YM., Lee Sh., Heo J., Leem SH., Birrer M., Bowtell DS., Verhaak F., Mills GB. Sood A., Lee JS. Silencing of the HIPPO pathway is associated with poor prognosis in ovarian cancer. Submitted.
709. Kaushik P., Molinelli E., Miller M., Liu W., Ju Z., Want W., Korkut A., Lu Y., Mills GB., Sander C. Spatial normalization of reverse phase protein array data. Submitted.
710. Hills SM,Hennessey BT., Lu Y., Mills GB., Mukherjee. STIC simultaneous topology inference and clusteting. Submitted.
711. Seviour EG., Luo Z., Lu Y., Sehgai V., Moss T., Zhang F., Azencot R., Hills S., Roompamula R., Prescott C., Sood A., Mukherjee S., Gray J., Mills GB., Ram T. System analysis of miRNA regulation of cell signaling. Submitted.
712. Kotlyar M., Pastrello C., Niu Y., Ding Z., Vafaee F., Froackes-Carter F., Mills GB., Jurisica I. Systematically characterizing human proteins without reported interactions. Submitted.
713. Schmandt R, Fung M, Arima N, Zhang N, Leung B, May C, Gibson S, Hill M, Green W, Mills Gb. T lymphocyte proliferation: Tyrosine kinases in interleukin 2 signal transduction Balliere's Clinical Hematology. Submitted.
714. Liu S., Meng X., Chen H., Liu W., Miller T., Lu Y., Zhang F., Iurascu MG., Artega CL., Mills GB., Meric-Bernstam F., Gonzalez-Angulo AM. Targeting tyrosine kinase and strogen receptor abrogates resistance to endocrine therapy in breast cancer. Submitted. PMID: 24979294.
715. Muranen T., Selfors LM., Thoreen CC., Coloff JL., Mills GB., Brugge JS. The Hippo pathway effector YAP1 is required for long-term drug resistance to PI3K/mTOR inhibitors. Submitted.
716. den Hollander P., Rawls K., Tsimelson A., Shepherd J., Mazmuder A., Hill J., Fuqua S., Chang J., Osborne K., Hilsenbeck S., Mills GB., Brown PH. The Phosphatase PTP4A3 is Critical for the growth of Triple-Negative breast cancer. Submitted.
717. Gopal V, Altman M, Carmin A, Yu S, Hall H, Prestwish G, Xu Y, Mills GB, Davies MA, Murph MA. The phosphonothionate analogue of carba cyclic phosphatidic acid inhibits metastatic melanoma growth and viability in vitro and in vivo. Submitted.
718. Watson IR., Li J., Cabeceiras PL., Mahdavi M., Stemke-Hale K., Mills GB., Chin L. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharamacological Inhibition of RAF. Submitted.
719. Hassan B., Akcakanat A., Sangai T., Evans KW., Adkins F., Eterovic AKT., Zao H., Chen K., Dhen H., Ann-Do K., Sie SM., Holder AM., Mills GB., Meric-Bernstam. TOR Inhibitor MLN0128 Has Antitumor Efficacy in Cancer Cells with Intrinsic as well as Acquired Rapamycin-Resistance. Submitted.
720. Park Y-Y, Kim SM, Kim S-B, Sohn BH, Kim JH, Lee SS, Kim S-C, Park E-S, Heo J, Kim YJ, Kim D-G, Leem S-H, Chu I-S, Kaseb A, Jeong W, Park YN, Wang XW, Thorgeirsson SS, Johnson RL, Mills GB, Lee J-S. YAP1 and TAZ activates the mTORC1 pathway by regulating amino acid transporters. Submitted.
721. Reipas KM., Hu., K., Pambid MR., Fotovati A., Stratford AL., Astanehe A., Berns R., Hamilton MJ., Bosiljcic M., Bennewith K., Mills GB., and Dunn SE.,. YB-1 is activated in residual disease following chemotherapy and serves as a potential molecular target to improve outcomes in patients S. Submitted.
722. Davies AH., Reipas KM., Islam S., Fotovati A.,Pambid MR., Strafford AL.,Maxwell C., Mills GB., Dunn SE. YB-1 promotes tumor-initiation through chromatin remodeling leading to the development of triple-negative breast cancer. Submitted.

Invited Articles

1. Akbani R., Becker K-F., Carragher N., Goldstein T., de Koning L., Korf U., Liotta L., Mills GB., Nishizuka S.S., Petricoin EF., Pollare HB., Serrels B., Shu J., For the The RPPA (Reverse Phase Protein Array) Society. Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational and Basic Research: A Workshop Report Mol Cell Proteomics. In Press.
2. Dawood M., Mills GB., Ding Z. Shifting Gears to Survive: AKT does the right stuff. Oncoscience. In Press.
3. Akbani R., Becker K-F., Carragher N., Goldstein T., de Koning L., Korf U., Liotta L., Mills GB., Nishizuka S.S., Petricoin EF., Pollare HB., Serrels B., Shu J.,. The RPPA (Reverse Phase Protein Array) Society 2014 Realizing the Promise of Reverse Phase Protein Arrays for Clinical, Translational and Basic Research: A Workshop Report. Mol Cell Proteomics. In Press.
4. Bailey AM., Mao Y., Zeng J., Holla V., Johnson A., Brusco L, Che K., Mendelsohn J., Mills GB., Meric-Bernstam F. Implementation of Biomarker-Driven Cancer Therapy: Existing Tools and Remaining Gaps. Discovery Medicine(17):101-114, 2014.
5. Dawood M., Mills GB., Ding Z.,. Shrewd AKT regulation to survive. Oncoscience(1):113-114, 2014.
6. Klempner SJ, Myers AP, Mills GB, Westin SN. Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother 14(16):2171-82, 11/2013. PMID: 23937415.
7. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB. Building a personalized medicine infrastructure at a major cancer center. J Clin Oncol 31(15):1849-51, 2013.
8. Klempner, SJ., MyersAP., Mills,GB Westin S. Clinical Investigation of Receptor and Non-Receptor Tyrosine Kinase Inhibitors for the Treatment of Epithelial Ovarian Cancer. Expert Opinion on Pharmacotherapy(14):2171-2182, 2013.
9. Ram P, Mendelsohn J, Mills GB. Bioinformatics and systems biology. Molecular Oncology 6:147-54, 2012.
10. Mitra S, Stemke Hale KA,, Mills GB, Claerhout S. Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy. Cell Science 103:400-7, 2012.
11. Kamel D, Hennessy B., Brady B, Tabchy A, Mills GB. Proteomic classification of breast cancer. Cancer Drug Targets 13:1495-509, 2012.
12. Mitra S, Cheng KW, Mills GB. Rab25 in cancer: a brief update. Biochemical Society Transactions 40:1404-8, 2012. NIHMSID: NIHMS516249.
13. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMet asis in cancer therapy. J Clinical Oncol 30:3287-96, 2012.
14. Tabchy A, Hennessy BT, Gonzalez-Angulo AM, Bernstam FM, Lu Y, Mills GB. Quantitative proteomic analysis in breast cancer. Drugs Today 47:169-82, 2011.
15. Mitra S, Cheng KW, Mills GB. Rab TTPases inplicated in inherited and acquired disorders. Semin Cell Dev Biol 22:57-68, 2011.
16. Lee JS, Kim JH, Mills GB. Systems Biology approaches to decode the genome of cancer. Cancer Research and Treatment 43:205-11, 2011.
17. McAuliffe PR, Mills GB, Gonzalez-Angulo AM. Deciphering the role of the PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clinical Breast Cancer Supplement 10(3):S59-S65, 2010.
18. Panupinthu N, Mills GB, Lee HY. Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression. British Journal of Cancer 102:941-6, 2010.
19. Agarwal R, Carey M, Hennessy B, Mills GB. PI3K pathway-directed therapeutic strategies in cancer. Current Opinion Investigative 11:615-28, 2010.
20. Tabchy A, Hennessy BT, Hortobagyi G, Mills GB. Systems Biology of breast cancer. Current Breast Cancer Reports 1:238-45, 2010.
21. Siwak DR, Carey M, Hennessy BT, Nguyen CT, McGahren Murray MJ, Nolden L, Mills GB. Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol 2010:568-93, 2010.
22. Gonzalez-Angulo AM, Hennessy BT, Mills GB. The future of personalized medicine in oncology: a systems biology approach. J Clin Oncol 28:2777-83, 2010.
23. Liu S, Murph M, Panupinthu N, Mills GB. ATX-LPA receptor asis in inflammation and cancer. Cell Cycle 15:3695-701, 2009.
24. Mills GB, Agarwal R, Cheng KW. Ras-superfamily GTP-ases in ovarian cancer. Cancer Treat Res 149:229-40, 2009.
25. Agarwal R, Jurisca I, Mills GB, Cheng KW. The emerging role of the Rab25 small GTPase in cancer. Traffic 10:1561-8, 2009.
26. Tuna M, Knuutila S, Mills GB. Uniparental disomy (UPD) in cancer trends. Molecular Medicine 15:120-8, 2009.
27. Murph M, Smith DL, Hennessy B, Lu Y, Joy C, Coombes K, Mills GB. Linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients. Adv Exp Med Biol 622:183-95, 2008.
28. Ashworth A, Balkwill R, Bast RC Jr, Berek JS, Kaye A, Boyd JA, Mills GB, Weinstein JN, Wooley K, Workman P. Opportunities and challenges in ovarian cancer research, a prospective from the 11th Ovarian cancer action/HHMT Forum. Gen Oncology 108(3):652-7, 2008.
29. Hennessy B, Murph M, Nanjundan M, Carey M, Auersperg N, Almeida J, Coombes K, Liu J, Lu Y, Gray JW, Mills GB. Ovarian cancer: linking genomics to new target discovery and molecular markers: the way ahead. Adv Exp Med Biol 617:23-40, 2008.
30. Murph M, Tanaka T, Pang J, Felix E, Liu S, Trost R, Godwin AK, Newman R, Mills GB. Liquid chromatography mass spectrometry for quantifying plasma lysopholipids: potential biomarkers for cancer diagnosis. Enzymology 433:1-25, 2007.
31. Bast RC Jr, Brewer M, Zou C, Hernandez M, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer. Recent Results in Cancer Research 174:91-100, 2007.
32. Murph M, Mills GB. Targeting the lipids LPA and S1P and their signaling pathways to inhibit tumor progression. Expert Reg Mol Med 9:1-18, 2007.
33. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust Meeting. Cancer Res 66(6):2904-6, 2006.
34. Stemke-Hale K, Mitra R, Hennessy B, Mills GM. Molecular screening for breast cancer prevention, early detection and treatment planning - combining biomarkers from DNA, RNA and protein. Current Oncology Reports 8:484-91, 2006.
35. Murph M, Tanaka T, Liu S, Mills GB. Of spiders and cancer: emergence of lysophospholipids and their metabolic pathways as targets for therapy in cancer. Clinical Cancer Research 15(11030-8), 2006.
36. Hennessy BT, Mills GB. Ovarian Cancer: Homeobox genes, autocrine/paracrine growth and kinase signaling. Int J Biochem Bell Biol 38:1450-6, 2006.
37. Davies M, Hennessy B, Mills GB. Point mutations of protein kinases and individualised cancer therapy. Expert opinion in pharmacotherapy 7:2243-7, 2006.
38. Cheng KW, Lu Y, Mills GB. Assay of Rab25 function in ovarian and breast cancers. Methods Enzymol 403:202-15, 2005. PMID: 16473588.
39. Cheng KW, Lahad JP, Gray JW Mills GB. Emerging role of Rab GTPases in cancer and human disease. Cancer Research 65:2516-19, 2005.
40. Spitz MR, Wu X, Mills GB. Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23:267-75, 2005.
41. Kohn EC, Lu Y, Wang H, Yu Q, Yu S, Hall H, Smith DL, Meric-Bernstam F, Hortobagyi GN, Mills GB. Molecular Therapeutics: promise and challenges . Semin Oncol Seminars in Oncology(1 Suppl 3):39-53, 2/2004. PMID: 15052542.
42. Drees BE, Mills GB, Rommel C, Prestwich GD. Therapeutic potential of phosphoinositide 3-kinase inhibitors . Expert Opinion on therapeutic patents 14:703-32, 2004.
43. Balkwill, FBast RC, Berek, J, Chevenix-Trench, G, Gore, M, Hamilton, T, Jacobs I, Mills, GBSouhami R, Urban, N, Ursulic S, Smyth J. Current Research and treatment for epithelial ovarian cancer: A position paper from the Helene Harris Memorial Trust. European Journal of Cancer 39:1818-1827, 2003.
44. Kohn EC, Fidler, IJ, Fishman, D, Jaffe, R, Liotta, LA, Van Trappen, P, Mills GB, Trope C. Metastasis and angiogenesis in epithelial ovarian cancer Therapeutics. Gynecological Oncology 88:S37-S42, 2003.
45. Feng, L, Mills GB, Prestwich, GD. Modulators of Lysophosphatidic Acid Signaling Expert Opinions on Therapeutic Patents . 13:1619-1634, 2003.
46. Kohn EC, Mills GB, Liotta L. Promising directions for the diagnosis and management of gynecological cancers . Int. J. Obstet Gyne 83:203-209, 2003.
47. Cheng, KW, Tanyi, JL, Mills GB. Genomic technologies in cancer research, drug discovery and development. CME Journal of Gynecologic Oncology 7:16-24, 2002.
48. Mills GB. Mechanisms underlying chemoprevention of ovarian cancer. Clinical Cancer Research 8:7-10, 2002.
49. Euhus DM, Esserman L, Ganz PA, Mills GB, Tomlinson G. Pretest Prediction of BRCA1 or BRCA2 Mutation by Risk Counselors and the Computer Model BRCAPRO. J Natl Cancer Inst 94:1583-1584, 2002.
50. Petricoin, ED, Mills GB, Kohn, EC, Liotta LA. Proteomic patterns in serum and identification of ovarian cancer Response to comments. Lancet 360:170-171, 2002.
51. Mills GB, Bast, RC, Srivastava, S. Future for ovarian cancer screening: Novel markers from emerging technologies of transcriptional profiling and proteomics. Journal of the National Cancer Institute 93:1437-1439, 2001.
52. Erickson, JR, Hasegawa, Y, Fang, X, Eder, A, Mao, M, Furui, T, Aoki, J, Morris, A, Mills GB. Lysophosphatidic Acid and Ovarian Cancer: A Paradigm for Tumorigenesis and Patient Management. Prostaglandins and Other Lipid Mediat 64:63-81, 2001.
53. Bast RC, Mills GB. Alterations in oncogenes, tumor suppressor genes and growth factors associated with epithelial ovarian cancer In: Methods in Molecular Medicine. Ovarian Cancer 39:Ovarian Cancer, 2000.
54. Erickson, JR, Espinal, G, Mills GB. Analysis of the Edg2 receptor based on the structure/activity relationship of LPA. Annals of the New York Academy of Science 95:279-81, 2000.
55. Siminovitch, KA, Lamhonwah, AM, Somani, AK, Cardiff, Rand Mills GB. Involvement of the SHP-1 tyrosine phosphatase in regulating B lymphocyte antigen receptor signaling, proliferation and transformation . Curr Top Microbiol Immunol 246:291-7, 1999.
56. Mills, GB, Schmandt, R, Gershenson, D, Bast, RCJr. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects. Clinical Cancer Research 5(9):2286-8, 1999.
57. Wolf, JW, Mills, GB, Bast, RC, Roth, JA, Gershenson, DM. P53 mediated gene therapy. Ovarian Cancer 5:259-272, 1998.
58. Kruzelock, RP, Wiener, JR, Mills GB. Human Cancer Genetics: Science Fiction Becomes Science Fact . Breast Diseases 8:15-19, 1997.
59. Schmandt R, Mills G. Growth regulation of ovarian cancer cells . Contemporary Obstetrics and Gynecology 40:81-92, 1995.
60. Mills G. Current research in ovarian cancer. Treating the female patient 8:4-10, 1994.
61. Schmandt, R, Mills, GB. Genomic components of carcinogenesis. Clinical Chemistry 39:2375-2385, 1993.
62. Mills GB. Transmembrane signaling through hematopoietin receptors: Interleukin 2 and erythropoietin . Seminars in Immunology 5:297-298, 1993.
63. Coles, JG, Tsao, P, Wilson, GJ, Mills G. Tyrosine kinase-dependent lymphocyte signaling during allograft rejection. Transplantation Proceedings 25:877-878, 1993.
64. Simon, H-U, Kozlowski, M, Hogg, D, Mills, GB, Siminovitch KA. Isolation of a possible human counterpart to the murine XLR genes. (Short paper) Fresenius . J.Anal.Chem 343:125-126, 1992.
65. Mills, GB, Hashimoto, SHurteau, JA, Campbell, S, Rubin Land PShaw. Role of growth factors, their receptors, and signalling pathways in the diagnosis, prognosis, follow-up and therapy of ovarian cancer. Diagnostic Oncology 2:39-54, 1992.
66. Schmandt R., Fung M., Arima N., Zhang N., Leung B ., May C., Ma C., Gibson S., Hill M., Green W., Mills G. T lymphocyte proliferation : Tyrosine kinase in interleukin 2 signal tranduction. Balliere's Clinical Hermatology(5):551-573, 1992.
67. Mills, GB, Zhang, N, Schmandt, R, Fung, M, Greene, W, Mellors, A, Hogg, D. Transmembrane Signalling by Interleukin 2. Biochem Transactions 115:277-285, 1991.
68. Mills GB. Activation of lymphocytes by lymphokines. Current Topics in Membranes and Transport 35:495-535, 1990.
69. Fung, MR, Mills, GB, Greene, WC. The multimeric high affinity Interleukin 2 receptor: Insights into structure and signal transduction. Serono Symposia Publications: Cytokines: Basic Principles and Clinical Applications 68:101-107, 1990.
70. Sutherland, DR, Yeo, E, Ryan, A, Mills GB, Baker, MA. A mAb to KG1a cells recognizes an antigen (gp180) on activated T lymphoblasts and activated platelets. Leukocyte Typing IV:1045-1046, 1989.
71. Paetkau V, Mills GB. Cytokines and the mechanisms of lymphocyte activation Immunology and Allergy Clinics of North America . 9:21-44, 1989.
72. Marks, A, Buckman, R, Kwok, C-S, Kerr, I, Shaw, P, Michaels, H, De Angelis, C, Reed, R, Reilly, R, Mills, G, Law, J, Baumal, R. Preclinical and clinical studies of radioiodinated monoclonal antibody 2G3 for therapy of intraperitoneal effusions associated with carcinoma of breast and ovary. Antibodies, Immunoconjugates and Radiopharmaceuticals 2:83-92, 1989.
73. Gelfand, EW, Mills, GB, Cheung, RK, Lee, JW, Grinstein, S. Contrasting requirements for IL2 production, IL2 receptor expression, and lymphocyte proliferation. The role of calcium-dependent and calcium-independent signals. Lymphokines 14:155-175, 1987.
74. Paetkau, V, Shaw, J, Mills, GB, Caplan, B. Cellular origins and targets of costimulator (IL2). Immunol. Reviews 51:157-175, 1980.
75. Paetkau, V, Shaw, J, Caplan, B, Mills, GB, Lee, KC. Interleukin 2 in cell-mediated immune responses. J. Supramol. Structure 13:271-280, 1980.

Editorials

1. Muranen T., Meric-Bernstam G., Mills GB. Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors. Cancer Cell. In Press.
2. Mills GB. An emerging toolkit for targeted cancer therapies. Genome Research 14:322, 2012.
3. Bast RC Jr., Mills GB. Dissecting PI3Kness: the complexity of personalized therapy for ovarian cancer. Cancer Discovery 2:16-18, 2012.
4. Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol 28(22):3545-8, 8/2010. e-Pub 6/2010. PMID: 20547987.
5. Woodman SE, Mills GB. Are oncogenes sufficient to cause human cancer. Proc Natl Acad Sci 107:20599-600, 2010.
6. Halder G, Mills GB. Drosophila in cancer research: to boldly go where no one has gone before. Oncogene 30:4063-6, 2010.
7. Tabchy A, Tigyi G, Mills GB. Location, location, location: a crystal clear view of autotaxin saturating LPA receptors. Nature Structural Molecular Biology 18:117-8, 2010.
8. Bast RC Jr., Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Onc 102:1199-25, 2010.
9. Mills GB, Yarden Y. The rebirth of a phoenix: ovarian cancers are addicted to ERbB-3. Cancer Cell 16:217-8, 2010.
10. Mills GB, Jurisca I, Yarden Y, Norman JC. Genomic amplicons target vesicle recycling in breast cancer. J Clin Invest 119:2123-7, 2009.
11. Hung M-C, Mills, GB, Yu D. Less oxygen but more RTK: HIF links oxygen-sensing pathway to receptor tyrosine kinase (RTK) endocytosis. Nature Med 15:246-7, 2009.
12. Hennessy BT, Gonzalez-Angulo AM, Carey MS, Mills GB. Systems approach to molecular complexity in breast cancer. Clinical Cancer Research 15:417-9, 2009.
13. Brugge J, Hung M-C, Mills GB. A new muttaional AKTivation in the PI3K pathway. Cancer Cell 12:104-7, 2007.
14. Hennessy B, Nanjundan M, Cheng KW, Nolden L, Mills GB. Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13.5 as a putative oncogene in ovarian cancer. European J Human Genetics 14:381-3, 2006.
15. Lahad JP, Mills GB, Coombes KR. Stem cell-ness: a "magic marker" for cancer. J Clin Invest 115:1463-7, 2005.
16. Mills GB. Mechanisms underlying chemoprevention of ovarian cancer. Clinical Cancer Research 8:7-10, 2002.
17. Euhus DM, Esserman L, Ganz PA, Mills GB, Tomlinson G. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO: response to questions. J Natl Cancer Inst 94:1583-4, 2002.
18. Petricoin ED, Mills GB, Kohn EC, Liotta LA. Proteomic patterns in serum and identification of ovarian cancer: response to comments. Lancet 360:170-1, 2002.
19. Mills GB, Bast RC Jr., Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. Journal of the NCI 93:1437-9, 2001.
20. Mills GB, Lu Y, Kohn E. Linking molecular therapeutics to molecular diagnostics: inhibition of the FRAP/RAFT/TOR component of the phosphatidylinositol 3-kinase pathway preferentially blocks PTEN mutant cells in vitro and in vivo. Commentary Proceedings of the National Academy of Science 98:10031-3, 2001.
21. Mills GB, Schmandt R, Gershenson D, Bast RC Jr. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects. Clinical Cancer Research 5(9):2286-8, 1999.
22. Kruzelock RP, Wiener JR, Mills. Human cancer genetics: science fiction becomes science fact breast diseases. Breast Diseases 8:15-19, 1997.
23. Mills GB. Transmembrane signaling through hematopoietin receptors: interleukin 2 and erythropoietin. Seminars in Immunology 5:297-8, 1993.

Book Chapters

1. Naing A., Mills GB., Meric-Bernstam F. In: Combination Therapies Targeting the PI3K/AKT/mTOR Pathways In PI3K-mTOR in Cancer and Cancer Therapy Eds. Ed(s) Leyland-Jones, De, and Dey Springer I. In Press.
2. Bast. R.C., Romero I., Mills G.B. In: Molecular pathogenesis of ovarian cancer In Molecular Basis of Cancer. Ed(s) Mendelsohn, Israel, Gray, Thompson, Saunders Elsevier: Philadelpia. In Press.
3. Suh GK., Hennessy BT., Verhaak R., Yang JY., Mills GB., Bast RC. In: Molecular targets for epithelial ovarian cancer In Molecular Oncology. Ed(s) Gelmann, Sawyers and Rauscher. Cambridge University Press. In Press.
4. Mitra S., Molina J., Mills GB., Dennison JB. In: Characterization of the role Rab25 in Energy Metabolism and Cancer In Methods in Molecular Biology. Ed(s) Eds Guangpu Li Springer, 2014.
5. Mitra S., Mills GB. In: Aberrant Vesicular Trafficking Contributes to Altered Polarity and Metabolism in Cancer In Vesicle Trafficking in Cancer. Ed(s) Yosef Yarden and Gabi Tarcic, 95-123, 2013.
6. Panupinthu N., and Mills GB. In: Understanding the functions of lysophosphatidic acid receptors in cancer in Lysophospholipid receptors: signaling and biochemistry. Ed(s) Chun J., Hla T., Spiegel S., and Moolenaar W: John Wiley and Sons In. Hoboken, New Jersey, 641-659, 2013.
7. adevaia, S., Tabchy AB., Ram PT., and Mills GB. In: Clinical Applications of systems Biology Approaches in Cancer Systems Biology. Ed(s) Cesario A and Marcus F B. Springer Dordrecht Heidelberg: London New York, 409-428, 2011.
8. Hennessy BT., Bast RC., Mills GB. In: Molecular diagnostics in cancer Holland Frei Cancer Medicine VIII. Ed(s) Hong WK., Bast RC., Hait W., Kufe DW., Holland JF., Pollock RE., Weichselbaum BC Decker, 335-346, 2010.
9. Hennessy B, Carey M, Naora H, Agarwal R, Mills GB. Ovarian Cancer: Molecular, Cellular and Clinical Biology. In: Biology in Ovarian Cancer, In press, 2009.
10. Hennessy B, Bast RC Jr., Gonzalez-Angulo AM, Mills GB. Early detection of cancer: molecular screening. In: Molecular Basis of Cancer. Ed(s) J Mendelsohn, J Gray, et al. Elseview Saunders, 335-47, 2008.
11. Bast RC Jr. Mills GB. Molecular pathogenesis of epithelial ovarian cancer. In: Molecular Basis of Cancer. Ed(s) Mendelsohn, Isrea, Gray, Thompson, 441-54, 2008.
12. D Gewirtz, S Holt, S Grant. 2006 Chemo and Radiation Sensitization through inhibition of P13K/AKT signaling. In: Apoptosis, Senescence, and Cancer, 2007.
13. Smith DL, Nolden LK, Mills GB, Lu Y. Chemo- and radiation sensitization through inhibition of PI3K/AKT signaling. In: Apoptosis, Senescence and Cancer, 313-34, 2006.
14. Boyce, E, Kohn, EC, Mills Gordon B. Applications of proteomics to clinical questions in breast cancer. In: Breast Cancer, 2005.
15. Tanyi JLCroetzer, D, Wolf, J, Yu, S, Hasegawa, Y, Lahad, J, Cheng, KW, Umezu-Goto, M, Prestwich, GD, Morris A, Newman, RA, Felix, EA, Lapis, R, Mills GB. Functional Lipidomics: Lysophosphatidic Acid as a Target for Molecular Diagnosis and Therapy of Ovarian Cancer . In: Functional Lipidomics, 2005.
16. Tanyi, JL, Cheng, KW, Lahad JP, Mills GB. Genomic technologies in cancer research, drug discovery and development . In: EAGC Series, 2004.
17. Kohn EC, Lu, Y, Wang, H, Yu, Q, Yu, S, Hall, H, Smith, DL, Nolden L, Meric-Bernstam FHortobagyi, G, Mills GB. Targeted Therapeutics in Breast Cancer. In: Challenges to Success Diseases of the Breast, 2004.
18. Bast RC, Mills GB. Molecular mechanisms of pathogenesis and progression of epithelial ovarian cancer . In: The Ovary 2nd Edition, 2003.
19. Yu, Y, Xu, F, Peng H, Fang, X, Zhao, S, Li, Y, Cuevas, B, Kuo, W-L, Gray J, Siciliano, M, Pershad, R, Hogg, D, Berchuk, A,, Hunt K, Mills GB, Bast RC. ARHI (NOEY2) an imprinted tumor suppressor gene in epithelial ovarian cancer . In: Ovarian Cancer. Oxford University Press, 125-130, 2002.
20. Mills, GB, Rieger, PA. Genetic Predisposition to Breast Cancer . In: Breast Cancer. Springer Verlag, 55-92, 2002.
21. Lu, Y, Shayestri, L, Lapushin, R, Yu, S, Cuevas, B, Fang, X, Eder, A, Furui, T, Plikoff, D, Kuo, WL, Baldocchi, R, Vanhaesebroeck, B, Bast RC, Pinkel, D, Siminovitch, K, Jaffe, R, Gray, J, Mills GB. Phosphatidylinositol 3’kinase as a Target in Selected Ovarian Cancers: From Genomics to Therapeutics . In: Ovarian Cancer. Oxford University Press, 413-422, 2002.
22. Bast RC, Mills GB. The molecular pathogenesis of ovarian cancer. In: The molecular basis of cancer. W.B. Saunders Company, 361-384, 2001.
23. Shaw, P, Deavers, M, Mills GB. Clinical Characteristics of Genetically determined ovarian cancer. In: Genetic Predisposition to Female Cancers. Victor Vogel, 94-107, 2000.
24. Mills, GB, Lu, Y, Shyestri, L, Pinkel, D, Gray, J. From genetics to therapeutic targets: Phosphatidylinositol 3’kinase (PI3K) in ovarian and breast cancer. In: Cancer: investigatcion basica y aplicaciones clinicas. Erika Med, 6-16, 1999.
25. Mills GB, Rieger, P, Watt, MA, Graham, C, Pentz, R. Genetic Predisposition to Cancer . In: Manual of Clinical Oncology Seventh Edition. Wiley-Liss, 63-97, 1999.
26. Gray, JW, Collins, C, Pinkel, D, Shayesteh, L, Lu, Y, Mills GB. Genome scanning and gene discovery in breast and ovarian cancer . In: Pezcoller Foundation Symposia: The Biology of Tumors. Plenum Press, 65-72, 1999.
27. Gallion H,H, Kohn EC, Mills, GB, Bast RC. Clinical Applications of Basic Science Investigations . In: Current controversies in the management of ovarian cancer, 357-397, 1998.
28. Gray, JW, Collins, C, Daneshvar, L, Rommens, J, Kuo, W-L, Palazzolo, M, Martin, C, Hwang, S, Kowbel, D, Mills, G, AlbertsonD, Pinkel, D. Genome Scanning to Genes: Positional cloning at 3q26 and 20q13.2 . In: Genome Scanning to Genes: Positional cloning at 3q26 and 20q13.2. Princess Takematsu Cancer Research fund, 95-97, 1998.
29. Xu, Y, Fang, X, Furui, T, Sasagawa, T, Pustilnik, T, Lu, Y, Shen, Z, Wiener, JR, Shayesteh, L, Gray, JW, Bast Jr, RC, Mills, GB. Regulation of growth of ovarian cancer cells by phospholipid growth factors. In: Ovarian Cancer 5. ISIS Medical Media, 109-120, 1998.
30. Bast, RC, Xu, F, Yu, Y, Fang, X,Weiner, J, Mills, GB. The Molecular Biology of Ovarian Cancer. In: Ovarian Cancer 5. ISIS Medical Media, 87-98, 1998.
31. Shi, YF, Mills GB, Wang, R. Mitogenic Cytokine Promote Apoptosis: Possible Roles in Cellular Homeostasis. In: Current advances in programmed cell death. Plenum Publishing Corp, 113-124, 1997.
32. Mills, GB, Gibson, S, Schmandt, R, Fang, XJ, Wiener, JR. Signal Transduction . In: Transplantation Biology: Cellular and Molecular Aspects. Tilney, N., Strom, T.B., and Paul L. C., 31-54, 1996.
33. Bast, R, Mills, GB, Gibson, S, Boyer, C. Tumor Immunology . In: Cancer Medicine. Williams and Wilkins, Baltimore, 1996.
34. Xu, Y, Mills, GB. Activation of human ovarian cancer cells: Role of lipid factors in ascitic fluid. In: Ovarian Cancer III. Chapman and Hall Medical, 121-135, 1994.
35. Bast RC, Wiener J, Kassim, S, Wu, S, Boyer, C, DeSombre, K, Hurteau, J, Rodriguez, G, Mills, GB, Berchuk, A. Cell growth regulation in ovarian cancer: Tyrosine kinases, tyrosine phosphatases and tumor necrosis factor-a. In: Ovarian Cancer III. Chapman and Hall Medical, 109-114, 1994.
36. Gibson, S, Mills, GB. EMT Expressed mainly in T cells. In: Protein Kinase Factsbook. Academic Press, 85-86, 1994.
37. Schmandt, RE, Hogg, D, Mills, GB. TTK (Serine), threonine, tyrosine kinase (human) . In: Protein Kinase Factsbook. Academic Press, 371-373, 1994.
38. Mills GB. Functional and molecular aspects of T cell activation . In: Developmental Immunology. Oxford University Press, 333-364, 1993.
39. Mills, GB, Hashimoto, S, Hurteau, J, Schmandt, R, Campbell, S, May, C, Hill, P, Shaw, P, Buckman, R, Hogg, D. Regulation of growth of human ovarian cancer cells. In: Ovarian cancer 2-Biology Diagnosis and Management. Chapman and Hall Medical, 127-143, 1992.
40. Teodorczyk-Injeyan, JA, Mills, GB, Sparkes, BG, Peters, WJ. Expression of Functional Interleukin 2 Receptors in the burn patient may be regulated by Interleukin 3. In: Immune consequences of trauma, shock and sepsis. Springer-Verlag, Berlin, 1989.
41. Mills GB, May C. Regulatory mechanisms in ascitic fluid. In: Ovarian Cancer: Biologic and therapeutic challenges. Chapman and Hall Medical, 55-62, 1989.
42. Mills, GB, Benedict, S, Mellors, A, Grinstein, S, Gelfand EW. Transmembrane signaling by Interleukin 2. In: Interleukin 2. Academic Press, 113-135, 1988.
43. Gelfand, EW, Cheung, R, Mills, GB, Lee, J, Lederman, HM, Nisbet-Brown, E, Grinstein, S. Analysis of calcium-dependent and calcium-independent signals in triggering human T lymphocytes. In: Primary Immunodeficiency Diseases. Elsevier Science Publishers, 153-164, 1986.
44. Mills GB. Immunology of Cancer in Pregnancy. In: Cancer in Pregnancy. Futura Publishing Inc, 9-34, 1986.
45. Paetkau V, Mills GB, Bleackley C. Enhancement of antitumor responses with interleukin 2. In: The Potential Role of T Cell Populations in Cancer Therapy. Ed(s) MA Fefer, A Goldstein. Raven Press, 147-59, 1982.

Books (edited and written)

1. Mendelsohn, Israel, Gray, Thompson. Ed(s) Saunders, Elsevier. Molecular Basis of Cancer. In: Early Detection of Cancer: Molecular Screening, 2008.
2. Mendelsohn, Israel, Gray, Thompson. Ed(s) Saunders, Elsevier. Molecular Basis of Cancer. In: Molecular pathogenesis of epithelial ovarian cancer, 2008.

Grant & Contract Support

Title: Targeting ILK in cancer 2002
Funding Source: Kinetek
Role: Principal Investigator
Duration: 1/1/8888
 
Title: Systematic Functional Characterization of RNA Editing in Endometrial Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Han Liang
Duration: 4/22/2014 - 3/31/2019
 
Title: Rational combinational therapy of PARP inhibitors with inhibitors of the PI3K pathway.
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 4/1/2013 - 7/31/2015
 
Title: Functionalization of the cancer genome, enabling the identification of new opportunities for the existing AZ drug portfolio and the identification of novel targets for drug discovery
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 4/1/2013 - 7/31/2015
 
Title: Characterizing and Targeting CHD4 Deficiency in Endometerial Cancer
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Lin
Duration: 2/1/2013 - 1/31/2018
 
Title: Risk Prediction for ER negative breast cancer recurrence
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Brewster
Duration: 1/1/2013 - 12/31/2018
 
Title: Molecular Determinants and Clinical Implications of Breast Cancer Dormancy
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Co-Investigator
Duration: 9/15/2012 - 9/14/2014
 
Title: Combinatorial adaptive resistance therapy to find rational drug combinations to AZD drugs.
Funding Source: Astrazeneca
Role: Principal Investigator
Duration: 9/1/2012 - 12/31/2014
 
Title: Functional genomics of ovarian cancer
Funding Source: Adelson Medical Research Foundation
Role: Principal Investigator
Duration: 9/1/2012 - 8/31/2014
 
Title: Functional proteomics platform
Funding Source: Adelson Medical Research Foundation
Role: Principal Investigator
Duration: 9/1/2012 - 8/31/2014
 
Title: An Integrative Pipeline for Analysis & Translational Application of TCGA Data
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 9/1/2012 - 8/31/2013
 
Title: Biological annotation of TCGA data
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 5/1/2012 - 4/30/2017
 
Title: Uncovering metabolic heterogeneity in breast cancer subtypes
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 11/8/2011 - 12/28/2014
 
Title: Autotaxin and Lysophosphatidic acid (LPA) as a novel therapeutic target in breast cancer
Funding Source: Breast Cancer Research Foundation
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2014
 
Title: Combinatorial Adaptive Resistance Therapy to Find Rational Drug Combinations
Funding Source: GSK
Role: Principal Investigator
Duration: 7/28/2011 - 7/27/2013
 
Title: Investigation of Activites of AZD5363, a novel inhibitor of AKT/PKB, and AZD5582, an IAP inhibitor in breast, endometrial and ovarian cancer
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 2/1/2011 - 3/31/2013
 
Title: An Academic-Industry Dream Team Capitalizing on the Phosphatidylinositide 3 Kinase Pathway as a Target in Women.
Funding Source: American Association for Cancer Research (AACR)
Role: Co-Principal Investigator
Duration: 11/1/2010 - 10/31/2013
 
Title: Targeting the P13K signaling pathway in Endometrial Carcinoma
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Lu, Broaddus
Duration: 9/14/2010 - 8/31/2015
 
Title: Uterine SPORE
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 9/14/2010 - 8/31/2015
 
Title: Combatorial Adaptive Resistance Therapy to Lapantinib in Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 8/1/2010 - 6/30/2012
 
Title: Combinatorial Adaptive Resistance Therapy in Breast Cancer
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 7/1/2010 - 6/30/2014
 
Title: ARHI (DRAS 3) in autophagy and dormancy of ovarian cancer
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Bast
Duration: 7/1/2010 - 6/30/2011
 
Title: Mechanisms underlying delayed recurrence of ER positive breast cancer: a critical step in the development of effective biomarkers and therapies.
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 5/1/2010 - 10/31/2013
 
Title: Discovery and validation of novel cancer drug targets through synthetic lethal screening
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Principal Investigator
Duration: 5/1/2010 - 10/31/2013
 
Title: Developing Effective Therapies for ER-negative Breast Cancer using Genomics and Proteomics
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Co-Principal Investigator
Duration: 10/1/2009 - 12/7/2013
 
Title: Mechanisms of bypass of EGFR family inhibition: Improved targeting and rational combinatorial therapy
Funding Source: Wyeth-Ayerst Research Laboratories
Role: Principal Investigator
Duration: 10/1/2009 - 10/1/2012
 
Title: An integrative pipeline for analysis & translational application of TCGA Data
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/29/2009 - 7/31/2014
 
Title: Identification of predictive and pharmacodynamic markers, regulatory loops and on and off target activity for Celgene compounds
Funding Source: Celgene
Role: Principal Investigator
Duration: 9/11/2009 - 9/30/2012
 
Title: Inhibition of PARP in Women with Sporadic Ovarian Cancer
Funding Source: AstraZeneca
Role: Principal Investigator
Duration: 7/1/2009 - 8/31/2014
 
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Collaborator
Duration: 4/1/2009 - 3/31/2012
 
Title: Autophagy in Ovarian Cancer-PP-2
Funding Source: NIH/NCI
Role: Collaborator
Duration: 1/1/2009 - 12/31/2012
 
Title: Implications of Targeted Therapies: Accurate Determination of Mutation Cells
Funding Source: Susan G. Komen Breast Cancer Foundation
Role: Principal Investigator
Duration: 8/28/2008 - 5/31/2012
 
Title: Peptide arrays for early detection of cancer
Funding Source: CeMines
Role: Principal Investigator
Duration: 5/19/2008 - 9/30/2011
 
Title: 5 R01 CA123219-01
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 4/8/2008 - 2/28/2013
 
Title: Role of aberrant splicing of EVI1 in Ovarian Cancer Pathophysiology
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Duration: 4/8/2008 - 2/28/2013
 
Title: Molecular predictors of drug response in ovarian cancer
Funding Source: Exelexis
Role: Principal Investigator
Duration: 3/18/2008 - 6/30/2012
 
Title: Identification of modifiers of androgen receptor function
Funding Source: NIH/NCI
Role: Subcontract
Principal Investigator: Osborne
Duration: 3/1/2008 - 2/28/2013
 
Title: Molecular Predictors of drug response
Funding Source: Exelixis
Role: Principal Investigator
Duration: 3/1/2008 - 2/28/2009
 
Title: Project 5 Targeting IGF-1R in Breast Cancer
Funding Source: Baylor Breast
Role: Subcontract
Duration: 1/1/2008 - 12/31/2012
 
Title: Special Program in Molecular Markers Development
Funding Source: Komen Foundation
Role: Principal Investigator
Duration: 10/1/2007 - 9/30/2010
 
Title: Using RPPA and IHC to elucidate cellular protein and protein phosphorylation levels with P13K inhibitor
Funding Source: Semafore
Role: Principal Investigator
Duration: 6/1/2007 - 5/31/2008
 
Title: Lpath Therapeutics
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 5/16/2007 - 9/30/2011
 
Title: Effective Mammalian Two Hybrid Screening Approach
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/17/2007 - 3/31/2010
 
Title: Ligand Recognition by Phospholipid Growth Factor Receptors
Role: Subcontract
Duration: 12/1/2006 - 11/30/2007
 
Funding Source: NIH/NCI
Role: Subcontract PI
Duration: 11/1/2006 - 10/31/2011
 
Title: Using RPPA to Elucidate Cellular Protein and Protein Phosphorylation Levels with PLK Inhibitors
Funding Source: GlaxoSmithKline
Duration: 11/1/2006 - 10/31/2007
 
Title: Targeted and Global Proteomic Strategies for Early Breast Cancer Detection.
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/28/2006 - 8/31/2013
 
Title: 5 U24 CA126479-04
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/28/2006 - 8/31/2011
 
Title: Molecular Predictors of Drug Response in Ovarian Cancer
Funding Source: GSK
Role: Principal Investigator
Duration: 9/1/2006 - 9/1/2012
 
Title: Functional Proteomics and Reponse to Preoperative Chemotherapy in Breast Cancer
Funding Source: NIH/NCI
Role: Consultant
Principal Investigator: Gonzalez-Angulo
Duration: 9/1/2006 - 8/31/2008
 
Funding Source: Kerx
Role: Principal Investigator
Duration: 7/1/2006 - 6/30/2008
 
Title: Clinical Translation studies of AML
Funding Source: NIH/NCI
Role: Co-Director
Principal Investigator: Andreef
Duration: 9/1/2005 - 12/31/2012
 
Title: Spore in Breast Cancer
Role: CO-PI
Principal Investigator: Hortobagyi/Hung
Duration: 9/1/2005 - 8/31/2008
 
Title: Targeted Therapy for head and neck center
Funding Source: Spore Intervention Supplement
Principal Investigator: Grandis
Duration: 7/1/2005 - 6/30/2007
 
Title: Proteomics of Acute Myelogenous Leukemia
Funding Source: Leukemia and Lymphoma Society
Principal Investigator: Kornblau
Duration: 1/11/2005 - 12/31/2007
 
Title: Model-based predictions of responses to RTK pathway therapies-P1
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Gray
Duration: 9/30/2004 - 2/28/2015
 
Title: Model-Based Predictions of Responses to RTK Pathway Therapies - P4
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Gray
Duration: 9/30/2004 - 2/28/2015
 
Title: ILK as a therapeutic target
Funding Source: QLT
Duration: 1/8/2004 - 7/31/2006
 
Title: Molecular imaging of Perifosine
Funding Source: Keryx
Duration: 1/8/2004 - 7/31/2005
 
Title: Growth Factor Receptor Signaling in Breast Cancer
Funding Source: NIH/NCI
Role: Co-PI Admin core
Principal Investigator: MC. Hung
Duration: 4/1/2003 - 8/31/2015
 
Title: Project #4 The PI3K Pathway as a Target for Lung Cancer Prevention and Therapy
Funding Source: NIH/NCI
Role: Co PI
Principal Investigator: Minna/Roth
Duration: 4/1/2003 - 3/31/2008
 
Title: Lipomics in ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2/1/2003 - 1/31/2006
 
Funding Source: Lynn Cohen Foundation
Duration: 1/1/2003
 
Title: P50 supplement NCI/Avon collaborative grants
Funding Source: NIH/NCI
Role: Principal Investigator-MDACC
Duration: 12/1/2002 - 11/30/2005
 
Title: Project#4. Molecular Markers in Targeted Therapy in Head and Neck
Funding Source: SPORE in Head and Neck Cancer
Role: Project Leader
Principal Investigator: Lippman
Duration: 9/30/2002 - 7/31/2013
 
Title: Therapeutic Development
Funding Source: Breast Cancer Center of Excellence
Role: Principal Investigator
Duration: 9/1/2002 - 8/31/2007
 
Title: Breast Cancer Center of Excellence in therapeutic development
Funding Source: DODCoE Hortobagyi
Role: Co-Principal Investigator
Principal Investigator: DODCoE Hortobagyi (PI)
Duration: 9/1/2002 - 8/31/2006
 
Title: Breast Cancer Center of Excellence in molecular markers
Funding Source: DOD Urban
Role: Co-Principal Investigator
Principal Investigator: DOD Urban(PI)
Duration: 9/1/2002 - 8/31/2006
 
Title: ILK as a therapeutic target in ovarian cancer
Funding Source: Lynne Cohen Foundation
Principal Investigator: Lynne Cohen Foundation PI
Duration: 1/1/2002 - 12/31/2007
 
Title: AKT and synthetic lethality in ovarian cancer
Funding Source: Zarrow Family Foundation
Duration: 1/1/2002 - 12/31/2007
 
Funding Source: Lynn Cohen Foundation
Duration: 1/1/2002
 
Title: Ligand Recognition by Phospholipid Growth Factor Receptors
Funding Source: NIH/NCI
Role: Collaborator
Duration: 8/1/2001 - 7/31/2011
 
Title: The PI3K pathway as a target in Prostate Cancer Pilot Project
Role: Principal Investigator
Principal Investigator: C. Logothetis
Duration: 12/1/2000 - 11/30/2001
 
Title: Targeting the BRCAness and P13Kness in Ovarian Cancer
Funding Source: NIH/NCI
Role: Program Director - Project #4
Principal Investigator: Bast
Duration: 9/30/1999 - 8/31/2015
 
Title: Prevention of Cancer in Genetically Identified Individuals
Funding Source: Powell Brown
Role: Co PI, CoPI on core A
Duration: 9/30/1999 - 9/29/2005
 
Title: Project #5 PI3K in the prognosis and therapy of ovarian cancer
Funding Source: CA
Role: Principal Investigator
Duration: 9/1/1999 - 8/31/2005
 
Title: Early Detection Research Network
Funding Source: RFA
Role: Collaborator
Principal Investigator: D. Fishman
Duration: 9/1/1999 - 8/31/2004
 
Title: Role of the MMAC1 Tumor Suppressor in Human Breast Cancer
Funding Source: CA
Role: Principal Investigator
Duration: 7/1/1999 - 6/30/2005
 
Title: Chemoprevention of Ovarian Cancer
Role: Admin Core Co PI
Principal Investigator: David Gershenson
Duration: 7/1/1999 - 6/30/2002
 
Title: Role of the MMAC1 Tumor Suppressor in Human Breast Cancer
Funding Source: Komen Foundation
Role: Principal Investigator
Duration: 4/1/1999 - 3/30/2001
 
Title: Immunology
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Margaret Kripke
Duration: 9/1/1998 - 8/31/2003
 
Title: Bioimmunotherapy
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Moshe Talpaz
Duration: 9/1/1998 - 8/31/2003
 
Title: NOEY2, A Novel Ovarian Cancer Tumor Suppressor Gene
Role: Collaborator
Principal Investigator: R. Bast
Duration: 9/1/1998 - 8/31/2001
 
Funding Source: NIH/NCI
Role: Co-Director Emerging Characterized Cell Line Core
Duration: 7/1/1998 - 6/30/2013
 
Title: Tissue procurement and analysis core
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: John Mendelson
Duration: 7/1/1998 - 6/30/2003
 
Title: Differentially expressed genes in ovarian cancer and identification of novel markers for drug sensitivity and resistance
Funding Source: Millenium Pharmaceuticals
Role: Co Principal Investigator
Principal Investigator: R. Bast
Duration: 4/1/1998 - 3/31/2001
 
Title: Texas Cancer Genetics Consortium
Role: Core Co-Director
Principal Investigator: Louise Strong
Duration: 3/1/1998 - 2/28/2001
 
Title: CD28 signaling through the EMT/ITK tyrosine kinase
Role: Principal Investigator
Principal Investigator: Gordon B. Mills
Duration: 4/1/1997 - 1/31/2002
 
Title: Pediatric Oncology Research Training Program
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Francis Ali-Osman
Duration: 2/17/1997 - 11/30/2002
 
Title: Targets of the Von-Hippel-Lindau Tumor Suppressor Gene in Renal Carcinoma
Funding Source: Binational Science Foundation
Role: Co. P.I.
Principal Investigator: Karl Skorecki
Duration: 1/7/1997 - 6/30/2000
 
Title: The Putative Tumor Suppressor PTP1C in Breast Cancer
Funding Source: National Institutes of Health
Role: Principal Investigator
Duration: 9/1/1996 - 8/31/1999
 
Title: Training Program in Cancer Genetics/ Cancer Genetic Counseling
Role: Co-Investigator
Principal Investigator: Ellen Gritz
Duration: 9/1/1996 - 8/31/1997
 
Title: Project#4 Role of P13K in Diagnosis, Prognosis and Therapy of Ovarian Cancer
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: R. Jaffe
Duration: 4/15/1996 - 1/31/2008
 
Title: AHRI, A Novel Ovarian Cancer Tumor Suppressor Gene
Funding Source: CA
Role: Collaborator
Principal Investigator: R. Jaffe
Duration: 4/15/1996 - 1/31/2006
 
Title: Project #2 Role of LPA in the Diagnosis
Funding Source: CA
Role: Project Leader
Principal Investigator: R. Jaffe
Duration: 4/15/1996 - 1/31/2006
 
Title: Project #4 Role of PI3K in the Diagnosis
Funding Source: CA
Role: Project Leader
Principal Investigator: R. Jaffe
Duration: 4/15/1996 - 1/31/2006
 
Title: Therapy of AML
Funding Source: NIH/NCI
Role: Core co leader
Principal Investigator: Michael Andreeff
Duration: 4/1/1996 - 8/31/2012
 
Title: Phase II/III Trials of Anticancer agents
Role: Co-Investigator
Principal Investigator: J. Abbruzzese
Duration: 8/1/1995 - 3/31/1999
 
Title: Translational Resarch on Breast Cancer
Funding Source: Baylor College of Medicine
Role: Principal Investigator
Duration: 9/30/1992 - 11/30/2012
 
Title: Project 5 Targeting IGF-1R in Breast Cancer
Funding Source: NIH/NCI
Role: Subcontract
Duration: 9/30/1992 - 11/30/2011
 
Title: Role of the unique EMT and TTK kinase in T lymphocyte activation and proliferation#MT-11314
Funding Source: Medical Research Council of Canada
Duration: 1/1/1991 - 1/1/1994
 
Title: PRI Role of growth factors in diagnosis prognosis and treatment of ovarian cancer
Funding Source: Johnson and Johnson
Duration: 1/1/1991 - 1/1/1993
 
Title: Role of VPF in malignant ascites
Funding Source: Monsanto Corporation
Duration: 1/1/1991
 
Funding Source: Cangene Corporation
Duration: 1/1/1988
 
Title: Regulation of T lymphocyte proliferation by IL2 #MA-9867
Funding Source: Medical Research Council of Canada
Duration: 1/1/1987 - 1/1/1994
 
Title: Non-invasive tests of malignant hyperthermia: Cytoplasmic pyrogen Ca2+
Funding Source: Malignant Hyperthermia:Association
Duration: 1/1/1987 - 1/1/1989
 
Title: Non-invasive tests of malignant hyperthermia: Cytoplasmic Ca2+ and pyrogen
Funding Source: Physicians' Services Incorporated Foundation
Principal Investigator: u
Duration: 1/1/1987 - 1/1/1989
 
Title: Clinical Research Equipment Fund Dual-excitation fluorescence multiplexed measurement system
Funding Source: University of Toronto
Duration: 1/1/1987
 
Title: Dual-excitation fluorescence multiplexed measurement system
Funding Source: Medical Research Council of Canada
Duration: 1/1/1987
 
Title: Leukemia growth regulation
Funding Source: Leukemia Research Foundation
Duration: 1/1/1986 - 1/1/1994
 
Title: Regulation of Growth of Ovarian Cancer Cells #1055
Funding Source: National Cancer Institute of Canada
Duration: 1/1/1986 - 1/1/1994
 
Title: Growth regulation of ovarian cancer
Funding Source: Genesis Foundation
Duration: 1/1/1986 - 1/1/1992
 
Title: Role of growth factors in initiation, progression and therapy of malignant disease
Funding Source: University of Toronto
Duration: 1/1/1986
 
Title: Proliferation of normal and neoplastic lymphocytes
Funding Source: Dean's Fund, University of Toronto
Duration: 1/1/1986
 
Funding Source: Medical Research Council of Canada
Duration: 1/1/1986
 
Title: Immunotherapy with IL2-activated lymphocytes
Funding Source: Alberta Heritage Trust Fund for Cancer Research
Duration: 1/1/1979 - 1/1/1983

Last updated: 7/29/2014